Scripta Medica Volume 44 Issue 1

44
asopis Drutva doktora medicine Republike Srpske Journal of the Medical Society of the Republic of Srpska
Godina: 44. Broj 1 maj 2013. asopis Drutva doktora medicine Republike Srpske Vol. 44 No. 1 May 2013. Medical Society of the Republic of Srpska
EDITORIAL / Case Reports and Adverse Drug Reactions R. IGI, N. STOJAKOVI ORIGINAL ARTICLE/ Outpatient utilization of systemic antibiotics in the Republic of Srpska V. MARKOVI PEKOVI,
S. STOISAVLJEVI-ATARA, R. KRBI
ORIGINAL ARTICLE/ Gender and Laterality of Lesion on Severity of Post-Stroke Depressive Symptoms
S. DRAA
ORIGINAL ARTICLE/ Abbreviated UVA-Riboavin Corneal CollagenCross-linking for Keratoconus and Post-LASIK Ectasia R.L. EPSTEIN, G.L. EPSTEIN CASE REPORTS/ Subcutaneous Emphysema and Pneumomediastinum Following a Dental Filling Procedure
D. VORONOV, A. RUSSO, S. JULOORI, S. THOMAS
Atypical form of congenital excavated anomaly of the optic disc with characteristics of peripapillary staphyloma and morning glory anomaly B. MARKI, M. MAVIJA, E. IGNJATI IMAGES IN CLINICAL MEDICINE/ Dual Pulmonary Infections in a 57-Year-Old Male J.L. BERO SPECIAL ARTICLE-CLINICAL PRACTICE/ - Risk Factors for Venous Thromboembolism
N.M. ANTONIJEVI, A.V. KANJUH, I. IVKOVI, LJ. JOVANOVI
LETTER TO THE EDITOR/ IN REPLY/ CONTINUING MEDICAL EDUCATION/ Questions and Answers M. MAVIJA, S. ILI, V. PAVLI Medline
www.scriptamedica.com
Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com
Scripta Medica (Banja Luka)

asopis Drutva doktora medicine Republike Srpske
UREIVAKI ODBOR/EDITORIAL BOARD
Glavni urednik/Editor-in-Chief
MEUNARODNI UREIVAKI ODBOR INTERNATIONAL A DVISORY BOARD Pavle Anus, Belgrade, Serbia Shigetoshi Chiba, Matsumoto, Japan Nada okanovi, Toronto, Canada Ervin G. Erds, Chicago, USA Igor Franceti, Zagreb, Croatia Faruk Hadiselimovi, Basel, Switzerland Zoran Ivanovi, Bordeaux, France Vladimir Kanjuh, Belgrade, Serbia Neboja Lali, Belgrade, Serbia Slobodanka Latinovi, Novi Sad, Serbia Kafait U. Malik, Memphis, USA Momir Mikov, Novi Sad, Serbia Goran Milainovi, Belgrade, Serbia Satoshi Nakatani, Osaka, Japan Dragoslav Nenezi, Podgorica, Montenegro Aleksandar Nekovi, Belgrade, Serbia Momir Ninkovi, Munich, Germany Miodrag . Ostoji, Belgrade, Serbia Miralem Pai, Berlin, Germany Mirjana Pavlovi, Boca Raton, USA Shmuel Penchas, Tel Aviv, Israel Boina Radevi, Belgrade, Serbia Marin Sekosan, Chicago, USA Goran Stankovi, Belgrade, Serbia Ljuba Stojiljkovi, Chicago, USA Ksenija Vitale, Zagreb, Croatia Vladan Vukevi, Belgrade, Serbia Nathan D. Wong, Irvine, USA Slavica ii-Borjanovi, Belgrade, Serbia Web site Editor: Zdravko Gruba Tehniki sekretar: Biljana Radii Lektor za srpski jezik: Miodrag Milenovi Lektor za engleski jezik: Dalibor Kesi Prelom teksta/Layout: Medici.com, Banja Luka Dizajn/Design: CGM Design, Banja Luka Izdavai/Publishers: Drutvo doktora medicine RS, Medicinski fakultet, Banja Luka tampa/Printed by: Atlantic bb, Banja Luka
Rajko Igi
Urednici/Senior Editors
Aleksandar Lazarevi Stevan Trbojevi

lanovi/Members
Dejan Bokonji Marija Burgi-Radmanovi Radoslav Gajanin Nenad Ponorac Jelica Predojevi-Samardi Aida Rami Nela Raeta Duko Vuli Enver Zerem Milan Jokanovi
IZDAVAKI SAVJET/PUBLISHING COUNCIL

Predsjednici/Co-Presidents
Prof. dr Sinia Miljkovi Prof. dr Milan Skrobi

lanovi/Members
Prof. dr Ranko krbi Prof. dr Jasmin Komi Akademik Drenka eerov-Zeevi Doc. dr Momilo Biukovi Prof. dr Veljko Mari Prof. dr Brano Topi Prof. dr Gordana Teanovi Prof. dr Milan Kuli
ISSN 0350-8218 Tira: 1.000 primjeraka Copyright Drutvo doktora medicine Republike Srpske This issue of the SM is printed on acid-free paper
/ Contents
6 EDITORIAL
30
IMAGES IN CLINICAL MEDICINE
Dual Pulmonary Infections in a 57-Year-Old Male With Large Adrenal Mass 57 J.L. BERO
31 LETTER TO THE EDITOR
Case Reports and Adverse Drug Reactions

R. IGI, N. STOJAKOVI 8 ORIGINAL ARTICLE
Trans-Apical Trans-Catheter Aortic Valve Implantation: The Berlin Experience : J. COOCKBURN

32 LETTER TO THE EDITOR
Outpatient utilization of systemic antibiotics in the Republic of Srpska V. MARKOVI PEKOVI,

S. STOISAVLJEVI-ATARA, R. KRBI 14 ORIGINAL ARTICLE
On Keratoconus Incidence in ProspectiveRefractive Surgery Patients

R.L. EPSTEIN, G.L. EPSTEIN
The Inuence of Gender and Laterality of Lesion on Severity of Post-Stroke Depressive Symptoms S. DRAA
33
LETTER TO THE EDITOR
Burnout Syndrome Among Residents of Family Medicine M. JERINI

35 SPECIAL ARTICLE-CLINICAL PRACTICE
19
ORIGINAL ARTICLE
Abbreviated UVA-Riboavin Corneal Collagen Cross-linking for Keratoconus and Post-LASIK Ectasia UVA- crosslinking Post-LASIK
R.L. EPSTEIN, G.L. EPSTEIN
Risk Factors for Venous Thromboembolism and Duration of Anticoagulation Therapy N.M. ANTONIJEVI, V. KANJUH,
I. IVKOVI, LJ. JOVANOVI 43 CONTINUING MEDICAL EDUCATION
25
CASE REPORT
Subcutaneous Emphysema and Pneumomediastinum Following a Dental Filling Procedure o D. VORONOV, A. RUSSO, S. JULOORI, S. THOMAS
27 CASE REPORT
Questions and Answers M. MAVIJA, S. ILI, V. PAVLI

51 MEDLINE /INSTRUCTIONS FOR CONTRIBUTORS
54
Atypical form of congenital excavated anomaly of the optic disc with characteristics of peripapillary staphyloma and morning glory anomaly y B. MARKI, M. MAVIJA, E. IGNJATI
59
/In This Issue

Scripta Medica , , , , Questions & Answers, . ( - . .) 2007. 2011. je . , , , , . ( .) . (Epstein R. L. and Epstein G. L.). ( . .) . (Voronov D., et al) . , . K 57- ,
(Blastomyces/Pleumocystis jiroveci), (Bero J. L.). ( . . .) ; . Q & A . , , ( M. .) . SM . , , . ; . , , . Medline ( ). SM - . , . Scripta Medica
UDK 615.03:613.2-099
EDITORIAL
Case Reports and Adverse Drug Reactions

Case reportsdescriptions of one or more patientsused to be the most common type of publication in medical journals. Today only some journals accept case reports; these include open access journals, for example the Journal of Medical Case Reports. Such contributions generally illustrate some novel clinical problem or its solution.1 Case reports are most likely to be published if they describe any of the following: 1) an unreported adverse drug reaction or interaction, 2) a new, unexpected, or unusual pattern of a disease, 3) previously unsuspected causal association between two diseases, 4) presentations, diagnosis and/or management of new and emerging diseases, 5) an unexpected association between diseases or symptoms, 6) an unexpected event in the course of observing or treating a patient, 7) ndings that shed new light on the pathogenesis of a disease or an adverse effect or diagnosis, and 8) a previously unknown disease. (The unknown disease may happen quite rarely.) In the hierarchy of evidence-based medicine, single case reports remain at the very bottom.2 However, even a single case report can stimulate further conrmatory investigations, especially if the report goes beyond cursory observation. For example, a report of an increased incidence of leukemia within a single neighborhood can contribute to the dening characteristics of what may be an evolving disease cluster.3 Case reports on suspected adverse drug reaction (ADR) could also inspire subsequent systematic research that will ultimately contribute to the evidence based medicine. Any suspected ADR needs to be conrmed or refuted. Often suspected, new adverse drug reactions remain unveried; in fact, at least two reports indicate that from 26%4 to 83%5 of ADRs are not conrmed. Many published reports of suspected ADR are thus of limited value, because these signals are seldom investigated further. Furthermore, because this information is not incorporated consistently into drug reference sources, physicians and patients remain unaware of the potential adverse effects.6 In 1971, an international system for monitoring ADRs was established (WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, Sweden). The database in Uppsala currently contains over three million reports of suspected ADRs. These reports use common terminologies and classications and are supplied by phy-
sicians, qualied nurses, and pharmacists.7 This extensive system for voluntary reporting of ADRs has a quantitative advantage (especially if patient reports are included8) over the case reports of ADRs published in journals, yet the case reports provide a better quality of information. Scripta Medica publishes case reports, including those on adverse drug interactions, as well as review articles on this subject.9 Short description of a case that would not make a full-length paper may be published as a letter to the editor. Our journal accepts these contributions as well, so long as the letter is brief and to the point.10 The main purpose of case reports on ADRs is to stimulate vigilance and debate on this important subject. ADRs are frequently used as examples to provide practical advanced courses in clinical pharmacology and therapeutics. The ADR case,11 of diffuse myopathy presented here was used to stimulate discussion on drug interactions. An 83-year-old woman presented to our clinic with a chief complaint of progressive immobilizing myopathy starting a week ago. The patient also complained of lower back pain and revealed that her urine output had sharply decreased. This patient had a history of hypercholesterolemia and had taken simvastatin (20 mg once a day) for one year. She also had hypertension and was treated with a calcium channel blocker, amlodipine (5 mg four times daily) for ten months. Because she developed edema in her lower extremities, a loop diuretic, torasemide (5 mg once daily), was added. After six months her blood pressure remained at 180/90 mmHg, so her antihypertensive therapy was changed to mibefradil1* (50 mg once daily) one month prior to her admission. Three weeks after the change to mibefradil, the patent began experiencing muscle pain and gait disturbances. Although she has taken NSAIDs for several days, her problems have persisted. At the physical exam, it was found that she was unable to walk due to functional disability of her legs. She had a diffuse myopathy with suppressed deep-tendon reexes. Her blood pressure was 150/80, and she had a normal body temperature. The lab data were as follows: ALT 1.179 U/L, AST 988 U/L, phosphorus 2.45 nmol/L, creatine kinase 50.125 U/ml, potassium 7,2 mmol/L, serum creatinine 814 micromol/L, urea 46,1 mmol/l]L, with myoglo1 In 1998, Roche voluntarily withdraw mibefradil from the market because of its potentially harmful interactions with various drugs, especially statins. Pravastatin has a neutral drug interaction prole relative to cytochrome P450(CYP)-3A4 inhibitors (mibefradil, verapamil, itraconazole, bergamottin), but these substrates markedly increase systemic exposure to simvastatin and atorvastatin. Bergamottin, the primary furanocoumarin extracted from grapefruit juice, inhibits CYP-3A4 in liver microsomes and increases bioavailability of various drugs; a few deaths due to such food-drug interactions have been reported. Use of grapefruit during therapy with drugs that are metabolized by CYP-3A4 should be avoided.
binuria. Serum sodium, calcium and GGT were normal, and tests for HIV, hepatitis B and hepatitis C were negative. Serum levels of simvastatin and its metabolite betahydroxy-simvastatin acid, measured 24 hours after the last dose, were 4.95 and 1.02 ng/ml, respectively. The following questions related to this ADR case may be discussed with students or residents: 1) What is the cause of this adverse event? and 2) How could this adverse event have been prevented? To facilitate discussion, the students and residents should read several papers, including those given in the list of references.9-15 In conclusion, case reports may illustrate novel clinical problems and/or their solutions. These reports are published in the medical journals. However, case reports that make some important teaching point of what is already well known but often forgotten, are now rarely published in medical journals. Instead, such contributions sometimes appear as a Letter to the Editor or among the Images in Clinical Medicine journal section. An Interesting case report, especially if it is related to the ADR, can be used as teaching material, and it may be published in the manuals or handbooks of clinical pharmacology and therapeutics.16
Rajko Igi Nataa Stojakovi
References
Fraser J. How to publish in biomedicine500 tips for success, second edition. Oxford, Radcliffe Publishing, 2008. 2. Igi R, krbi R. Kako se piu i publikuju biomedicinska nauna saoptenja. Banja Luka/Laktai, GrafoMark, 2012. 3. Taylor RB. The clinicians guide to medical writing. New York, Springer, 2005. 1.
4. Loke YK, Price D, Derry D, Aronson JK. Case reports of suspected adverse drug reactionssystematic literature survey of follow-up. BMJ 2006;332:5. 5. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. BMJ 1982;284:24952. 6. Loke YK. Assessing the benet-harm balance at the bedside. BMJ 2004;7-8. 7. Ulfarson J, Mejyr S, Bergman U. Nurses are increasingly involved in pharmacovigilance in Sweden. Pharmacoepidemiol Drug Saf 2007;16:532-7. 8. Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011;15:1234. 9. Kai T. Statinineeljena dejstva i interakcije. Scr Med 2011; 42:132-9. 10. Ljubojevi G, Tomi N, Stojakovi N. Statin-induced leg pain at night. Scr Med 2011;42:110. 11. Stojakovi N, Igi R. Simvastatin-induced leg pain disapperas with pravastatin substitution. Srp Arh 2013 (in press). 12. Ratain M, Shepard D. Adverse drug reactions. In: Advanced clinical pharmacology and therapeutic s, course syllabus. Chicago, University of Chicago, 1999. 13. Jacobson RH, Wang P, Glueck CJ. JAMA 1997;277:296. doi:10.1001 14. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefadil from market? Lancet 1998;351:1829-930. 15. Jacobson TA. Comparative pharmacokinetic interaction proles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6. 16. Igic R. Praktikum iz farmakologije, toksikologije i klinike farmakologije. Tuzla, Medicinski fakultet, 1988.
UDK 615.33.03(497.6RS)
ORIGINAL ARTICLE
Outpatient Utilization of Systemic Antibiotics in the Republic of Srpska

ABSTRACT Introduction. Information on antibiotic utilization in the Republic of Srpska is limited. The aim of this study was to analyze antibiotic utilization in the community from 2007 to 2011 and to compare this data with antibiotic use in other European countries. Materials and Methods. We did a population-based study to analyze systemic antibiotic utilization by an outpatient population using Anatomical Therapeutic Chemical/Dened Daily Dose methodology. The results were expressed as the dened daily dose (DDD) per 1000 inhabitants per day. The data were obtained from the annual reports of the Agency for Drugs and Medical Devices of the Republic of Srpska and Public Health Institute. Results. Outpatient use of systemic antibiotics ranged between 21.51 DDD in the year with the highest use (2010) and 17.01 DDD in the year with the lowest use (2011). Penicillins were the most frequently prescribed antibiotic group, and amoxicillin was the most frequently prescribed drug. Cefalexin was the most frequently prescribed cephalosporin. Increased use of a second-generation cephalosporin, cefuroxime constituted almost a third of cefalexin consumption in 2011. Second-generation quinolones, mostly ciprooxacine, accounted for about 70% of total quinolones consumption, with rising third-generation drugs also in proportion to the increasing use. Erythromycine was the most frequently used macrolide, followed by long-acting azithomycin. Conclusion. Outpatient use of systemic antibiotics in the Republic of Srpska, at about 19 DDD, does not exceed that in Europe. As in other European countries, a shift between generations of drugs was noted for antibiotic use. Additional studies, including monitoring of seasonal variation impact on antibiotic use, are needed. KEY WORDS Antibiotics, drug utilization, outpatient care, pharmacoepidemiology.
DOI: 10.7251/SMD1301010M (Scr Med 2013;44:8-13)
Vanda Markovi Pekovi1 Svjetlana Stoisavljeviatara2 Ranko krbi2

1 Ministry of Health and Social Welfare 2 Department of Pharmacology and Toxicology School of Medicine University of Banja Luka Banja Luka, Republic of Srpska Bosnia and Herzegovina
Correspondence Vanda Markovi Pekovi Ministry of Health and Social Welfar Trg Republike Srpske 78 000 Banja Luka Republic of Srpska Bosnia and Herzegovina Tel + 51 339 427 e-mail: [email protected]
Submitted: February 23, 2013 Accepted: April 20, 2013
The overuse of antibiotics is the main force driving increased bacterial resistance, which poses a major threat to public health.1,2 The vast majority of human antibiotic utilization occurs within the community,3,4 where as much as 20 to 50% of antibiotic use may be questionable.5 Although antibiotics are prescription-only medicines, their use may also include selfmedication.6,7 In addition to higher rates of antimicrobial resistance, the consequences of antibiotic overuse and misuse include the risk of adverse side effects and higher costs.8,9 Costeffectiveness studies on antibiotic therapy now consider the inuence of bacterial resistance.10 In order to assess the extent
of the problem, it is necessary to collect and analyze data on antimicrobial prescribing in different clinical settings. The number of antibiotic prescriptions has remained fairly stable in recent years,11 but prescribing practices and outpatient antibiotic utilization vary widely across Europe.12,13 Data on the prevalence of resistance in human pathogens show geographic differences in resistance to various classes of antibiotics in Europe. For example, resistance remains low in northern European countries.3,14 Countries with the highest per capita antibiotic utilization have the highest resistance.15
Vanda, et al
Southern and Eastern European countries are recognized as high antibiotic-consuming countries with increasing use by outpatients.3,11,16 Taking these ndings into consideration along with its geographical location in Southeastern Europe, we assumed that the Republic of Srpska might have a high rate of antibiotic utilization compared with other European countries. However, information on outpatient antibiotic utilization in the Republic of Srpska is limited.17,7 The aim of this study is to measure and analyze the utilization of systemic antibiotics in the Republic of Srpska from 2007 to 2011 and to compare these data with those from other European countries. Materials and Methods A retrospective, observational, population-based study analyzed antibiotic utilization in the Republic of Srpska during the 5-year period from 2007 through 2011. The analysis covered antibacterials for systemic use (class J01, according to Anatomical Therapeutic Chemical (ATC) classication), excluding antifungals, antibacterials for tuberculosis, antitumoral and topical antibiotics. By legislation, antibiotics for systemic use are prescription-only medicines prescribed by a physician and dispensed by a pharmacist; they are only available in pharmacies. The data were collected from the annual reports of the Agency for Drugs and Medical Devices of the Republic of Srpska (Agency) for 2007-2008 and Public Health Institute (Institute) for 2009-2011 period. Although the Agency ceased to exist in 2009, data collection procedures were transferred to the Institute. Because of the mandatory annual reporting reTable 1. Yearly outpatient antibiotic use expressed in DDD
quired of health institutions on drug utilization, the collected data constitute the overall outpatient utilization of antibiotics for systemic use from 2007-2011. Drug utilization was analyzed using Anatomic Therapeutic Chemical/Dened Daily Dose (ATC/DDD) methodology, and the results were expressed as the dened daily dose (DDD) per 1000 inhabitants per day (DDD/TID). The ATC system classies the drugs according to the organ or system on which they act and by their chemical, pharmacological and therapeutic properties. All drugs were classied into ATC groups by their international nonproprietary names (INN). The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD/TID is a useful indicator for national and international comparisons, especially when areas to be compared have different numbers of inhabitants. Hereafter, for the purposes of this study, the acronym DDD will indicate DDD/TID. The DDD was calculated according to new DDD values.18 Although DDDs do not take into account different doses for children and might not adequately address differences in dosage and length of treatment for specic classess of antibiotic between countries,3 it was conrmed that DDD/TID is an acceptable measurement unit to express and compare outpatient antimicrobial use among countries.19 Statistics on total population number were taken from Republic of Srpska Institute of Statistics.20 Results Outpatient antibiotic use varied from 21.51 DDD in the year with a highest use (2010) to 17.01 DDD in the year with the lowest use (2011). Penicillins were the most frequently pre-
INN J01A J01C J01CA J01CE J01CR J01D J01DB J01DC J01DD J01EE J01F J01FA J01FF J01M J01 tetracyclines penicillins extended-spectrum beta-lactamase-sensitive combination of penicillins* cephalosporins rst generation second generation third generation sufonamides & trimethoprim macrolides and lincosamides macrolides lincosamides quinolones total
2007 1,89 11,58 8,56 2,35 0,64 1,96 1,51 0,45 na 1,55 1,67 1,67 na 1,33 19,98
2008 1,79 9,29 7,49 1,38 0,42 1,82 1,57 0,24 0,01 1,77 1,46 1,46 na 1,57 17,70
2009 1,85 10,98 9,20 1,40 0,37 2,64 2,04 0,57 0,03 0,92 1,44 1,43 0,006 1,46 19,29
2010 1,75 12,12 10,15 1,57 0,39 2,86 2,16 0,66 0,041 1,55 1,72 1,71 0,007 1,51 21,51
2011 1,55 8,41 6,10 0,98 1,33 2,30 1,58 0,68 0,040 1,40 1,70 1,68 0,013 1,64 17,01
INN = International Nonproprietary Name;*combination with -lactamase inhibitors; N/A = not applicable, i.e. not on the market
10
Figure 1. Outpatient use of J01 subgroups, expressed as % of total J01 consumption in DDD
Second-generation quinolones accounted for 67,8% of the total drugs in that class, and rst-generation quinolones contributed 32,2%, with the rising third generation contributing only a small proportion (0,3% 2009; 1,0% 2011). Utilization of a rst-generation quinolone, pipemidic acid, declined continuously from 0.24 DDD in 2007 to 0.17 DDD in 2011, while noroxacin utilization was approximately 0.3 DDD. Ciprooxacine was the most prescribed second-generation quinolone with increased consumption over time (Table 2) while ooxacin use decreased (0.07 DDD 2007; 0.003 DDD 2011). Doxycycline accounted for 93,4% of total outpatient tetracycline use; oxytetracycline and tetracycline use was minor and decreased over time. A short-acting macrolide, erythromycin, was the most prescribed drug of this class, followed by the long-acting azithomycin (Table 2) and an intermediate-acting macrolide clarithromycin (0.2 DDD 2007; 0.4 DDD 2011). Table 2 shows the ten most commonly prescribed antibiotics during the period observed in this study. Discussion Total outpatient antibiotic utilization was not as high as expected, based upon reported antibiotic use in Southern and Eastern Europe.3,12,14 Indeed, our average consumption of 19.1 DDD over the ve year period of 2007-2011 is comparable to that in European countries, where an average of 19.9 DDD was reported in 2009.21 The total outpatient antibiotic utilization in the Republic of Srpska in 2009 was similar to that in countries in our near surroundings, such as Croatia (21.2 DDD) or Bulgaria (18.6 DDD). The moderate use of systemic antibiotics in our country is comparable to that in countries with a long history of low antibiotic utilization, such as the Nordic countries.22 In contrast, there were large differences between neighboring Northern European countries. Outpatient antibiotic use in Europe in 2009 differed widely, varying by a factor of 3.5 between the country with the highest (38.6 DDD in Greece) and the lowest (11.1 DDD in Estonia).21 Unlike the increase noted in most European countries,16,21 our outpatient antibiotic use remained stable over the ve year period of observation. Differences in antibiotic use between countries might be explained by a number of factors, such as variations in incidence of community-acquired infections, culture, education, differences in drug regulation and in the structure of the national pharmaceutical market.3 Some differences in total outpatient antibiotic use in the European countries were likely inuenced by uctuations in availability of certain antibiotics, e.g., mostly narrow-spectrum penicillins, and the seasonality of outpatient antibiotic use.3,16,21 Fluctuations in antibiotic availability also occurred in our market, but due to the lack of relevant data, we were unable to evaluate the inuence of seasons. Further investigation of such variations may help to identify sources of inefciency in antibiotic therapy.12 Penicillins were the most frequently prescribed antibiotics in the Republic of Srpska and showed an increasing use, similar to other countries. Proportional use of NSP in total penicillin
J01C = Penicillins; J01D = Cephalosporins; J01F = Macrolides and lincosamines; J01M = Quinolones; J01A = Tetracyclines; J01E = Sulfonamides and trimethoprim DDD = Dened Daily Dose
scribed antibiotics in all years, ranging between 59% (2007) and 49,4% (2011), followed by cephalosporins, which ranged from 13,5% (2011) to 9,8% (2007) for total outpatient antibiotic use. The proportion of macrolides within the total antibiotic use ranged from 10,0% (2011) to 7,5% (2009); quinolones ranged from 9,6% (2011) to 6,7% (2007, and tetracyclines ranged from 10,1% (2008) to 8,1% (2010). Sulfonamides and trimethoprim were solely represented by sulfomethoxazole with trimethoprim, and their use varied from 8,2% (2011) to 4,8% (2009) (Table 1, Figure 1). Narrow-spectrum penicillins (NSP, J01CE) represented 14,5% of total antibiotic use, broad-spectrum penicillins (BSP, J01CA) 78,9% and combinations of penicillins with -lactamase inhibitor (COP, J01CR) made up 6,6% of total outpatient penicillin use (Table 1). Benzathine phenoxymethylpenicillin was the most used NSP with 11,2% of the total penicillin utilization by 2011 (1.4 DDD 2007; 1.0 DDD 2010; 0.2 DDD 2011), followed by phenoxymethylpenicillin, where we noted considerable uctuations in use (Table 2). Amoxicillin was the most used BSP (Table 2). The proportion of amoxicillin in total penicillin use was the form given with an enzyme-inhibitor (co-amoxicillin); this gure increased from 3,2% (2010) to 15,8% (2011) (Table 2). First-generation cephalosporins, namely cefalexin, represented 77% of the total use of that drug class. Second-generation cephalosporins contributed 22,1%, and third-generation drugs contributed 0,9% (Table 1). Cefuroxime was the most prescribed secondgeneration cephalosporin (Table 2), followed by cefaclor (0.2 DDD 2007; 0.1 DDD 2011).
Vanda, et al
11
Table 2. Ten most prescribed antibiotics for systemic use (DDD)
ATC J01CA04 J01DB01 J01AA02 J01EE01 J01CR02 J01MA02 J01CE02 J01FA01 J01FA10 J01DC02
INN amoxicillin cefalexin doxycycline sulfamethoxazole and trimethoprim amoxicilline and enyzme inhibitor ciprooxacin phenoxymethylpenicillin erythromycin azythromycin cefuroxime
2007 7.82 1.51 1.66 1.55 0.64 0.77 0.92 0.99 0.49 0.24
2008 6.64 1.57 1.66 1.77 0.42 1.03 0.33 0.75 0.45 0.06
2009 8.41 2.04 1.75 0.92 0.37 0.94 0.37 0.88 0.30 0.44
2010 9.62 2.16 1.67 1.55 0.39 1.00 0.15 1.10 0.32 0.50
2011 5.72 1.58 1.48 1.41 1.33 1.13 0.81 0.71 0.59 0.56
ATC = Anatomic Therapeutic Chemical; INN = International Nonproprietary Name; DDD = Dened Daily Dose
utilization was considerably less than that in Nordic countries (50%) but much higher than in France, Greece, Spain and Belgium (5%).16,23 We prescribed benzatin phenoxymethylpenicillin more often than phenoxymethylpenicillin, as did Austria, Croatia and the Czech Republic but not the Nordic countries.23 Both of these NSP were reimbursed. Amoxicillin was the most prescribed of all penicillins, accounting for about 70% of total outpatient penicillin utilization. It was used far more than ampicillin, which is almost entirely superseded by amoxicillin in most European coutries.23 Continuous decline in ampicillin use was also noted in our study. Amoxicillin utilization declined by 40% in 2011 followed with a 3.5 times increase in the use of co-amoxiclav (Table 2). Versporten et al. reported that BSP (mainly amoxicillin) use decreased in favor of COP in most countries participating in the European Surveillance of Antimicrobial Consumption (ESAC) project, where co-amoxiclav use reached 7 to 10 DDD in the high-consuming countries.23 This nding raises concern regarding the appropriate prescribing of co-amoxiclav for respiratory tract infections, which are one of the main reasons that antibiotics are prescribed in outpatients.24 Our co-amoxiclav utilization is still comparable to that of the low-consuming countries (Denmark, Finland),25,26 but close monitoring of COP utilization is needed especially because one more amoxicillin combination (with sulbactam) became available in 2011. Cefalexin was the most prescribed cephalosporin, mostly because it has been the only reimbursable cephaloporin for years. Predominant prescribing of a rst-generation cephalosporin was reported as well in Finland, Sweden and Iceland, but since 1997, cefalexin use decreased while most countries recorded proportionate increases in second- and third-generation cephalosporins, mostly cefuroxime.27 Increased utilization of oral cefuroxime (second-generation) and cexime (third-generation) was also noted in our study. Cephalosporin treatment of uncomplicated respiratory infections with a presumed etiology has increased, despite the lack of clinical indication.27,28 The appropriateness of cephalosporin use in
such circumstances should be questioned and closely monitored in compliance with existing guidelines for treatment of respiratory tract infections. We noted a shift from the quinolones that were predominantly used to treat urinary tract infections (pipemidic acid, noroxacin) to those used systematically (ooxacin, ciprooxacin, levooxacin). In addition, the use of quinolones in treatment of respiratory infections (third generation moxioxacin) has increased over time, similar to the ESAC study ndings on outpatient quinolone use in Europe.29 Ciprooxacin was the most prescribed quinolone with a continous increase in utilization (Table 2). Our rising quinolones utilization should be closely monitored in the view of seasonal variations, because other studies indicate a substantial increase in use of respiratory quinolones as well as an increase in use of so-called urinary tract quinolones, e.g. ciprooxacin, in the winter months.28 This inappropriate use of both older and respiratory quinolones will inevitably lead to emergence of resistant pneumococci, Escherichia coli and also of resistant Gram-negative bacteria.29,30 Removal of subsidisation in Denmark of both tetracyclines and uoroquinolones resulted in a rapid drop in utilization of these antibiotics.3 Noroxacine is now the only reimbursed quinolone. Tetracycline use with high seasonal variations declined signicantly in the European countries. This may reect the fact that prescription of antibiotics for respiratory tract infection is limited.31 Doxycyclin was the third most prescribed antibiotic over the ve year period of observation, but its use has diminished. Because of problems with resistance, doxycylin is no longer among the antibiotics recommended in the Netherlands for lower respiratory tract infections.31,32 Like in most European countries, we also noted that the newer antibiotics in almost all classes displaced older drugs, although narrow-spectrum and rst-generation penicillins are still widely prescribed for treatment of community-acquired infections in certain northern European countries.3 Pharma-
12
ceutical marketing can make doctors less sensitive to the costs and quality of prescribing drugs, and inuence their choice of competing drugs, as observed in the Netherlands.3 This could account for the growing use of newer antibiotics, 3 although most physicians eventually switch to newer antibiotics.12 Diagnostic labelling of respiratory tract infections as commom cold or bronchitis can affect antibiotic use as well, along with the propinsity of some physicians (high prescribers) to diagnose more bacterial infections than others (low prescribers).33 Under the capitation payment scheme, our doctors have less incentive to prescribe antibiotics, and the quality of treatment is not directly related to the quantity of antibiotics prescribed. Instead, it may be improved by our doctors ability to solicit patient compliance and reduce inappropriate antibiotic use. Educated individuals may refrain from using antibiotics because they are concerned about contributing to increased bacterial resistance.12 A combination of educational and restrictive interventions seems to be more efcient than any single intervention for reduction of antibiotic utilization.15 Thus far, data on the extent of antibiotic resistance and utilization are limited in the Republic of Srpska, although several studies2,3 indicate a correlation between antibiotic resistance and outpatient antibiotic use. However, a steady decline in utilization of some antimicrobial drug classes does not reect concomitant decline of resistance in pathogens under selective pressure. Mathematical models, as well empirical data, suggest that after reduction in prescribing, resistance will take longer to decline than it took to rise.34 For example, no decline in resistance against co-trimoxazole was observed in the United Kingdom even 10 years after it was no longer precribed.35 Besides legislative regulating of prescribing and dispensing of anibiotics, our policy interventions to improve antibiotics use included standard treatment guidelines, reimbursment prescribing policy restricted to rst-generation antibiotics and infection prevention (infection control and immunization). Unfortunately, comprehensive and systematic data on interventions designed to control outpatient antibiotic utilization are limited. In conclusion, outpatient use of systemic antibiotics in the Republic of Srpska does not exceed that in Europe. The trends in time and the shift between generations in our antibiotic use need further examination, including monitoring of seasonal variation and antibiotic resistance impact on antibiotic use. Better and continuous surveillance of antibiotic use and resistance rates, optimization of antibiotic use with diagnostic tests, strict compliance to the guidelines, and education of professionals and public could all improve antibiotic therapy in our community and others.
Authorship statement All authors contributed equally. Financial disclosure We declare that we have no conicts of interest.
References
1. Minalu G, Aerts M, Coenen S, et al. Application of mixed-effects models to study the country-specic outpatient antibiotic use in Europe: a tutorial on longitudinal data analysis. J Antimicrob Chemother 2001;66:vi79-vi87. Filippini M, Gonzlez Ortiz L, Masiero G. Assessing the impact of antibiotic policies in Europe. Quaderno n. 12-02. Decanato della Facolt di Scienze economiche. Lugano, 2011. Goosens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance a crossnational database study. Lancet 2005;365:579-87. European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union, November 2012. Available at: http://www.ecdc.europa. eu/en/eaad/documents/esac-net-summary-antibiotic-consumption.pdf. Accessed January 30, 2013. Wise R, Hart T, Cars O, et al. Antimicrobial resistance. BMJ 1998;317:609-10. Grigoryan L, Haajer-Ruskamp F, Burgerdorf J, et al. Self-medication with antimicrobial drugs in Europe. Emerg Infect Dis 2006;12:452-59. Markovi-Pekovi V, Grubia N. Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior. Pharmacoepidemiol Drug Safety 2012;21:1130 33. Gold HS, Moellering RC. Antimicrobial drug resistance. N Engl J Med 1996;335:1445-53. McGowan JE.Economic impact of antimicrobial resistance. Emerg Infect Dis 2001;7:28692. Sabes-Figuera R, Seg J, Puig-Junoy J, et al. Inuence of bacterial resistances on the ef ciency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2008;9:2332. Elseviers M, Ferech M, Vander Stichele R, et al. Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal uctuations. Pharmacoepidemiol Drug Saf 2007; 16:115-23. Masiero G, Filippini M, Ferech M, et al. Socioeconomic determinants of outpatient antibiotic use in Europe. Int J Public Health 2010;55:46978. Filippini M, Masiero G, Moschetti K. Socioeconomics determinants of regional differences in outpatient antibiotic consumption: Evidence from Switzerland. Health Policy 2006;78:77-92. Molstad S, Stalsby Lundborg C, Karlsson A, et al. Antibiotic Prescription Rates Vary Markedly Between 13 European Countries. Scand J Infect Dis 2002; 34:366-71. iman M, Srovin T, Pokorn M, et al. Analysis of the causes and consequences of decreased antibiotic consumption over last 5 years in Slovenia. J Antimicrob Chemotherapy 2005;55:758-63. Ferech M, Coenen S, Dvorakova K, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother 2006;58:408-12 Markovi-Pekovi V, Stoisavljevi-atara S. Outpatient utilization of antibiotics in the Republic of Srpska, in 2007 and 2008. Scr Med 2010; 41:22-28. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. WHO, Oslo. Available at: http://www.
2.
3.
4.
5. 6.
7.
8. 9. 10.
11.
12.
13.
14.
15.
16.
17.
18.
Vanda, et al
13
19.
20. 21.
22. 23.
24.
25.
26.
whocc.no/atc_ddd_publications/guidelines/. Accessed January 30, 2013. Monnet A, Molstad S, Cars O. Dened daily doses of antimicrobials reect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother 2004; 53:1109-11. Republic of Srpska Institute of Statistics. Statistical Yearbook of Republic of Srpska. Banja Luka, 2012. Adriaenssens N, Coenen S, Muller A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011;66: vi3-vi12. Bergan T. Antibiotic usage in Nordic countries. Int J Antimicrob Agents 2001;18:279-82. Versporten A, Coenen S, Adriaenssen N, et al. European Surveillance of Antimicrobial Consumption (ESAC):outpatient penicillin use in Europe (1997-2009). J Antimicrob Chemother 2011;66:vi13-vi23. Centre for Clinical Practice at NICE (UK). Respiratory Tract InfectionsAntibiotic Prescribing: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care. NICE Clinical Guideline 69, July 2008. National Institute for Health and Clinical Excellence, London, UK. Available at: www.nice.org.uk/nicemedia/pdf/ CG69FullGuideline.pdf. Accessed February 8, 2013. National Agency for Medicines and the Social Insurance Institution (Kela). Finnish statistics on medicines. Available at: http:// www.mea./instancedata/prime_product_julkaisu/mea/embeds/meawwwstructure/20681_Suomen_laaketilasto_2010_ netti.PDF. Accessed January 25, 2013. Statens Serum Institut, medstat.dk and date. Available at:
http://www.medstat.dk/en. Accessed January 25, 2013. 27. Versporten A, Coenen S, Adriaenssen N, et al. European Surveillance of Antimicrobial Consumption (ESAC):outpatient cephalosporin use in Europe (1997-2009). J Antimicrob Chemother 2011;66:vi25-vi35. 28. Woodhead M. Prescribing and guidelines: both must improve to combat antimicrobial resistance. Eur Respir J 2011;38:9-11. 29. Adraenssen N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009) J Antimicrob Chemother 2011;66:vi47-vi56. 30. iman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents 2003; 21:297-307. 31. Coenen S, Adriaenssens N, Versporten A, at al. Antimicrobial Consumption (ESAC): outpatient use of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in Europe (1997-2009) J Antimicrob Chemother 2011;66:vi57-vi70. 32. Verheij T, Hermans J, Mulder J. Effects of doxycycline in patients with acute cough and purulent sputum:a double blind placebo controlled trial. Br J Gen Pract 1994;44:400-4. 33. Hutchinson J, Jelinski S, Hefferton D, et al. Role of diagnostic labeling in antibiotic prescription. Can Fam Physician 2001;47:1217-24. 34. Austin D, Kristinsson K, Anderson R. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Poc Natl Acad Sci USA 1999; 96:1152-6. 35. Enne V, Livermore D, Stephens P, et al. Persistence of sulphonamide resistance in Echerichia coli in the UK despite national prescribing restriction. Lancet 2001;357:1325-8.
Vanbolnika upotreba antibiotika za sistemsku primjenu u Republici Srpskoj

APSTRAKT Uvod. Jo uvijek nema dovoljno objavljenih podataka o upotrebi antibiotika u Republici Srpskoj. Cilj ove studije je analizirati vanbolniku upotrebu antibiotika od 2007. do 2011. godine, i podatke uporediti sa podacima drugih Evropskih zemalja. Materijal i metode. Da bi se analizirala vanbolnika upotreba antibiotika za sistemsku primjenu provedena je retrospektivna studija upotrebe lijekova, uz primjenu metodologije anatomsko-hemijsko-terapijske klasikacije lijekova i denisane dnevne doze. Rezultati su izraeni u denisanim dnevnim dozama (DDD) na 1000 stanovnika na dan. Podaci su preuzeti iz godinjih izvjetaja Agencije za lijekove i medicinska sredstva Republike Srpske i Instituta za javno zdravstvo. Rezultati. Vanbolnika upotreba antibiotika za sistemsku primjenu kretala se izmeu 21,51 DDD u godini sa najveom upotrebom (2010.) i 17,01 DDD u godini sa najniom upotrebom (2011.). Penicilini su bili najee propisivana grupa antibiotika, a amoksicilin najpropisivaniji antibiotik. Cefaleksin je bio najee propisivan cefalosporinski antibiotik. Primijeen je porast upotrebe cefalosporina druge gerenacije cefuroksima, ija je upotreba 2011. godine inila treinu upotrebe cefaleksina. Upotreba druge generacije hinolonskih antibiotika, uglavnom ciprooksacina, inila je oko 70% ukupne upotrebe hinolonskih antibiotika, uz porast tree generacije hinolona. Eritromicin je bio najee propisivan makrolidni antibiotik, a slijedi dugodjelujui makrolidni antibiotik azitromicin. Zakljuak. Vanbolnika upotreba antibiotika za sistemski primjenu u Republici Srpskoj nije iznad evropskog prosjeka, i kree se oko 19 DDD. Slino drugim evropskim zemljama, i kod nas je primijeen prelazak na propisivanje novijih generacija antibiotika. Potrebno je provesti daljnja istraivanja upotrebe antibiotika, ukljuujui i uticaj sezonskih varijacija na upotrebu. KLJUNE REI Antibiotici, upotreba lijekova, vanbolnika zdravstvena zatita, farmakoepidemiologija.
14
UDK 616.89-008.454-056.24
ORIGINAL ARTICLE
Sanja Draa
College of Applied Sciences Kruevac 37000, Serbia Correspondence Sanja Draa, MD, PhD College of Applied Sciences irila i Metodija 22-24 Kruevac 37000, Serbia Phone: + 38137423050 Fax: + 38137420761 E-mail: [email protected]
The Inuence of Gender and Laterality of Lesion on Severity of Post-Stroke Depressive Symptoms
ABSTRACT Introduction. This prospective study evaluates the effects of gender and stroke lateralization-related differences on the severity of depressive symptoms. Materials and Methods. A total of eighty right-handed patients (20-80 years of age) were enrolled prospectively. These individuals were in the subacute phase of their rst, single unilateral stroke. Thirty-ve (44%) were women. The majority of patients (74%) had cerebral infarcts, and 26% had an intracerebral hemorrhage. The Beck Depression Inventory (BDI) edition 2, was used to assess the severity of depressive symptoms. (A cutoff point of 14 or higher was applied to distinguish patients with depressive symptoms). Results. At discharge from rehabilitation, the BDI-II identied depressive symptomatology in 33% of patients (n=26 patients). Although the frequency of depressive symptoms was similar in both sexes, we identied signicant differences in the frequencies of post-stroke depressive symptoms between men and women with different localization of stroke. Females with poststroke depressive symptomatology were more likely to have a cortical lesion, whereas males with poststroke depressive symptomatology were more likely to have a subcortical lesion. We also noted that women had signicantly more severe depressive symptoms (higher mean BDI-II scores) than men. In addition, the severity of depressive symptoms was related to the laterality of lesion in men but not in women. Men with left-sided stroke had signicantly more severe depressive symptoms than men with right-sided stroke. Conclusion. Our paper emphasizes the association of gender and laterality of lesion with the severity of post-stroke depressive symptoms. KEY WORDS Gender, stroke, lateralization, depressive symptoms.
DOI: 10.7251/SMD1301014D (Scr Med 2013;44:14-18)
Submitted: January 2, 2013 Accepted: February 3, 2013
Common behavioral and cognitive sequalae of stroke include depression, psychosis, anxiety and personality changes among others.1,2 The prevalence of post-stroke depression (PSD) is reported to range from less than 30% to more than 50%, depending on methodological differences between studies and especially on the criteria for depression and the period over which depression is assessed.2,3Neither the causes nor the mechanisms of PSD are well understood. The higher prevalence of mood symptoms in stroke survivors, as compared with orthopedic patients with the same degree of functional disability, argues against PSD as a purely psychological reaction. 4 PSD likely
has a multifactorial etiology with both reactive and organic components. The evidence in humans suggests that injury of specic brain areas with hemispheric and anterior-posterior asymmetries increases the risk of developing PSD. Robinson et al in a series of articles emphasized that leftsided stroke may be associated with a higher incidence of depression,5,6 although some investigators were unable to replicate these results.3 It has been suggested that the strength and direction of experienced emotions should be evaluated within the context of asymmetrical activation of left-frontal (dominance) versus right-frontal (submis-
Draa
15
sion) brain regions.7 More recently, changes of noradrenergic, serotonergic, and dopaminergic pathways, and neurotransmitter receptor sensitivity have been implicated in the pathogenesis of PSD. The question of much higher lifetime prevalence of major depressive disorders in women compared to men, including stroke survivors, remains unanswered.8,9 However, numerous gender-related differences in neuroanatomy and neurochemistry are documented. It appears that males and females recruit different brain regions during emotion recognition of happy or sad facial expression.10 A wealth of preclinical and clinical evidence indicates gender-related differences in serotonin (5-hydroxytryptamine, 5-HT) neurotransmission.11 Serotonin has been implicated in the pathology of mood disorders, sleep and eating disorders and schizophrenia. It is important to emphasize that patients with improved depression perceived their recovery as signicantly greater than those with continued depression; they also felt that their physical condition and social participation had improved in contrast to those with less improvement in depression.12 This prospective study was designed to evaluate the severity of depressive symptoms related to gender- and stroke lateralization in patients after their rst, single unilateral stroke. Materials and Methods All patients in the subacute phase of stroke admitted to the rehabilitation clinic Dr M. Zotovi in Belgrade, during a 3-year period were registered prospectively and considered for inclusion for this study. The mean time period from the onset of illness to admission into the study was 91.7 days. During the acute phase of stroke the patients were hospitalized at neurology departments in several hospitals, where the diagnosis of stroke was based on history, clinical examination and neuroradiological ndings obtained by head computed tomography (CT) or magnetic resonance imaging (MRI). On admission to rehabilitation, all patients were assessed by clinical and neurological examinations and neuropsychological and language testing. The severity of the initial stroke was measured by the National Institutes of Health Stroke Scale (NIHSS) score, which is a widely used and validated tool for assessment of stroke severity.13 According to CT and/or MRI ndings, the patients were classied based on localization of the cerebral lesion in the right hemisphere (RH) or left hemisphere (LH) as well as in the cortex or subcortex. Inclusion criteria were: the rst-ever single unilateral stroke, both genders, age 20-80 years, CT or MRI examination performed in the acute hospital phase of stroke and right-handedness (dened by the Clinical test of hand dominance, Kimura & Vanderwolf, 1970). Exclusion crite-
ria were: history of previous stroke, bilateral or multiple cerebral lesions caused by stroke, history of previous psychiatric illness, severe post-stroke cognitive impairment, severe post-stroke aphasia and presence of chronic disabling conditions. None of the selected patients were treated with antidepressant medication or any drug with depression as a known side effect. The rehabilitation plan was designed by the same physiatrist for all patients; it included physical therapy, occupational therapy, and if necessary, speech therapy. The rehabilitation program was performed 5 days per week over 6-8 consecutive weeks. All patients included in this study completed the rehabilitation program. After receiving a detailed study description, participants provided informed consent to a research protocol, which was carried out in accordance the principles of the Declaration of Helsinki (1964). At the time of discharge, on average 5.5 months after stroke onset (range 3.5-6 months), we evaluated the severity of PSD. The patients completed the 21-item Beck Depression Inventory, edition 2 (BDI-II), which is a screening instrument designed to assess the severity of depression, not whether a patient meets diagnostic criteria for that disorder.14 The inventory contains 21 items and identies symptoms and attitudes associated with depression. The respondent must recall, based on the previous two weeks, the relevance of each statement relating to the following: sadness, pessimism, sense of failure, loss of pleasure, guilt, expectation of punishment, dislike of self, self accusation, suicidal ideation, episodes of crying, irritability, social withdrawal, indecisiveness, worthlessness, loss of energy, insomnia, irritability, loss of appetite, preoccupation, fatigue, and loss of interest in sex. A BDI-II cutoff point of 14 or higher was applied to distinguish the patients with a depressive symptomatology in the clinical range from those with less severe symptomatology. Statistical analysis. Characteristics of the participants are described by mean and standard deviation (SD) for continuous variables and by frequency and percentage for categorical variables. A difference in mean values of BDI-II or NIHSS scores between two groups of patients was determined by Student t-test. The chi square test was used to assess differences in categorical variables between men and women. Probability values <0.05 were considered signicant. Results A total of eighty right-handed patients (mean age 55.4 years, SD = 10.6 years, range 20-80 years) in the subacute phase of their rst-ever single unilateral stroke were enrolled prospectively. Thirty-ve (44%) were female, and 45 (56%) were male. There was no signicant difference in mean ages between men and women (55.1 and 55.6, respectively).
16
Fifty-seven % of females (20 of 35), and 45% of males (20 of 45) had a stroke in the LH, whereas 43 % of females (15 of 35) and 55% of males (25 of 45) had a stroke in the RH. Further, 57 % of females (20 of 35), and 40 % (18 of 45) of males had a stroke localized cortically, whereas 43 % of females (15 of 35) and 60 % of males (27 of 45) had a subcortical stroke. Prior to the initiation of rehabilitation the mean NIHSS score was similar for both men (6.51) and women (6.57) (Table 1).
Table 1. Frequencies of post-stroke depressive symptomatology in men and women with different localization of stroke (Chi square test = 14.197; DF = 3; p<0.01)
cies of post-stroke depressive symptoms between men and women with different localizations of stroke (Chi square test = 14.197; DF = 3; p<0.01). Females with poststroke depressive symptomatology were more likely to have a cortical lesion (83%, 10 of 12 patients), whereas males with poststroke depressive symptomatology were more likely to have a subcortical lesion (86%, 12 of 14 patients, Table 1). We also found that women had signicantly (p<0.01) more severe depressive symptoms (higher mean BDI-II score) than men. The severity of depression was dependent on stroke lateralization in males, but not in females. Men with left-sided stroke had signicantly (p<0.01) more severe depressive symptoms (higher mean BDI-II score) than men with right-sided stroke (Table 2). Discussion The frequency of depressive symptoms (33%) in our study is comparable to the prevalence of PSD reported in previous clinical trials. The prevalence of PSD ranges from less than 30% to more than 50%, depending on the methodological differences between studies, specically the criteria for depression and the period over which depression is assessed.2,3 Bearing in mind that previous clinical trials indicate that recognized risk factors for post-stroke depression include stroke severity and disability, it is important to note that prior to initiation of rehabilitation we noted no gender-related difference in the severity of clinical stroke. However, we found that women with a rst-ever single unilateral stroke had signicantly more severe depressive symptoms than men. Furthermore, the severity of symptoms was related to the laterality of lesion in men, but not in women. Men with left-sided stroke had signicantly more severe depressive symptoms than men with right-sided stroke. Our results concur with previous studies that demonstrated a greater prevalence of post-stroke depressive symptoms in women than in men. However, all of these results remain inconclusive because the question of much higher lifetime prevalence of major depressive disorders in women remains unanswered.9 Gender-related differences in neuroanatomy and neurochemistry have drawn increasing interest over the past
Stroke localization Women (n = 12 with depressive symptoms) RH cortically LH cortically RH subcortically LH subcortically Men (n = 14 with depressive symptoms) RH cortically LH cortically RH subcortically LH subcortically
Frequency (n)
33 % (4 of 12) 50 % (6 of 12) 0 % (0 of 12) 17 % (2 of 12)
14 % (2 of 14) 0 % (0 of 14) 29 % (4 of 12) 57 % (8 of 14)
Abbreviations: RH = right hemisphere, LH = left hemisphere
Frequency and severity of post-stroke depressive symptomatology At discharge from rehabilitation, the BDI-II identied depressive symptomatology in 33% of patients (26 of 80) where the cutoff point of 14 or higher was applied. The frequency of depressive symptoms in the clinical range was 32% in males (14 of 45) and 34% in females (12 of 35). There was no signicant difference between these frequencies (Chi square test = 0.09; DF = 1; p>0.05). However, we identied a signicant (p<0.01) difference in the frequen-
Table 2. Differences in mean values of BDI-II scores between men and women, as well as between men or women with right-sided or left-sided stroke
BDI-II Mean (SD)
Men/Women (n = 45) (n = 35) 10.14 (7.30)/13.25 (8.35)
Men RH/Men LH (n = 25) (n = 20) 8.96 (6.92)/11.60 (7.51)
Women RH/Women LH (n =15) ( n=20)
12.47 (7.97)/13.85 (8.74) 1.211 (DF =33) >0.05
T P
4.568 (DF =78) <0.01
3.198 (DF =43) <0.01
Abbreviations: BDI = Beck Depression Inventory, SD = standard deviation, RH = right hemisphere, LH = left hemisphere.
Draa
17
decades, including differences in the size of brain nuclei, regional concentrations of neuroregulators, pharmacological response and behavior.9,12 Men synthesize 5-HT signicantly faster than women,15 whereas 5-HT transporters are selectively decreased in an age-specic manner in depressed women, but not in depressed men.10 Also, gender-specic differences are apparent in brain regions involved in regulating negative or positive emotions.11,16,17 Numerous clinical measurements on functional cerebral asymmetries indicate that women are less lateralized than men for a variety of cerebral functions. The facial recognition of emotion is distributed more bilaterally in females compared to males, whereas studies of transient mood induction triggered by viewing emotional pictures registered more neural activities in the bilateral superior temporal gyri and cerebellar vermis in females who viewed negative emotional pictures than in male viewers.18-20 Furthermore, reports on gender-specic differences in hemispheric recruitment suggest that men are right-hemisphere dominant, while the female pattern indicates dominance of the left hemisphere.21 Importantly, functional cerebral asymmetries likely uctuate across the menstrual cycle as a result of estrogen and/or progesterone-related modulation of inter-hemispheric inhibition.22 Evidence suggests that the injury of specic brain areas in humans increases the risk of developing PSD. In particular, the occurrence of PSD has been linked to injuries of the left anterior frontal lobe and left caudate nucleus, as well as bilateral injuries of the anterior frontal and temporal lobes and caudate nuclei.6,23 Astrom et al. found that a left-sided lesion was the most important predictor of immediate depression; the occurrence of major depression in left-sided lesions was 10 times greater than in lesions in the right hemisphere.24 Some other authors have been unable to replicate this association of lesion location and PSD.3 A wealth of preclinical and clinical evidence supports the concept of functional cerebral asymmetries for neurotransmitter systems, including neurotransmitter levels, reuptake transporters and receptors, and the effects of drugs that act on these neurotransmitter systems. Two decades ago Mayberg et al. reported right-left asymmetry in functioning of serotonin in healthy normal subjects and stroke patients..25 Later Fitzgerald suggested that 5-HT preferentially activates the right hemisphere through some unknown mechanism.26 Postmortem binding studies done with brain tissue from mentally normal humans and the tricyclic antidepressant imipramine (which binds with high af nity to the 5-HT reuptake transporter) indicated higher binding values in the orbitofrontal cortex (connected by the efferent projections with the serotonergic raphe nuclei) of the right hemisphere than in the left hemisphere.27,28 If men are more lateralized than women for a variety of cerebral functions,18-20 if the male pattern of dominance is characterized by the right hemisphere,21 and if there is se-
rotonergic predominance in the right hemisphere, 26 this might explain why we found more severe depressive symptoms in men with left-sided lesions. We recognize that our study has limitations. The sample size is small, and the stroke patients participating in the study cannot be considered a random sample. We assessed the severity of depressive symptoms, but not the presence of a diagnosis of depression. For all these reasons, the results of this study cannot be generalized to the entire population of unselected stroke survivors. Despite these shortcomings, our paper emphasizes the association of gender and laterality of lesion with the severity of post-stroke depressive symptoms. The nature of this complex association requires further investigation with a larger number of patients and tools for examining neurotransmitter systems.
Financial disclosure I declare that I have no conicts of interest.
References
1. Starkstein SE, Robinson RG. Neuropsychiatric aspects of cerebral vascular disorders. In: Yudofsky SC, Hales RE, editors. The American Psychiatric Textbook of Neuropsychiatry. Washington DC, APA Press, 1992. Kneebone II, Lincoln NB. Psychological Problems after Stroke and Their Management: State of Knowledge. Neurosci Med 2012;3:83-9. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005;36:133040. Folstein MF, Maiberger R, McHugh PR. Mood disorder as a specic complication of stroke. J Neurol Neurosurg Psychiatry 1977;40:1018 20. Morris PL, Robinson RG, Raphael B, Hopwood MJ. Lesion location and post-stroke depression. J Neuropsychiatry Clin Neurosci 1996;8:399403. Shimoda K, Robinson RG. The relationship between poststroke depression and lesion location in long/term follow up. Biol Psychiatry 1999;45:187-92. Demaree HA, Everhart DE, Youngstrom EA, Harrison DW. Brain lateralization of emotional processing: Historical roots and a future incorporating Dominance. Behav Cogn Neurosci Rev 2005;4:3-20. Paradiso S, Robinson RG. Gender differences in post-stroke depression. J Neuropsych Clin Neurosci 1998;10:41-7. Angst J, Gamma A, Gatspar M, Lepine JP, Mendlewicz J, Tylee A. Gender differences in depression: Epidemiological ndings from the European DEPRES I and II studies. Eur Arch Psychiatry Clin Neurosci 2002;252:201-9. Lee TMC, Liu HL, Hoosain R, Liao WT, Wu CT, Yuen KSL. Gender differences in neural correlates of recognition of happy and sad faces in humans assessed by functional magnetic imaging. Neurosci Lett 2002;333:13-16. Staley J, Sanacora G, Tamagnan G et al. Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry 2005;59:407.
2.
3.
4.
5.
6.
7.
8. 9.
10.
11.
18
12. Saxena SK, Ng TP, Koh G, Yong D, Fong NP. Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? Acta Neurol Scand 2007;115:33946. 13. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology af rms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711. 14. Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screeening instruments for depression in stroke patients. Psychosomatics 2002;43:386-93. 15. Nishizawa S, Benkelfat C, Young S et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 1997;94:530813. 16. Hofer A, Siedentopf CM, Ischebeck A, Rottenbacher MA, Verius M. Gender differences in regional cerebral activity during the perception of emotion: A fMRI study. Neuroimage 2006;32:854-62. 17. Mak AKY, Hu Z, Zhang JXX, Xiao Z, Lee TMC. Sex-related differences in neural activity during emotion regulation. Neuropsychologia 2009;47:2900-8. 18. Crucian GP, Berenbaum SA. Sex differences in right hemisphere
tasks. Brain Cogn 1998;36:37789. 19. Dra a S. Gender-specic functional cerebral asymmetries and unilateral cerebral lesion sequalae. Rev Neurosci 2010;21:421-5. 20. Borod J. Interhemispheric and intrahemispheric control of emotions: a focus on unilateral brain damage. J Consult Clin Psychol 1992;60:339-48. 21. Dra a S. Differences in cerebrogenic cardiac disturbance in men and women. Lancet Neurol 2012;11:842. 22. Hausmann M. Functional cerebral asymmetries during the menstrual cycle: a crossectional and longitudinal analysis. Neuropsychologia 2002;40:808-16. 23. Tuppler LA, Ranga K, Krishnan R et al. Anatomic location and laterality of MRI signal hyper-intensities in late-life depression. J Psychosom Res 2002;53:66576. 24. Astrom M, Adolfsonn R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993;24:97682. 25. Mayberg HS, Robinson RG, Wong DF, et al. PET imaging of cortical S2-serotonin receptors after stroke; lateralized changes and relationship to depression. Am J Psychiatry 1988;145:937-43. 26. Fitzgerald PJ. Whose side are you on: Does serotonin preferentially activate the right hemisphere and norepinephrine the left? Med Hypotheses 2012:79;250-4. 27. Demeter E, Tekes K, Majorossy K, et al. The asymmetry of 3Himipramine binding may predict psychiatric illness. Life Sci 1989;44:140310. 28. Arato M, Frecska E, Tekes K, MacCrimmon DJ. Serotonergic interhemispheric asymmetry: gender difference in the orbital cortex. Acta Psychiatr Scand 1991;84:11011.
Uticaj pola i lateralizacije lezije na teinu postapoplektine depresivnosti

APSTRAKT Uvod. Cilj ove prospektivne studije bio je da se utvrdi postojanje razlika u teini postapoplektine depresivnosti u zavisnosti od pola i lateralizacije lezije. Materijal i metode. Ukljueno je ukupno 80 desnorukih bolesnika u subakutnoj fazi prvog unilateralnog modanog udara, starosti 20-80 godina. Od ukupnog broja bolesnika 35 (44%) su bile ene. Prema kategoriji modanog udara, 59 (74%) bolesnika je imalo cerebralnu ishemiju, a 21 (26%) intracerebralnu hemoragiju. Kao instrument istraivanja je koriena Bekova skala za procenu depresivnosti-II (upotrebljen je granini skor 14). Rezultati. Po zavretku rehabilitacije, registrovana je postapoplektina depresivnost u 33% (n=26) bolesnika. Iako je uestalost postapoplektine depresivnosti bila priblino jednaka kod oba pola, registrovana je znaajna razlika u uestalosti postapoplektine depresivnosti izmeu polova sa razliitom lokalizacijom modanog udara. ene sa utvrenom depresivnom simptomatologijom su znaajno ee imale leziju korteksa, dok su mukarci sa utvrenom depresivnom simptomatologijom znaajno ee imali leziju subkorteksa. Pokazano je da ene ispoljavaju znaajno teu simptomatologiju postapoplektine depresije (vie srednje vrednosti BDI-II skora) u odnosu na mukarce. Takoe, registrovana je statistiki znaajna razlika u teini depresivne simptomatologije u zavisnosti od lateralizacije lezije kod mukaraca, ali ne i kod ena. Zakljuak. Rezultati ove studije ukazuju na znaaj pola i lateralizacije lezije na teinu postapoplektine depresivne simptomatologije. KLJUNE REI Pol, modani udar, lateralizacia, depresivni simptomi.
19
UDK 615.03:613.2-099
ORIGINAL ARTICLE
Robert L. Epstein Greg L. Epstein

College of Applied Sciences Mercy Center for Corrective Eye Surgery McHenry, Illinois Correspondence Robert L. Epstein, MD, MSEE Mercy Center for Corrective Eye Surgery McHenry, IL USA Email: [email protected]
Abbreviated UVA-Riboavin Corneal CollagenCross-linking for Keratoconus and Post-LASIK Ectasia

ABSTRACT Introduction. To determine the effect of corneal collagen cross-linking treatment on keratoconus and post-LASIK ectasia particularly after an abbreviated exposure to ultraviolet light exposure. Materials and methods. Fifty-one eyes of 34 patients were treated with epithelium-off UVA-riboavin corneal collagen cross-linking for either 20 minutes or 30 minutes as part of a US.FDA clinical study. The study involved eyes with keratoconus but with no prior operation (virginal), patients who had undergone prior intracorneal ring segments, those with keratoconus regression after keratoplasty, and those with post-LASIK ectasia. We report follow up results from three months to one year. Results. In the virginal keratoconus group all 83% ofeyes having 20-minute UVA exposure and 75% of those having 30-minute of UVA exposure experienced corneal attening or stabilization at 6 months post-operatively with visual improvement in both groups. The average patient age in the virginal keratoconus group was 34.5 years. Seventy ve percent of virginal keratoconus eyes of patients under age 40 but only 33% of eyes of patients over age 40 experienced statistically signicant corneal attening at six months postoperatively. Average vision improved at six months post-operatively over pre-operative levels by -0.0744 logMAR units in the 20 minute group, and by -0.0869 logMAR units in the 30 minute group. Post-LASIK ectasia patients, with an average age of 58.2 years, had slight overall curvature attening of -0.75D but without visual improvement one year post-operatively. No one experienced peri-operative complications. Topographic subtraction mapping revealed variations in the power of the cross-linking effect on different portions of the cornea Conclusion. Cross-linking appears safe. It is effective in most young patients causing corneal attening and can stabilize eyes with post LASIK ectasia but acts more slowly in older patients. The cross-linking effect may be more pronounced in individuals with darker pigmentation. Cross-linking can produce occasionalverysignicant corneal attening. The cross-linking effect increases with time. KEY WORDS Cross-linking, keratoconus, riboavin, post-LASIK ectasia, collagen cross-linking
DOI: 10.7251/SMD1301019E (Scr Med 2013;44:19-24)
Submitted: January 30, 2013 Accepted: March 28, 2013
Keratoconus is an important cause of visual loss that can severely affect relatively young and otherwise apparently healthy people. Also there is association of keratoconus with disease. Keratoconus is associated with eczema, allergy and asthma 1, as well as with Marfan syndrome and with Down syndrome 2. There is a high incidence of sleep
apnea among keratoconus patients 3, and keratoconus patients may have reduced life expectancy 4. Early visual decline may resemble the optical changes of youth. But what is not normal is the need for increasing astigmatic correction that is typically seen in developing
20
keratoconus. With disease progression eyeglasses cannot correct vision to normal. Visual loss from keratoconus is often misdiagnosed at rst as being from amblyopia unless there is a search for and comparison with old records from previous eye doctors. Soft lenses and then rigid contact lenses become necessary for adequate vision, but when these lenses become increasingly uncomfortable and more poorly tting, surgical treatment is necessary to improve vision. Vigorous eye rubbing makes the disease worse and patients should be discouraged from this practice.5,6 The mainstay of surgical treatment for keratoconus has included corneal transplantation with its long healing period, risk of rejection, infection, and corneal rupture. Commonly transplantation requires the patient to wear rigid contact lenses after surgery in order to achieve optimum vision. Surface excimer laser treatment of the cornea after healing may be indicated to help vision in some cases. Corneal grafting, either full thickness or deep anterior lamellar keratoplasty remains necessary for some cases of advanced keratoconus, yet even that may not stop visual decline because keratoconus persists in the host cornea. More recently, the implantation into the corneal wall of two, or possibly more effectively just one7, polymethy methacrylate ring segment has helped to regularize the shape of the keratoconus cornea. However, this bracing effect does not stop the basic disease process which usually continues. A condition called post-LASIK ectasia can occur as a result of the normal sculpting of the cornea in laser refractive surgery, including either LASIK or the surface laser vision correction known as PRK. It closely mimics the visual distortion of keratoconus. Some of the victims of post-LASIK ectasia may have had an unrecognized early stage of keratoconus, or forme fruste keratoconus, but others show no signs of the disease whatsoever, even when tested by any method in current technology. Detection of risk factors for post-LASIK ectasia is a subject of considerable interest and research. 8-14 An increased number of patients with forme fruste keratoconus tend to seek laser vision correction; the incidence has been documented to be in some cases as high as 9%. 15 Fortunately, some years ago Spoerl, Huhle, and Seiler 16 published a procedure called corneal collagen cross-linking with riboavin that provided a partial solution to the problem of ectatic and keratoconic corneas. Studies from their institute and many others have advanced the eld with over 400 papers having been published since that time. Although the complete mechanism of keratoconus is not known, it is due in part to inadequate cross-linkages between collagen brils in the cornea and further degradation by metalloproteinases. 17,18 Corneal collagen crosslinking with riboavin is an oxidatative process that riboavin promotes in the presence of ultraviolet light.
Cross-linking causes immediate corneal stiffening even in cadaver tissue. Along with that stiffening cross-linking causes actual keratocyte destruction, swelling and corneal stromal remodeling in living corneas. 19,20 Riboavin presently is critical to the cross-linking process and riboavin penetrates poorly 21 through an intact corneal epithelium, however much work is occurring to increase the epithelial permeability including recently the addition on an experimental basis of vitamin E TPGS to the riboavin solution22. Collagen cross-linking is a successful adjunct to the use of antibiotics in certain dif cult corneal infections 22, and there is evidence that cross-linking may actually reduce the degree of edema and improve vision in some patients with persistent corneal edema occurring after cataract surgery and corneal edema from Fuchs dystrophy 23. Corneal collagen cross-linking is not yet approved by the United States Food and Drug Administration (US FDA) although it is freely available in certain eye centers worldwide Materials and Methods Fifty-one eyes of 34 patients underwent UVA-riboavin, corneal collagen cross-linking, with epithelial removal. This was the rst part of a three year clinical study on the safety and effectiveness of cross-linking as well as a comparison of the relative effects of 30 minutes versus 20 minutes of ultraviolet exposure. Cross-linking was performed for eyes with advancing keratoconus, with post-LASIK ectasia, and with advancing keratoconus recurring years after corneal transplantation. This report details the results of the cross-linking in forty-ve eyes where patients were re-evaluated with three months to one year of follow up. All patients received complete eye exams at each visit including endothelial cell photography and also ve Pentacam Scheimpug photographs of each eye. Individuals who would most likely benet from cross-linking and also from intracorneal ring segments (ICRS) were given a choice of two protocols: either having ICRS rst and cross-linking 90 days later or having cross-linking rst, then ICRS one year later. Because the measure, maximal anterior corneal curvature, Kmax, is the most sensitive indicator of corneal curvature change from cross-linking, 24 those values were tabulated as part of the current clinical study. We have shown 25 that based on a comparison of the average of ve Kmax values taken at each visit, the 95% condence level of true Kmax change is a measured difference of at least 0.678 D using the Pentacam HR (Oculus Optikgerte GmbH, Wetzlar, Germany). Thus, one reasonable criterion for judging the ef cacy of cross-linking is a change of 0.678D or more Kmax based on ve readings. That criterion is used here. All eyes in the study had the cross-linking procedure following the removal of corneal epithelium. Then an initial
Epstein
21
14 minute corneal soaking was done by dripping 0.1% riboavin upon the cornea every two minutes. This step was followed by the application by random assignment of either 20 minutes or 30 minutes of ultraviolet light at 370 nm using the UV-X device (Peschke Meditrade, Huenenberg, Switzerland). Either Mediocross brand (Streuli Pharma distributed by Peschke Meditrade) isotonic riboavin 0.1% in 20% dextran or the hypotonic 0.10% riboavin in 0.9% saline was used based on the minimal corneal pachymetry readings. All patients signed detailed consent forms, and the clinical study was performed in a manner approved by both the U.S. Food and Drug Administration and by the Institutional Review Board of the Mercy Health System, the parent company of this surgical practice. SPSS 16.0 (IBM Armonk, New York , USA) and Excel 2007 (Microsoft Corp. Redmond, WA, USA) were used for the statistical analyses. Cross-linking was done under sterile conditions. Pachymetry of each eye averaged at least 400 microns throughout the treatment. Any eye undergoing cross-linking that developed stromal corneal pachymetry less than 410 microns was treated with hypotonic riboavin, and the thicker corneas were cross-linked with isotonic riboavin. Ultrasonic pachymetry was measured at three minute intervals. Under rare circumstances when pachymetry dipped below 400 microns during cross-linking a single drop of sterile water was applied to the cornea. Within seconds this treatment increased the corneal thickness by 20 microns or more. Epithelium was removable gently with an Amoils brush but for post-surgical eyes just ten seconds of 70% ethanol and gentle rubbing with a WeckCell sponge was found to be suf cient. All eyes with post-LASIK ectasia had epithelium removed using alcohol rather than the Amoils brush. In general the epithelium in eyes with keratoconus was found to be less rmly attached than in normal eyes. Eyes in our study included those with virginal keratoconus and no prior surgery, those with prior refractive surgery, those with prior intracorneal ring treatment, and those with prior corneal transplantation for keratoconus. Included in the study were a total of 41 eyes with virginal keratoconus, that is, keratoconus as distinguished from post-LASIK ectasia in eyes that had not had intracorneal ring placement or corneal transplantation. Of these 41 eyes, 36 were at least one month post cross-linking. The overall patient age in the study was 38.9 +/-13.7 years with the post-LASIK ectasia patients being considerably older at 58.2 +/-4.6 years and the keratoconus patients being 34.5 +/-11.5 years. Results None of our patients had any operative or peri-operative complications. Corneal edema was common during the rst week. Except in the younger patients, correctable vision typically was better pre-operatively than one month post-operatively
There was no tendency towards endothelial cell loss. In the combined group, the pre-operative average cell count was 2306 +/- 590. Cross-linking resulted in essentially no change in endothelial cell count. Cell count changes from the pre-operative level were -2.9%+/-13.2%, +1%+/-28.3%, -5.2% +/-14.1%, and -0.2% +/-17.4% at one month, three months, six months and one year postoperatively respectively. There were no patient complaints of dry eye occurring after cross-linking that had not also been documented preoperatively. Tables 1 through 4 describe the behavior of the corneal curvature, as measured by maximal anterior equivalent keratometry, Kmax. Table 1 documents the number of statistically signicant increases and decreases of Kmax at six months postoperatively. Based on the modest sample size, results from both the twenty and thirty minute UV-A riboavin cross-linking treatments appeared to be equivalent six months postoperatively. In Table 2 shows that there was a general tendency for some reduction in the curvature of the cornea in most patients by six months postoperatively and this effect was rst noticeable at three months postoperatively.
Table 1. Behavior of Kmax at 6 months postoperative after collagen cross-linking in virginal keratoconus eyes (no LASIK, corneal transplant, or intracorneal rings)
Group> 20minute 30minute Kmax Decrease(better) 9 6 Increase(worse) 2 3 Same 0 3

Note: Same is dened as having the ve easurement post-operative Kmax average within 0.678D or pre-operative average Table 2. Behavior of Kmax after Collagen Cross-linking by Postoperative Time All eyes including virginal keratoconus, post-LASIK ectasia, post Intrstromal rings, and post corneal transplant
Kmax Decrease(better) Increase(worse) Same

1month 13(28.3%) 19(41.3%) 14(32.7%)
3months 15(41.7%) 12(33.3%) 9(25%)
6months 18(52.9%) 11(32.4%) 5(14.7%)
1year 7(53.8%) 4(28.6%) 3(21.4%)
Note: Same=Five measurement Kmax average is within 0.678D or pre-operative average
Despite the small sample size, Table 3 shows that crosslinking reduces or stabilizes the maximal corneal curvature of post-LASIK ectasia eyes similarly to what is seen in keratoconic eyes. However, it had a slightly weaker effect
22
on the ectasia eyes that visible at all until six months. Table 4 lists results from the combined group of virginal keratoconic eyes and shows a continuing and increasing crosslinking effect on the maximal corneal curvature extending beyond six months. Five eyes were cross-linked after having had intracorneal ring segments (ICRS) at least three months before. Four had ICRS for keratoconus and one had ICRS for postLASIK ectasia. The Kmax values of those eyes decreased an average of -2.12 D (range -0.94 to -2.82 D) and one eye with post LASIK ectasia had no statistical change six months after cross-linking (Kmax change +0.08D).
Table 3: Behavior of Kmax in Post LASIK Ectasia Eyes at one year (patient average age 58.2 years)
early cataract formation showed no changes in the eyes of patients followed for cross-linking. Clearly, the purpose of cross-linking is to stop visual loss. There was detectable visual improvement in virginal keratoconus corneas at six months. Some patients who had the cross-linking procedure had other problems that caused visual loss. For example, one patient had bilateral subluxated lenses, and another one had bilateral cataracts. The referring surgeon planned corrective operations after completion of the cross-linking one year follow up period. Comparing vision in virginal keratoconus treatment groups, the 20-minute exposure eyes improved from an average pre-operative vision of .3535 logMAR (Snellen 20/45.1) to .2791 LogMAR (Snellen 20/38) at six months postoperatively for a visual improvement of -0.0744 log units. In the 30 minute group vision improved from preoperative .4044 LogMAR (Snellen 20/50.7) to .3175 logMAR (Snellen 20/40.5) for an improvement of -0.0869 log units at six month postoperative. The small post-LASIK ectasia group improved slowly but had yet to recover pre-operative vision (an average of 0.3088 LogMAR 20/40.5) compared to an average vision at the one year follow up evaluation [0.419 LogMAR (20/52.9) ]. The average age of the post-LASIK ectasia group was 58.2 years compared with an average age of 34.5 years for the virginal keratoconus patients. Combination of data from the post-LASIK group and other smaller groups diminished the overall average visual change, with vision changing from a preoperative average of 0.3394 LogMAR (Snellen 20/43.7) to a six-month postoperative average of 0.3546 LogMAR (Snellen 20/45.25) Age was also a factor in the cross-linking effectiveness in the virginal keratoconus eyes with 76.5% of eyes in patients under age 40 actually have corneal attening as compared to only 33.3% of eyes in patients over age 40. Table 5 presents the details on that subject. One patient with post-LASIK ectasia had only slight improvement in Kmax yet a 6.4 diopter change in refraction due to attening of most of the central cornea. Figure 1 shows the change in corneal curvature caused by cross-linking in this patient. Discussion The patients enrolled in our study had experienced worsening of their keratoconus and post-LASIK ectasia prior to recruitment. Results from our clinical study, which is still in progress, indicate that corneal collagen cross-linking provides stabilization and partial reversal of the corneal irregularity resulting from keratoconus and post-LASIK ectasia. We also used cross-linking to stabilize corneas with keratoconus that had prior intracranial ring segments, and we used it as well for previously transplanted corneas where initial good vision had gradually declined from residual keratoconus in the host tissue.

1month 3(33.3%) 4(44.4%) 2(22.2%)
3months 1(11.1%) 5(55.6%) 3(33.3%)
6months 3(60%) 2(40%)
1year 3(60%) 2(40%)
Note: Same=Five measurement Kmax average is within 0.678D or pre-operative average Table 4: Behavior of Kmax in Virginal Keratoconic Eyes

1month 10(29.4%) 13(38.2%) 11(32.4%)
3months 13(52%) 6(24%) 6(24%)
6months 15(65.2%) 5(21.7%) 3(13%)
1year 4(66.7%) 1(16.7%) 1(16.7%)
Table 5: Effect of Patient Age on Cross-linking Effect in Virginal Keratoconus Eyes At 6-month Postoperative

Ageunder40
Ageatleast40

13(76.5%) 3(17.6%) 1(5.9%)

2(33.3%) 2(33.3%) 2(33.3%)
There appeared to be very minimal yet detectable reduction in corneal thickness after cross-linking. The preoperative and postoperative corneal thickness measurements of the virginal keratoconus group were as follows. Pre-operative minimal pachymetry in the twenty minute group was 468.7+/-29.3 microns and was at six months postoperatively 466.38 +/- 3.94 microns and in the thirty minute group was pre-operatively 464.4 +/28.3 and postoperatively was +/- 462.2 +/- 4.3 microns. Preoperative maximal anterior equivalent keratometry, Kmax, was 55.3 +- 4.2 D overall, with 55.3+/-4.D in the 20-minute group and 55.5+/3.9D in the 30-minute group. The Pentacam nuclear scale for detecting and quantifying
Epstein
23
Figure 1. Pentacam HR comparative topometric map of the anterior corneal curvature. At left are the postoperative contour maps. In the middle is the pre-operative map. The subtraction is shown at right. A signicant change has occurred that has markedly improved the patients unaided and spectacle corrected vision.
corneas have been from people who were genetically either completely or partially African. Because there is signicant variability in the response to cross-linking, it would seem prudent to refrain from combine cross-linking with laser vision correction in the same operation until there is a way to predict the outcome of cross-linking. However, outside of clinical studies to determine the effect of cross-linking alone, combining crosslinking with insertion of intracranial ring segments is recommended. The more vigorous response in younger eyes is not surprising. This observation only underscores the fact that crosslinking as treatment to reverse or stabilize keratoconus should be employed while patients are young. The largest published study to date is by Vinciguerra et al. Their series of cross-linking of 401 eyes with data lasting as much as 4 years and with 53.5% of patients with one year or more of follow up, shows stabilization and some reversal of corneal curvature in patients under age 40 with visual improvement and shows stabilization with no aver-
The results of cross-linking are quite variable both with respect to which patients have the desired effect and also in the uniformity of the effect on parts of the cornea. Thus far, we lack predictors of which corneas will respond and whether additional treatment may be helpful. Generally the changes in curvature are toward more uniformity of curvature, but not always. We noted good, but imperfect correlation in the effectiveness of cross-linking between two eyes of the same patient. The measure of Kmax is very useful in determining whether a keratoconic or post-LASIK ectasia cornea has worsened, but the Kmax metric does not always speak to the actual power of the cross-linking effect as in the patient illustrated in Figure 1. Two of the most highly responsive
24
age functional visual improvement on for patients over age 40. They publish on simK data rather than Kmax and sim K continues to decrease over a twenty four month period. They state that their results are best in the age range of 18 to 39 with lesser in the over 40 group possibly because age has already cross-linked the eyes and in the younger group because of the aggressiveness of the disease. These ndings are not at odds with the ndings of our younger study. Our study is in its early stages at this point. We anticipate increased patient enrollment and extended follow up of all individuals, which should enable us to achieve greater statistical signicance of the results.
Authorship statement Both authors contributed equally. Financial disclosure No potential conicts of interest was reported.
References
1. 2. Bawazeer AM, Hodge WG, Lorimer B. Atopy and keratoconus: a multivariate analysis. Br J Ophthal 2000;84:8346. Kumar, Vinay. Eye: Cornea, Degenerations and Dystrophies. Robbins Basic Pathology (8th ed.). Philadelphia: Saunders/Elsevier, 2007. ISBN 978-1416029731. Saidel MA, Paik JY, Garcia C, et al. Prevalent of sleep apnea syndrome and high-risk characteristics among keratoconus patients. Cornea. 2012;31:600-3. McMonnies CW, Quo vadis older keratoconus patients? Do they die at younger ages? Cornea. 2013;32:496-502. Jafri B, Lichter H, Stulting RD. Asymmetric keratoconus attributed to eye rubbing. Cornea 23:5604. Koenig SB. Bilateral recurrent self-induced keratoconus. Eye Cont Lens 2008;34:3434. Chan CC, Sharma F, Wachler BS. Effect of inferior-segment Intacs with and with C3-R on keratoconus J Cataract Refract Surg 2007;33:75-80. Randleman JB, Woodward M, Lynn MJ, et al. Risk assessment for ectasia after corneal refractive surgery. Ophthalmology 2008; 115:37-50. Reinstein DZ, Archer TJ, Gobbe M. Stability of LASIK in topographically suspect keratoconus conrmed non-keratoconic by Artemis VHG digital ultrasound epithelial thickness mapping: 1-year follow-up. J Refract Surg. 2009;25:569-77. Schweitzer C, Rogert CJ, Mahmoud AM, et al. Screening of forme fruste keratoconus with the ocular response analyzer. Invest Ophthalmol Vis Sci 2010; 51:2403-10. Saad A, Gatinel D, Topographic and tomographic properties of forme fruste keratoconus corneas. Invest Ophthalmol Vis Sci 2010 Nov;51(11):5546-55. Ambrosio R Jr, Caiado AL, Guerra FP, et al. Novel pachymetric parameters based on corneal tomotraphy for diagnosing keratoconus. J Refract Surg 2011;27:753-8.
3.
4. 5. 6. 7.
8.
9.
10.
13. Piero DP, Nieto JC, Lopez-Miguel A. Characterization of corneal structure in keratoconus. J Cataract Refract Surg. 2012;38:2167-83. 14. Fukuda S, Yamanari M, Lim Y, et al. Keratoconus Diagnosis Using Anterior Segment Polarization-Sensitive Optical Coherence Tomography. Invest Ophthalm Vis Science, 2013;54:1385-91. 15. Kozomara B, Boha M, Potkonjak E, et al. Prevalence of keratoconus in candidates for refractive surgical procedures. Scr Med 2012;43:25-7. 16. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res 1998;66:97-103. 17. Zhang Y, Mao X, Schwend T, et al. Resistance of corneal RFUVA-cross-linked collagens and small leucine-rich proteoglycans to degradation by matrix metalloproteinases Invest Opthalmol Vis Sci 2013; IOVS 12-11277v1. 18. Dudakova L, Liskova P, Trojek T, et al. Changes in lysyl oxidase (LOX)distribution and its decreased activity in keratoconus corneas, Exp Eye Res 2012;104:74-81. 19. Martins SA, Combs JC, Noguera G, et al. Biomechanical evidence of the distribution of cross-links in corneas treated with riboavin and ultraviolet A light. J Cataract Refract Surg 2006;32:279-83. 20. Wollensak G, Spoerl E, Wilsch M, et al. Keratocyte apoptosis after corneal collagen cross-linking using riboavin/UVA Treatment. Cornea 2004 ;23:43-9. 21. Baiocchi S, Mazzotta C, Cerretani D, et al. Corneal cross-linking: riboavin concentration in corneal stroma exposed with and without epithelium. J Cataract Refract Surg. 2009;35:893-9. 22. Ostacolo C, Cafuso C, Tronimo D, et al. Enhancement of corneal permeation of riboavin 5-phosphate through vitamin E TPGS: a promising approach in corneal trans-epithelial cross linking treatment. Int J Pharm 2013; 440:148-53. 23. Martins SA, Combs JC, Noguera G, et al. Antimicrobial ef cacy of riboavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402-8. 24. Hafezi F, Dejica P, Majo F. Modied corneal collagen crosslinking reduces corneal oedema and diurnal visual uctuation in Fuchs dystrophy. Br J Ophthalmol 2010;94:660-1. 25. Koller T, Iseli HP, Hafezi F, et al. Scheimpug imaging of corneas after collagen cross-linking. Cornea. 2009;28:510-5. 26. Epstein RL, Chiu YL, Epstein GL. Pentacam HR Criteria for Curvature Change in Keratoconus and Postoperative LASIK ectasia. J Refract Surg. 2012:28:890-4. 27. Vinciguerra R, Romano MR, Camesasca FL, et al. Corneal Cross-Linking as a Treatment for Keratoconus: Four-Year Morphologic and Clinical Outcomes with Respect to Patient Age. Ophthalmology 2013 Epub prior to print January 2013.
11.
12.
25
UDK 616.314.163-089
CASE REPORT
Subcutaneous Emphysema and Pneumomediastinum Following a Dental Filling Procedure

ABSTRACT We report a patient who underwent a routine dental procedure and developed subcutaneous emphysema (SCE) and pneumomediastinum (PM). Clinical management included oxygen therapy, pain control, rest and supportive therapy as needed. Our patient clinically improved with this treatment, and was discharged home two days later. It is important to be aware that even minimally invasive dental procedures can lead to SCE and PM. KEY WORDS Dental procedure, subcutaneous emphysema, pneumomediastinum.
DOI: 10.7251/SMD1301025V (Scr Med 2013;44:25-26)
Dimitry Voronov Alyson Russo Sangeeta Juloori Sajan Thomas

Vanguard MacNeal Hospital Department of Internal Medicine Berwyn, IL 60402, USA Correspondence Dimitry Voronov Internal Medicine Residency Program 3249 S. Oak Park Ave. Berwyn, IL 60402, USA [email protected]
Submitted: March 15, 2013 Accepted: April 18, 2013
A 38-year-old female presented to the Emergency Department (ED) with shortness of breath, left-sided facial swelling, and pain on the left side of her neck and face. She was unable to fully open her mouth. She also had blurring of vision in her left eye, and decreased hearing in her left ear. One day prior to her arrival at the ED, she underwent a dental lling procedure on a left maxillary molar. She denied undergoing an endodontic treatment or extraction. She reported some swelling in her face immediately after the procedure. At the dentists of ce, the swelling was attributed to an allergic reaction to the injected local anesthetic. However, she reported no known allergies. She was prescribed oral penicillin, and she returned home. Later that night, the swelling worsened, and the patient experienced shortness of breath along with increasing pain in her face and neck. She was subsequently taken to the ED for further evaluation. Physical examination revealed an alert, afebrile, normotensive patient, who saturated well with a non-rebreather mask. She was noted to have left periorbital, facial, submandibular and anterior cervical edema, with mild crepitus and tenderness over the left temporal bone and cheek. Examination of her ears revealed clear external canals and gray tympanic membranes bilaterally. She had minimally decreased hearing on her left side compared with the right. Her oropharynx was non-erythematous, without signs of infection or gingival complications; however, she was unable to fully open her mouth because of the pain. She
was tender to palpation over the left upper chest, and the same painful sensation was elicited by left upper extremity movement. Also, her lungs were grossly clear on bilateral auscultation. Laboratory studies showed a white blood cell count of 9,900/mm3, with a normal differential. An EKG showed normal sinus rhythm. The troponin levels were also within normal limits. A chest X-ray revealed a normal cardiac silhouette with clear lung elds. The head and chest computed tomography (CT) revealed gas in left temporal, preorbital and perimandibular areas, which extended down the left neck to the upper mediastinum (Fig. 1-3).
Figure 1. CT scan of the head, showing perimandibular subcutaneous emphysema (arrows).
26
Figure 2. CT scan of the neck, showing peritracheal subcutaneous emphysema (arrow).
We have described a case in which SCE and PM developed from a dental lling procedure of a maxillary molar. Although air-turbine drills are frequently used in both procedures; routine dental llings typically involve only the enamel and dentin layers of the teeth, whereas endodontic treatments include the deeper pulp. This case emphasizes the propensity of dental procedures to cause SCE and PM, regardless of the type of procedure or the location of the affected tooth. One should consider SCE and PM in patients with a similar presentation following any dental procedure, irrespective of its invasiveness. The treatment for PM includes initial oxygen therapy, analgesia, and rest.5 Prophylactic antibiotics can also be added to prevent mediastinitis. This treatment, in our patient, contributed to a satisfactory outcome.
Authorship statement DV gathered patient history and participated in the writing and organization of the case report. AR gathered patient history and treated the patient during hospitalization. SJ contributed to the writing of the manuscript. ST participated in the design, supervision and nal approval of the submitted manuscript. DV, AR, SJ and ST all contributed to the nal critical revision of this manuscript. Financial disclosure The authors declare no conict of interest involved with this case study. Figure 3. CT scan, showing pneumomediastinum (arrow).
The patient was started on prophylactic ampicillin/sulbactam, and remained on a 100% non-rebreather mask for the next day; she was then slowly weaned off the oxygen. She received acetaminophen/hydrocodone for pain relief. Because the patient complained of dif culty swallowing solid foods as her diet was advanced, a gastrogran swallow study was performed but showed no esophageal perforation. The facial swelling and breathing dif culty improved over the hospital course, and the patient was discharged home on oral antibiotics two days after admission. Discussion Spontaneous pneumomediastinum (PM) classically occurs in the setting of increased intra-alveolar pressure, leading to alveolar rupture and diffusion of air into the mediastinum via vascular sheaths.1 Common triggers include asthma attacks or prolonged Valsalva. Less commonly, invasive dental procedures such as dental extractions or endodontic treatments can trigger PM. Numerous case reports describe subcutaneous emphysema (SCE) and PM after dental extractions of mandibular molars.2-4 Molars are in close proximity to the submandibular, sublingual, pterygomandibular and retropharyngeal spaces. The proposed mechanism is the introduction of air into these spaces via pressure appliances such as commonly used air-turbine drills causing PM via diffusion.
References
1. Macklin CC. Transport of air along sheaths of pulmonic blood vessels from alveoli to mediastinum: clinical implications. Arch Intern Med 1939;64:913. Dngel I, Bayram M, Uysal IO, et al. Subcutaneous emphysema and pneumomediastinum complicating a dental procedure. Ulus Travma Acil Cerrahi Derg 2012;18:361-3. Afzali N, Malek A, Attar AH. Cervicofacial emphysema and pneumomediastinum following dental extraction: case report. Iran J Pediatr 2011;21:253-5. Sood T, Pullinger R. Pneumomediastinum secondary to dental extraction. Emerg Med J 2001;18:517-8. Macia I, Moya J, Ramos R, et al. Spontaneous pneumomediastinum: 41 cases. Eur J Cardiothorac Surg 2007;31:1110-4.
2.
3.
4. 5.
27
UDK 617.7-007.681-06
CASE REPORT
Atypical Form of Congenital Excavated Anomaly of the Optic Disc With Characteristics of Peripapillary Staphyloma and Morning Glory Anomaly
ABSTRACT We present a 51-year-old female with a unilateral congenital excavated optic disc anomaly. After clinical examination and appropriate diagnostic procedures we were unable to determine with certainty whether it is a morning glory anomaly or a peripapillary staphyloma. The atypical nding was an optic disc with characteristics of both states. The affected eye had almost normal visual acuity (0.9 Snellen chart), which is a rare nding in congenital anomaly of the optic disc. Confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomograph, HRT 3.0)was not of diagnostic value in comparison with optical coherence tomography (OCT). KEY WORDS Peripapillary staphyloma, morning glory, optic disc anomaly, optical coherence tomography, confocal scanning laser ophthalmoscopy (HRT 3.0).
DOI: 10.7251/SMD1301027M (Scr Med 2013;44:27-29)
Bojana Marki Milka Mavija Emira Ignjati

Clinic of Ophthalmology, Clinical Center Banja Luka, 78 000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina Correspondence Bojana Marki, MD Department of Ophthalmology, Clinical Center Banja Luka 12 beba, 78 000 Banja Luka Republic of Srpska, Bosnia and Herzegovina email: [email protected]
Submitted: February 19, 2013 Accepted: April 25, 2013
A 51- year-old Caucasian woman with no visual complaints went to her local ophthalmologist for an eye examination after developing peripheral paresis of the left facial nerve. Cranial CT ndings were within the normal range, and an ENT specialist found no abnormality. With the exception of peripheral facial nerve paralysis, neurological ndings were normal. The patients best-corrected visual acuity was OD: 0.9 and OS: 1.0 distance (Snellen chart) and Jaeger 1 near for both eyes. Her color vision, external examination, slit lamp biomicroscopy, intraocular pressures, and motility were all normal in both eyes. Funduscopic examination was normal in the left eye with an optic nerve cup to disc ratio of 0.2-0.3. Dilated funduscopic examination of the right eye showed signicant excavation on the posterior globe, in which the optic disc was hardly recognizable. It had a poorly visible temporal border and the appearance of hyperpigmentation at the 12 oclock position of the excavation. Blood vessels radiating from the papillary region seemed to be increased in number and appeared tortuous
in the center of the excavation. The macula and periphery were normal (Figure 1).
Figure 1. Patients right optic disc
A deep excavation was noted on an ultrasonography B-scan of the right eye. Automated perimetry showed an enlarged blind spot and a relative superior altitudinal defect on the right and a full eld on the left. Optical coherence tomography (OCT) revealed a deeply seated right optic nerve and the depth of staphyloma was measured 1,2 mm. Retinal pigment epithelium showed signicant atrophic changes (Figure 2). OCT of the left optic disc showed it to be normal.
28
Figure 2. OCT showed a deeply seated right optic nerve
disorders of the eye; often they accompany central nervous system malformations1 or renal hypodysplasia, where they are part of an autosomal dominant condition called renal coloboma syndrome (RCS) or papillorenal syndrome2. In addition, these optic disc anomalies may be associated with retinal detachment, retinochisis, macular edema, choroidal neovascularisation and lipid exudation. Rarely are they associated with the optic disc contractility3. In peripapillary staphyloma the area around the disc is deeply excavated, with atrophic changes in the retinal pigment epithelium. The disc remains well-dened, relatively normal in appearance with an absence of glial and vascular anomalies1. As opposed to the morning glory disc anomaly, the blood vessels in the peripapillary staphyloma lesion have a normal pattern4. Unlike other excavated optic disc anomalies, peripapillary staphyloma is rarely associated with other congenital defects or systemic diseases5. Morning glory disc anomaly has a less deep funnel-shaped excavation, along with a grossly anomalous, poorly dened optic disc, including a white tuft of glial tissue that covers the central portion of the cup. Blood vessels appear to be increased in number and emanate from the edge of the disc. After arising from the disc, the vessels turn sharply at the edge of the cup and follow an abnormally straight pattern within the peripapillary region1. In our case, optic disc was poorly dened, deeply seated at the bottom of the excavation, without central tuft of glial tissue and with blood vessels abnormal according to the number and arrangement. Due to the atypical form of this optic disc which has the same qualities of peripapillary staphyloma and morning glory anomaly, problem appeared in establishing the diagnosis between these two conditions. We used two important diagnostic tools for structural analysis of the optic disc: optical coherence tomography (OCT) and confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomograph, HRT, 3.0)6.We were interested in establishing their ability to distinguish optic disc head, as in our case, from a normal optic disc. OCT showed signicant atrophic changes in retinal pigment epithelium and structural changes most similar to those in peripapillary staphyloma. In contrast, HRT 3.0 showed poorly ability to detect structural changes on this atypical disc. In summary, this case presents an atypical optic disc with characteristics of both peripapillary staphyloma and morning glory anomaly. An accurate diagnosis is still unclear. Because we found no other ocular or systemic congenital disorders usually associated with morning glory disc anomaly, we believe that the malformed optic disc presented in our case is likely a variant of peripapillary staphyloma. The retention of good visual acuity by our patient is rare in cases like this, so we believe that it is a mild
An examination of both eyes was also performed with HRT 3.0, and analysis of the left eye was completely normal. There was a problem in setting the contour line on the right eye due to the decreased visibility of the optic disc. Using the funduscopic picture of the right eye, we placed the contour line as precisely as we could. Stereometric analysis showed an enlarged disk area (3.20 mm2 ) as well as an enlarged rim area (3.20 mm2), so that the Cup/Disc area ratio was 0.00. Moor elds Regression Classication was within normal limits for all segments (Figure 3). Glaucoma probability score classication (GPS) was not classied, because the GPS model was not compatible with the shape of this optic nerve head.
Figure 3. Moorelds Regression Classication on HRTwas within normal limits globally and in all segments
After completion of all diagnostic procedures, we concluded that this atypical optic disc is a congenital anomaly, most likely mild form. Its adequate function was conrmed by the fact that the patient had almost normal visual acuity. However, we were unable to determine with certainty whether the anomaly is a peripapillary staphyloma or a morning glory anomaly, because the atypical optic disc had characteristics of both conditions. Discussion Congenital excavated optic disc anomalies include optic disc coloboma, morning glory disc anomaly, peripapillary staphyloma, megalopapilla, and optic pit. These are all extremely rare conditions, which are most commonly are found in early childhood when they cause decreased vision, strabismus and nystagmus. In both morning glory disc anomaly and peripapillary staphyloma, an excavation of the posterior globe surrounds and incorporates the optic disc. Usually, these conditions are associated with unilateral appearing. Visual acuity in the involved eye may be minimally or severely affected, depending on the extent of lesion. These disc anomalies may be associated with other congenital
Marki, et al
29
form . Our ndings of visual eld, coupled with results from ultrasonography and OCT are important for understanding the structure and function of the optic nerve like this as well as for further monitoring. Finally, we assert that HRT 3.0 is not useful for differentiation of abnormal from normal optic discs in cases like this.
Contributors BM has performed examination of anterior segment, ultrasound, examination of color vision, analysis of visual eld test and HRT examination. MM has performed OCT examination and was consultant on writing this article. EI has performed dilated funduscopic examination and made fundus photography. Conict of interest We declare that we have no conicts of interest.
References
1. Brodsky MC. Congenital optic disc anomalies. In: Yanoff M, Duker JS, eds. Ophthalmology. 3rd ed. Philadelphia: Mosby; 2009:956-9. Schimmenti LA. Renal coloboma syndrome. Eur J Hum Genet 2011;19:1207-12. Sawada Y, Fujiwara T, Yoshitomi T. Morning glory disc anomaly with contractile movements. Graefes Arch Clin Exp Ophthalmol 2012; 250:1693-5. Kim SH, Choi MY, Yu YS, et al. Peripapillary Staphyloma: Clinical Features and Visual Outcome in 19 cases. Arch Ophthalmol 2005; 123:1371-6. Blair M P, Blair N P, Rheinstrom S D. et al. A case of peripapillary staphyloma. Arch Ophthalmol 2000;118:11389. Yang B, Ye C, Yu M, et al. Optic disc imaging with spectraldomain optical coherence tomography: variability and agreement study with Heidelberg retinal tomography. Ophthalmology 2012; 119:1852-7.
2. 3.
4.
5. 6.
Atipini oblik kongenitalne ekskavacije optikog diska s karakteristikom peripapilarnog staloma i morning glory anomalije
APSTRAKT Prikazan je sluaj 51-godinje pacijentice sa unilateralnom kongenitalnom anomalijom optikog diska. Klinikim pregledom i uinjenim dijagnostikim pretragama nije se moglo sa sigurnou utvrditi da li se radi o peripapilarnom stalomu ili o morning glory anomaliji optikog diska zbog atipinog javljanja papile sa karakteristikama oba stanja. Ustanovljena je gotovo normalna vidna otrina zahvaenog oka (0,9 kuke po Snellen-u), to je izuzetno rijedak nalaz u sluaju sa prisutnom kongenitalnom anomalijom optikog diska poput ove. Konfokalna skening laser oftalmoskopija (Heidelberg Retina Tomograph, HRT 3.0)se nije pokazala od dijagnostikog znaaja u ovom sluaju, za razliku od optike koherentne tomograje (OCT).
KLJUNE REI Peripapilarni stalom, morning glory anomalija, optika koherentna tomograja, konfokalna skening laser oftalmoskopija (HRT 3.0)
30
UDK 616.24-006.04-074
IMAGES IN CLINICAL MEDICINE
Jennifer L. Bero
Pathology Department University of Illinois Stroger Hospital of Cook County Chicago, IL 60612 USA Correspodence Jennifer L Bero, MD Pathology Department Stroger Hospital of Cook County Chicago, IL 60612 USA E-mail: [email protected]
Dual Pulmonary Infections In a 57-Year-Old Male With Large Adrenal Mass

DOI: 10.7251/SMD1301030B (Scr Med 2013;44:30)
Figure 1. High power photomicrograph showing Blastomyces with broad based budding (arrows).
Figure 2. A GMS stain of the lung nodule demonstrating Pneumocystis jiroveci.
A 57-year-old male presented with complaints of progressive dry cough, fever, headaches and weight loss, suggesting a pulmonary infection and/or possible malignancy. Bronchial washings from the area of consolidation revealed broad-based budding yeast consistent with Blastomycosis (Figure 1). The CT scan showed two nodules in the right lung that might be malignant. Biopsy of one nodule showed Pneumosystis jiroveci (Figure 2). Blastomycosis and pneumocystis jiroveci pneumonia are both opportunistic infections most often seen in immunosuppressed patients. This individual had no known medical condition to cause immuno-suppression. A CT scan of the chest showed consolidation of the left lung indicating possible pneumonia (Figure 3, double arrows).Abdominal imaging demonstrated a large adrenal mass (Figure 3, single arrow). Serum and 24-hour urine cortisol levels were signicantly elevated. These ndings are consistent with a cortisol-producing adrenal tumor. The left adrenal mass was surgically removed, and the diagnosis of a cortisol producing adreno-cortical carcinoma was conrmed.

Figure 3. A CT scan demonstrating the left adrenal gland mass (single arrow) and consolidation of the left lung (double arrows).
We conclude that a cortisol-producing adrenal cortical carcinoma caused systemic immuno-suppression that resulted in a dual pulmonary infection with Pneumoncystis jiroveci and Blastomyces. The pulmonary infections resolved upon removal of the adrenal mass.
31
UDK 616.126-089
Trans-Apical TransCatheter Aortic Valve Implantation: The Berlin Experience

DOI: 10.7251/SMD1301031C (Scr Med 2013;44:31)
In the latest edition of Scripta Medica, DAncona et al gave a comprehensive review of trans-apical trans-catheter aortic valve implantation (TAVI). Their impressive results obtained within a short period of time involved a large cohort of patients.1 The German experience with this new technology differs from most other centres world wide in that there have been no limitations of procedural funding and patient choice. Consequently, over 30% of all aortic valve interventions performed use TAVI technology. For any unit setting up a TAVI program, the main point is the need for a multi-disciplinary heart team to facilitate optimal patient selection. This is key to achieving successful outcomes for both the short and longer terms. It is the responsibility of this heart team to determine an individual patients risk from previously identied variables independently associated with mortality and poor treatment response,2 as well to oversee a systematic anatomical work up from access site to implantation site. What does TAVI offer over surgical AVR? There is no doubt that, in the majority of cases, surgical AVR is a successful procedure supported by robust long-term follow-up data. However, the less invasive TAVI offers a number of advantages, not the least of which is procedural recovery within a matter of days, often with immediate symptomatic improvement. Indeed, the two year PARTNER outcome follow-up data comparing TAVI with surgical AVR continues to show the benets of TAVI.3 What does the future hold for TAVI? We anticipate further development with regard to patient selection in which imaging modality affords optimal anatomical assessment of the aortic valve complex and peripheral vasculature. Technology will continue to develop the minimally invasive approach, which is the biggest advantage of TAVI over surgical AVR. Consequently, a trans-apical approach may be used less frequently than retrograde trans-femoral access in all but the minority of patients. In patients where
femoral access is borderline, use of other access sites (axillary, subclavian and direct aortic [trans-aortic]) will become routine. Delivery technology will continue to improve with further reductions in calibre; this will lessen vascular access site bleeding. Finally, the rst-generation re-positional valves now under evaluation, and secondgeneration valves with sealing skirts, will help to reduce the extent of para-valvular AR. Procedural changes will develop as well. For example, all retrograde trans-femoral TAVI, trans-aortic and subclavian cases in our centre are performed under conscious sedation. This eliminates the potential risks associated with general anaesthesia in our elderly patient cohort. If the accumulated long-term data show continued superiority of TAVI over surgical AVR, this promising technology will likely be extended to lower risk patients. Indeed, as mentioned by DAncona et al, SURTAVI and also the UK TAVI trial will shortly begin evaluating this group; both trials are currently recruiting. 4 There is no doubt that TAVI is here to stay. In time it may well have as much of an impact on the treatment of symptomatic aortic stenosis as angioplasty and stent insertion has had on symptomatic angina pectoris.
Dr. James Cockburn Sussex Cardiac Centre, Brighton, UK
References
DAncona G, Pasic M, Drews T, et al. Transapical transcatheter aortic valve implantation: The Berlin experience. Scr Med 2012;43:79-84. 2. Thomas M, et al. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010;122:629. 3. Kodali SK, Williams MR, Smith CR, et al. PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95. 4. www.clinicaltrials.gov 1.
32
UDK 616-089.843-06
On Keratoconus Incidence in ProspectiveRefractive Surgery Patients

DOI: 10.7251/SMD1301032E (Scr Med 2013;44:32)
After crosslinking is complete, some of these keratoconus patients may be candidates for intra-corneal rings; a few may be candidates for subsequent partial surface excimer laser correction of astigmatism with continued follow up.
Robert L. Epstein, MD Greg L. Epstein, BS Mercy Center for Corrective Eye Surgery McHenry, Illinois, USA [email protected]
Dear Editor, We read with interest the article, Prevalence of Keratoconus in Candidates for Refractive Surgical Procedures, and we congratulate the authors, Kozomara et al.1 on their important work. The fact that there was such a high prevalence of keratoconus among their patients, a prevalence far above that of the normal population, underscores the need for a high index of suspicion of keratoconus when seeing patients for elective surgery. The advanced Scheimpug technology that the authors used must have been helpful in detection of keratoconus. In patients where keratoconus is suspected, and who avoid use of contact lenses for two weeks, collection of baseline data with ve Scheimpug scans per eye will allow for even more rapid detection of change in the corneal curvature with time.2 Some cases of keratoconus, initially considered to be unilateral, end up showing progressive curvature change with time. Crosslinking, a safe and highly effective procedure for the stabilization and partial reversal of keratoconus3, is certainly indicated in cases of keratoconus with progression and also for individuals under age 18 with keratoconus even before there is evidence of progression. 4,5
References
1. Kozomara B, Boha M, Potkonjak E, et al. Prevalence of keratoconus in candidates for refractive surgical procedures. Scr Med 2012;43:25-7. Epstein RL, Chiu YL, Epstein GL, et al. Criteria for curvature change in keratoconus and postoperative LASIK ectasia. J Refract Surg 2012;28: 890-4. Koller T, Mrochen M, Seiler T. Complications and failure rates after corneal crosslinking. J Cataract Refract Surg 2009;8:1358-62. Chatzis N, Hafezi F. Progression of keratoconus and ef cacy of corneal collagen cross-linking in children and adolescents. J Refract Surg 2012;28:7538. Randleman JB. Corneal Collagen Cross-linking: New and expanding applications. J Refract Surg 2012;28:744-5.
2.
3.
4.
5.
33
UDK 005.311.12:331.101.3:[61
Burnout Syndrome Among Residents of Family Medicine

DOI: 10.7251/SMD1301033J (Scr Med 2013;44:33)
Dr. Staneti et al.1 studied burnout syndrome among residents in Family Medicine, using the Maslach Burnout Inventory, a well-known questionnaire. Using this method, they assessed the inuence of gender, marital status, and number of children in the families of participants and reported that 77% of the respondents had high level of stress. However, in similar studies,2 severe burnout syndrome (also measured using the Maslach Burnout Inventory) was reported in about 50% of critical care physicians. Those who work in Intensive care units (ICU) also have a high level of work-related stress, a factor known to increase the risk of burnout syndrome. In addition, physicians who work in the ICU have a high number of working hours including a number of night shifts and limited vacation time. This syndrome is also prevalent among medical oncologists. Whippen and Canellos3 surveyed members of the American Society of Clinical Oncology and reported that 56% of participants fulll the criteria for burnout syndrome. On the contrary, medical students at the University of Sao Paulo exhibited a low prevalence of burnout syndrome (10.3%). 4 Other studies estimate that burnout syndrome affects between 10% and 45% of medical students.5 Unexpectedly, severe burnout syndrome that was reported by Staneti et al affects family practice residents more often than critical care physicians. If the family medicine residents in the Republic of Srpska did not exaggerate their
answers, the authors should offer some possible explanations for this discrepancy. Perhaps they should note additional factors that increase burnout syndrome among the family residents, such as vacation time, moonlighting, or other contributing factors. For vacation time, the report should include physicians satisfaction both with vacation duration (<15 days; 15-30 days; >30 days) and quality (consider vacation time suf cient: yes or no). Vacation time is an important factor that may prevent/cause burnout at work, not only in physicians and nurses, but in many other workers as well.
Dr. Miroslav Jerini Regional hospital Liberec, Husova 10 460 63 Liberec 1, Czech Republic
References
1. Staneti K , Teanovi G, Burgi-Radmanovi M. Sindrom sagorevanja na poslu specijalizanata porodine medicine. Scr Med 2011; 42:14-7. Papazian L, Kentish-Barnes NEmbriaco N, Pochard F, Azoulay E. Burnout syndrome among critical care healthcare workers. Curr Opin Crit Care 2007;13:482-8. Whippen DA, Canellos GP. Burnout syndrome in the practice of oncology: results of a random of 1,000 oncologists. J Clin Oncol 1991;9:1916-20. Costa EF, Santos SA, Santos AT, Melo EV, Andrade TM. Burnout Syndrome and associated factors among medical students: a cross-sectional study. Clinics (Sao Paulo) 2012; 67:5739. Dyrbye LN, Thomas MR, Massie FS, et al. Burnout and suicidal ideation among U.S. Medical students. Ann Inter Med 2008;149:33441.
2.
3.
4.
5.
34
In Reply
Throughout 2010 we studied the incidence of stress and burnout syndrome among Family Medicine residents. We used three questionnaires: a sociodemographic data questionnaire created for our particular research objectives; a questionnaire for self-assessment of stress and the Maslach Burnout Inventory (MBI) for assessment of the risk of burnout syndrome Results from the questionnaire for self-assessment of stress level showed that 77% of the participants met the criteria for high level of stress. Results from the MBI questionnaire showed that Family Medicine residents who participated in the survey had a moderate risk of burnout syndrome. The average degree of emotional exhaustion in this cohort was 21.9, a result that falls into the category of moderate risk. The average degree of depersonalization was 7.45, and the average level of personal satisfaction was 39.65, both of which also indicate moderate risk. If we compare the results from the Family Medicine residents in the Republic of Srpska with results obtained from the other studies cited, it seems obvious that the Family Medicine residents had a signicantly lower risk of burnout syndrome than the ICU doctors or the oncologists in the US, but not as low as the risk for medical students.1 The results of our study are similar to those from studies conducted among residents in Lebanon, 2 France 3 and the Netherlands. 4
Dr. Jerinis observations about the inuence of vacation time and quality on the development of burnout syndrome are important. Our questionnaire did not contain a question about the length of vacation time, because it is an issue dened by the law in our country. The average number of vacation days for the residents is 20 workdays per year. We agree with Dr. Jerini that the length of vacation time is an important factor that may inuence burnout syndrome. A high quality of vacation time may also help to prevent of burnout.
Kosana Staneti, MD, Ph.D. Primary Health Centre Banja Luka Department of Family Medicine Medical Faculty Banja Luka, Bosnia and Herzegovina
References
Whippen DA, Canellos GP. Burnout syndrome in the practice of oncology: results of a random of 1,000 oncologists. J Clin Oncol 1991;9:1916-20. 2. Ashkar K, Romani M, Musharraeh U, et al. Prevalence of burnout syndrome among medical residents: expirience of a developing country. Postgrad Med J 2010;86:266-71. 3. Blanchaed P, Truchot D, Albiges-Sauvin L, et al. Prevalence and causes of burnout among oncology residents: A comprehensive nationwide cross-sectional study, Eur J cancer; 2010. 4. Prins JT, Hoekstra-Weebers JE, Gazendam-Donofrio SM, et al. Burnout and engagement among resident doctors in the Netherlands: a national study. Med Educ. 2010;44:236-47. 1.
35
UDK 616.14-005
SPECIAL ARTICLE-CLINICAL PRACTICE
Risk Factors for Venous Thromboembolism and Duration of Anticoagulation Therapy

ABSTRACT An adequate regimen for prophylaxis of venous thromboembolism (VTE) requires indentication of reversible and irreversible risk factors. Recent data conrm that the greatest number of pulmonary emboli (PE) occur in non-surgical patients. VTE also develops in many surgical patients upon hospital discharge. These ndings emphasize the need for adequate VTE prophylaxis in inammatory diseases, acute medical illness, and other conditions, as well as the need to optimize anticoagulant regimens after surgery. Establishing VTE risk factors, identifying acquired or inherited thrombophylias and occult or previously undiagnosed malignancy will help design an adequate anticoagulant regimen as secondary VTE prophylaxis for surgical and other patients. Follow up measures should include D-dimer values, ultrasonographic assessment of residual venous thrombosis and echocardiographic parameters, along with other relevant clinical data to assess the risk of VTE reoccurrence. These procedures will ensure the optimal duration of individually tailored anticoagulant therapy, with special attention to comorbidities and tendency to hemorrhage.
Neboja M. Antonijevi1,2 Vladimir Kanjuh1,3 Ivana ivkovi2 Ljubica Jovanovi2

School of Medicine, University of Belgrade 2 Clinic for Cardiology, Clinical Center of Serbia, Belgrade 3 Serbian Academy of Science and Arts, Committee on Cardiovascular Pathology
1
Correspodence Dr. Neboja Antonijevi, Clinic for Cardiology, Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia e-mail: [email protected] Cell phone: +381641939785
KEY WORDS Venous thromboembolism, thromboprophylaxis, recurrent thrombosis, risk for bleeding.
DOI: 10.7251/SMD1301035A (Scr Med 2013;44:35-42) Submitted: October 13, 2012 Accepted: January 17, 2013
Venous thromboembolism (VTE) is the third leading vascular cause of mortality after myocardial infarction and cerebrovascular insult.1 It is the most preventable disorder. Thus improving measures to prevent VTE remains a top clinical priority.2 Over two-thirds of all symptomatic VTE occur in patients that were not subjected to surgical procedures.3 It was reported that 47-76% of all clinical VTE events after hip and knee surgery occur after hospital discharge, and it is recommended to extend VTE prophylaxis in such patients.3,4 Although venous thromboembolism is often present in surgical patients during the postoperative period, 70-80% of fatal pulmonary emboli (PE) develop in nonsurgical hospital patients. In 40% of such cases, an age factor is associated with other risk factors, such as previous VTE, malignancy, cerebrovascular accident, heart failure, chronic obstructive pulmonary disease, sepsis and immobilization or connement to bed.5 The incidence of venous thrombo-
embolism increases with age, ranging between 1/10,000 per year in younger patients and 5-6/1,000 per year in people over 80 years.5 An increase in VTE-related morbidity correlates with a number of associated comorbidities, such as inammatory conditions, elevated acute-phase reactants and reduced anticoagulant proteins.5 Prevention and treatment of VTE requires key decisions for further management. These include determining the duration of anticoagulant treatment, selection of measures to prevent recurrent venous thromboembolism and VTE sequelae (pulmonary hypertension, post-thrombophlebitic syndrome) as well as appropriate diagnostic screening for thrombophilia and occult malignancy, along with dening reversible and irreversible risk factors for VTE.6 A number of authors give priority to establishing optimal anticoagulant treatment over detecting possible congenital thrombophilic states that indicate clinical risk factors for VTE.6
36
Classication of risk factors for VTE The various classications and categorizations of risk factors for VTE are a mainstay for tailoring the optimal treatment of VTE patients to their individual characteristics.7 For example, Kaatzs categorization of VTE is particularly useful: VTE provoked by risk factors, cancer-related, idiopathic, thrombophilia-related and recurrent VTE.7 Another classication is based on the strength of risk factors for VTE: strong risk factors for VTE with odds ratio > 10 include trauma or fracture, major orthopedic surgery, oncology surgery; moderate risk factors with odds ratio 2-9 include non-oncology surgery, use of oral contraceptives and hormone replacement therapy, pregnancy and puerperium, hypercoagulability state and previous VTE; weak risk factors with odds ratio <2 include advanced age, bed connement for longer than three days, imobility on long trips, metabolic syndrome and air pollution.8 The life-style or disease-associated risk factors for arterial and venous thromboembolism include obesity, diabetes mellitus, hypertension and smoking,8 with special consideration given to the impact of dyslipidemia on VTE occurence. (Commonly known VTE risk factors4-10 are presented in Table 1.)
Table 1. Risk factors for VTE
vastatin (20 mg daily) compared to the control (untreated) group.9 Bauer and Previtali8,10 group the VTE risk factors into acquired (including antiphospholipid syndrome, myeloproliferative neoplasms, paroxysmal nocturnal hemoglobinuria, inammatory bowel disease, Wegener granulomatosis, paresis/paralysis of lower extremities, etc.), inherited (deciencies of antithrombin, proteins C and S, factor V Leiden and prothrombin G20210A mutations, disbrinogenemias) and mixed risk factors (hyper-homocysteinemia, resistance to activated protein C in the absence of factor V Leiden mutation, increased activity of factors VIII, IX, XI, thrombin-activated brinolysis inhibitor (TAFI), reduction of tissue factor pathway inhibitor (TFPI), and brinolytic activity). Patients heterozygous for factor V Leiden have a three times higher risk for an initial VTE while homozygous individuals carry a 15-20-fold increased risk.9 Goldhaber considers the combination of homozygous factor V Leiden mutation, double heterozygotes for factor V Leiden and prothrombin G20210A mutation, deciencies of proteins C, S and antithrombin as well as antiphospholipid syndrome to be a particularly ominous setting for thrombophilia.9
Surgery, trauma (major or lower limb trauma) Immobility, lower limb paresis Malignancy (active or occult), malignancy therapy (hormonal, chemotherapy, radiation, treatment with angiogenesis inhibitors) Previous VTE Use of estrogen-containing contraceptives, hormone-replacement therapy, or selective estrogen receptor modulators, agents stimulating erythropoiesis Acute medical illness Inammatory bowel disease, nephrotic syndrome, myeloproliferative disease, chronic obstructive pulmonary disease, congestive heart failure, paroxysmal nocturnal hemoglobinuria Dehydration, transfusion Venous compression (tumor, hematoma, arterial abnormalities) Obesity, advanced age Pregnancy and puerperium Congenital or acquired thrombophilia Application of central venous catheters Risk factors for VTE often overlap with those for coronary heart disease (smoking, obesity, high consumption of red meat instead of a healthier diet of sh, fruit and vegetables, psychosocial stress, hypertension). The JUPITER study (Justication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) provides a convincing example of how risk factors for arterial and venous thromboembolism converge. Results of that study showed a reduction in VTE by 43% in the group treated with rosuAlthough estrogens in the form of oral contraceptives or postmenopausal hormone therapy are well-known risk factors for VTE, it is interesting to note that the third-generation progestins, dezogestrol and gestodene also rank among risk factors for VTE. 9 In order to optimize an anticoagulation regimen for patients with VTE, one should establish the importance of their specic VTE risk factors by distribution into these
Antonijevi, et al
37
three categories: 1. Reversible major (occuring a month after surgery where general anesthesia lasted longer than 30 minutes, hospitalization longer than three days, plaster immobilization of lower limbs); 2. Reversible - minor (hormone replacement therapy, pregnancy and puerperium, an eight-hour or longer ight or travel in a sitting position [a stricter limitation is 4-6 hours] or the presence of major reversible risk factors during 1-3 months); 3. Nonreversible or permanent risk factors for VTE (malignancy, molecular thrombophilias).11 Long-term anticoagulant therapy is strongly recommended for patients with persistent nonreversibile risk factors, such as homozygous mutation of factor V Leiden, double heterozygotes for factor V Leiden and prothrombin G20210A mutations, protein C/S deciency, antiphospholipid antibodies.11 Interruption of anticoagulant therapy constitutes a greater risk for recurrent VTE in patients with previous proximal deep vein thrombosis (DVT) compared with the distal lower limb DVT.12 Agnelli classies risk factors for VTE as transient (surgery, trauma, immobilization) or persistent (cancer and paralysis), but considers those individuals with idiopathic and spontaneous VTE to have no identied risk factors for thrombosis. Numerous studies identifed male gender as a risk factor for recurrent VTE [relative risk (RR) 1,6; 95% condence interval (CI) 1,2-2,0].13 The observation that the risk of fatal pulmonary embolism is two-three times greater after an episode of PE than after a DVT episode is also of clinical relevance.13 Classication based on risk for recurrent VTE Prandoni14 denes several groups of risk factors for recurrent VTE: 1) persistent acquired risk factors (active malignancy, especially with metastasis and treated with chemotherapy, patients with chronic nonsurgical diseases who are immobilized for long periods of time), 2) major transient risk factors (previous surgery or trauma), 3) minor transient risk factors (minor trauma, long-haul ights, estrogen therapy, pregnancy and puerperium), 4) spontaneous VTE, 5) congenital thrombophilias (with special emphasis on the deciencies of proteins C and S and antithrombin, increase of factors VIII and IX, hyper-homocysteinemia). Although recent studies associating recurrent VTE with homozygous factor V Leiden and prothrombin 20210 remain controversial, it is indisputable that patients on one-year anticoagulation therapy regimens have a lower percentage of recurrent VTE than those on conventional three-month anticoagulation regimens. Lowering homocysteine levels with vitamin B12 supplementation does not reduce the risk of recurrent VTE. Prophylaxis of VTE in pregnancy must not be discontinued before the end of the puerperium (6 weeks after childbirth). Patients with signicant transient risk factors should be treated for three months, but the duration of treatment
could be less (six weeks) if thrombosis is localized to veins in the lower legs. Patients with minor transient risk factors require treatment tailored to the degree of hemorrhagic risk for each individual.15 Indenite anticoagulant treatment is recommended for patients with multiple episodes of VTE. This might include an implanted vena cava lter if anticoagulants are contraindicated as well as for individuals with antiphospholipid syndrome.14 Table 1 lists the most important risk factors for recurrence of VTE upon anticoagulant therapy discontinuation.15 Prospective studies in patients with VTE indicate a greater risk of recurrent VTE in patients who have high levels of D-dimer a month after termination of anticoagulant therapy.13 Identication of these patients by D-dimer monitoring can single out those at greatest risk and help to prevent recurrent VTE.14 In the PREVENT trial (Prevention of Recurrent Venous Thromboembolism), one group of patients with spontaneous VTE received anticoagulant (warfarin) therapy for six months, but measurement of D-dimer for seven weeks following warfarin withdrawal showed that those with increased D-dimer levels had a twofold higher recurrence rate.
Table 2. Risk factors for recurrent VTE15
When anticoagulation therapy has already been administered Advanced Age Immobilization Malignancy Chronic obstructive pulmonary disease Enlargement or dyskinesia of right heart ventricle After the termination of anticoagulant therapy Male gender Body overweight Signs and symptoms of PE before DVT Low levels of HDL Absence of recanalization of lower limbs veins on ultrasound scan However, a meta-analysis of 1888 patients with spontaneous VTE suggests that the problem is not that simple. That study reported that 3.5% of patients have an annual risk for recurrent VTE despite normal D-dimer levels measured upon discontinuation of anticoagulant therapy.15 In a separate meta-analysis of idiopathic VTE studies, the recurrence rate was 7.2% for patients who had normal Ddimer values measured one month after discontinuation of anticoagulant therapy. Some reports suggest that elevation of D-dimer one or two months after therapy is associated with signicant risk of spontaneous recurrent thrombosis [hazard ratio 2.0, 95% condence interval (CI) 1.01 to
38
3.9].16 The risk of recurrent VTE is 10% per year in men who have had spontaneous VTE with elevated D-dimer, whereas the risk of spontaneous VTE, or VTE caused by dened factors with negative D-dimer, in women is about 2%. Consequently, the benet of long-term anticoagulant therapy in these women remains vague. 16 According to Agnelli, the main predictors of recurrent thromboembolism are D-dimer levels and the presence of residual thrombosis.13 The hazard ratio for recurrent VTE was 2.4 in patients with persistent residual thrombosis (shown by venous ultrasonography) compared with those who had vein recanalization.13 The same author notes that recurrent VTE can be as high as 29% in patients positive for anti-cardiolipin antibodies after a rst episode of VTE compared with 14% of those without the antibodies (p <0.01). The PREVENT study established the ef cacy of prolonged anticoagulant therapy in patients with factor V Leiden and prothrombin G20210A mutations by showing that the annual incidence of recurrent VTE was reduced from 8.6% to 2.2% per year.13 The Vienna Prediction Model for Recurent VTE identies the risk of recurrent VTE in relation to sex, clinical presentation and laboratory values of D-dimer.14,17 Besides the aforementioned risk factors, this model indicates that a number of other abnormalities can be involved, including elevated factor VIII, factor IX, increased hematocrit, low levels of apolipoprotein AI, HDL and vitamin B6, and FSAP Marburg (Marburg I polymorphism of factor VII activating protease), overweight, pregnancy and puerperium, even chronic renal disease, are associated with increased risk for recurrent VTE.17-27 Duration of anticoagulant therapy for secondary prophylaxis depends upon the category of VTE According to Goldhaber,9 the recommended duration of anticoagulant therapy for a rst attack of PE and/or DVT related to an identied risk factor for VTE (surgery, trauma, oral contraceptives, pregnancy, hormone replacement therapy) is from three to six months with a target International Normalized Ratio (INR) 2-3. For patients with a rst episode of upper limb DVT or isolated lower leg DVT with identied risk factors, a three-month course of anticoagulant therapy with an INR of 2-3 is advised. For a second attack of VTE provoked by an identied risk factor, most clinicians recommend doubling the duration of anticoagulant therapy; a few of them favor so-called lifelong anticoagulation therapy, or indenite treatment. The ACCP (American College of Chest Physicians), NCCN (National Comprehensive Cancer Network) and ASCO (American Society of Clinical Oncology) reached a consensus that patients with malignancies should be treated with low-molecular-weight heparin (LMWH) during the rst from three to six months and then indenite anticoagulation therapy (vitamin K antagonists or LMWH). Table 3 shows the recommended duration of anticoagulant therapy for secondary prophylaxis of VTE15
Table 3. Optimal duration of therapy for secondary prophylaxis of VTE15
CATEGORY OF VTE
GUIDELINES FOR DURATION OF ANTICOAGULANT REGIME
First episode of PE or proximal DVT related to an 3-6 months identied risk factor First episode of upper-limb DVT or isolated lower-leg 3 months DVT related to an identied risk factor Second episode of DVT related to an identied risk Uncertain factor Third episode of DVT DVT in malignancy Spontaneous PE/ proximal DVT of lower limb Second unprovoked DVT of calf Indenite duration Indenite duration until malignancy is resolved Consider indenite duration
First unprovoked DVT of calf 3 months Uncertain
Aggressive use of anticoagulant therapy after the rst six months of treatment remains debatable. Many physicians continue the standard anticoagulant regimen with a target INR 2-3, whereas others consider a low-intensity anticoagulant regimen with a target INR 1.5-2 to be effective and safe.15 Three studies achieved a 90% risk reduction in patients with standard anticoagulation therapy and a target INR of 2.5 (range 2-3) with the extended regimen, while a low-dose regimen (INR 1.5-2) resulted in 60% risk reduction.16 Any decision on anticoagulant therapy cessation in individual patients should take into account that the annual incidence of major bleeding in patients on long-term anticoagulant therapy is 1.5-2%, and that case fatality rate or frequency of major bleeding episodes with fatal outcome is greater than the frequency of recurrent VTE. Consequently, for certain patients with high hemorrhagic risk, unconventional oral anticoagulant therapy with a target INR 1.5 to 2 should be considered.14 Persistent dysfunction or right ventricular enlargement after acute PE, residual DVT, non-recanalised DVT (conrmed by venous ultrasonography), low HDL, male sex and body overweight are considered risk factors for recurrent VTE. In contrast, the nding of a persistent thrombus on chest computed tomography (CT) has no predictive value for the recurrence of pulmonary emboli (PE) since about half of PE appear as persistent defects in chest CT recordings six months after the initial event.9,15 Also, most thrombophilias do not increase the risk of recurrent VTE.15 Clus-
Antonijevi, et al
39
tered data from 10 studies (3104 patients enrolled with a rst episode of VTE) indicate an odds ratio for recurrent VTE to 1.72 (95% CI 1.27 to 2.31) in those with prothrombin mutation G20210A and a ratio of 1.41 (95% CI 1.14 to 1.75) with factor V Leiden mutation.13 Meta-analyses indicate that the incidence of recurrent VTE is higher immediately after discontinuation of anticoagulant therapy, but it tends to decrease over time. In addition, the onset of recurrent VTE nine months after discontinuation of anticoagulation therapy does not depend on the prior therapy duration.13 Recommended duration of primary prophylaxis anticoagulant therapy depends upon VTE category Based on of cial recommendations, primary prevention of VTE depends upon the type of previous surgery. In addition to selecting the appropriate type of thromboprophylaxis (mechanical, medication, or combined) and the type and dose of anticoagulant agents, it is necessary to consider the duration of treatment and to tailor it to the specic requirements of a particular surgical procedure. This would apply as well for protection against VTE in nonsurgical (medical) patients, too. The National Institute for Health and Clinical Excellence (NICE) clinical recommendations (2010) advise thromboprophylaxis over a period of 28-35 days for patients with elective hip surgery or hip fractures and 10-14 days for patients with elective knee surgery, while major surgery for abdominal or pelvic malignancy requires thromboprophylaxis for 28 days from the day of the intervention. 4, 28 American College of Chest Physicians (ACCP) guidelines recommend continuing thromboprophylaxis up to 28 days, continuing after hospital discharge for those with malignancies and for other high-risk patients after general or gynecological surgery. 28 Thromboprophylaxis is advisable for individuals with reduced mobility, such as those who have had general, gynecologic, urologic, thoracic surgery, coronary artery bypass graft or bariatric surgery as well as those with major trauma or spinal cord injury. It should be continued until the patient has regained mobility, usually about ve - seven days.28 Where there is lower limb immobilization in a cast, the physician should prescribe the appropriate thromboprophylaxis after evaluating the risk and benet in each patient.28 ACCP (2008) recommends thromboprophylaxis for acutely ill patients admitted to the hospital due to congestive heart failure, severe respiratory diseases, and for those who are bedridden or who have additional risk factors for VTE, such as: active malignancy, previous VTE, sepsis, acute neurologic disease or inammatory bowel disease.28 The ACCP also advises tailoring thromboprophylaxis according to the type of cancer surgery and bedridden patients.28 The ACCP guidelines from the CHEST 2008 do not recommend pharmacotherapy for prevention of thrombosis caused by venous catheters or as routine thromboprophylaxis in patients receiving hormone or chemotherapy;
similarly, thromboprophylaxis is not recommended as a means of increasing survival rates in patients with malignancies.28 Thromboprophylaxis should be initiated as soon as possible for patients with burns and additional risk factors for VTE (one or more of the following: advanced age, morbid obesity, extensive burns, particularly in lower extremities, concomitant lower extremity injuries, the use of femoral venous catheters and prolonged immobility). For travellers on long-haul ights for more than eight hours (even over 4-6 hours), the ACCP emphasizes the importance of general measures, such as maintaining adequate hydration, avoidance of tight clothing around the waist and lower extremities and exercising the lower-leg muscles. If these travelers have additional risk factors for VTE, they should also wear lower-leg elastic stockings that provide 15-30 mm Hg pressure at the level of ankle. Alternatively, they could be given a prophylactic dose of LMWH prior to the ight. 4, 29-31 Thromboprophylaxis is recommended for pregnant women and those who gave birth in the last six weeks (without surgery). This is particularly important if they have one or more of the following risk factors presented in Table 4.
Table 4. Risk factors for VTE in pregnancy and puerperium.4
Reduced mobility for three days or more Active malignancy or malignancy treatment Age over 35 years Obesity (BMI before pregnancy or in early pregnancy over 30 kg/m2) Admission to the intensive care unit Dehydration, major blood loss or transfusion Comorbidities (cardiac, metabolic, endocrine and respiratory diseases) Acute infective diseases and inammatory conditions Positive family history of VTE in rst-degree relatives Ovarian hyperstimulation Hyperemesis gravidarum, multiple pregnancy, preclampsia Varicose veins with phlebitis Known thrombophilia Thromboprophylaxis is also advised for nonsurgical patients, i.e. those with acute medical illness, stroke, malignancy, central venous catheters or those who are conned to bed for longer than three days. Thromboprophylaxis is indicated for patients with stroke, especially for those with excluded hemorrhagic stroke or ruptured cranial and spinal vascular malformations. Despite the generally lower risk of hemorrhagic transformation of stroke or hemor-
40
rhage in other locations, mitigating factors such as reduced mobility, previous VTE, dehydration, presence of comorbidity like malignancy should inuence the decision for prophylactic treatment. 4 Because of the high incidence of arterial cardiovascular events in patients with previous spontaneous VTE antiplatelet agents should be considered as part of the regime for long-term secondary prevention of VTE.13 In addition, to prevent VTE, other general, non-pharmacological measures can be used, such as weight reduction, prevention of dehydration, and mechanical means (elastic stockings, compression devices such as intermittent pneumatic compression or foot pumps). 14 Temporary anticoagulant therapy should be considered in a setting of inammation, immobilization, estrogen therapy etc. A number of studies indicate that up to 40% of patients with previous VTE develop recurrent VTE. It should be noted that recurrent VTE occurs more frequently in those with spontaneous VTE than in patients with clearly dened risk factors.14 The decision to terminate anticoagulation therapy requires individual assessment of each patient, including their Ddimer values and ultrasound ndings in lower limb veins. A balanced approach takes into account the risk of hemorrhage. 14 The choice of an anticoagulant regime must include assessment of the risk of venous thrombosis caused by heparin-induced thrombocytopenia type II while selecting an adequate non-heparin anticoagulant. 15-17, 28, 32-37 Management of bleeding associated with oral anticoagulants Because the use of any anticoagulant (old and new) may be complicated by the potential of bleeding, the clearance mechanisms, and the half-life of each of these agents one should understand in order to plan strategy for rapid reversal.38 Options for reversing anticoagulation include: (1) withholding anticoagulation therapy (observation); (2) administering a specic reversal agent (e.g. oral or intravenous vitamin K if the bleed-related to a vitamin K antagonist); and (3) administering supplemental clottingfactor substitutes (e.g. fresh frozen plasma or prothrombin complex concentrates). However, appropriate supportive and symptomatic treatment is also needed (e.g. mechanical compression or surgical intervention). Dabigatran and rivaroxaban have relatively short halflives (dabigatran 12-17h, rivaroxaban 7-11h), in majority of patients with minor or mechanically controlled bleeding, observation and supportive care is the preferred strategy. In the event of a bleed or the need to take a patient emergently to surgery, there are pharmacodynamic parameters that can be measured to determine the approximate level of anticoagulation. For example, fordabig atran monitoring includes following: ecarin clotting time (ECT), thrombin time (TT) and activated partial thromboplastin time (aPTT), which, being relatively insensitive especially at
high plasma concentrations, is not suitable for precise quantication of anticoagulant effect. Anticoagulation reversal agent for dabigatran is recombinant factor VIIa (rFVIIa). Epilogue Anticoagulation is a common intervention in the prevention and treatment of thrombosis in multiple clinical settings. Its duration, both in primary and in secondary prevention, depends upon the risk for recurrent VTE as well as the risk for bleeding and present comorbidities.7 Therefore, determining the length and type of an anticoagulant regimen must be guided by achieving the proper balance between the benet of therapy and the risk of hemorrhage.13 New oral anticoagulants (direct thrombin inhibitor and factor Xa inhibitors) may present simpler and safer treatment and prevention of VTE. Their immediate onset of anticoagulant effect, convenient administration, and lack of needed regular anticoagulation monitoring are of interest both for the patients and medical profesionals. Dabigatran is the rst oral thrombin inhibitor approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial brillation and one or more risk factors for stroke. Dabigatran has also been approved in several countries for the prevention of venous thrombosis in patients undergoing total knee or hip replacement. The RE-NOVATE study on the prevention of venous thromboembolism (VTE) after hip arthroplasty and RE-MODEL study on VTE prophylaxis after knee arthroplasty showed non-inferiority of dabigatran compared with enoxaparin adminstered in European doses of 40 mg daily, while the RE-MOBILISE study after hip arthroplasty conrmed dabigratan inferiority compared with enoxaparin at the North American dose of 30 mg twice daily. However, in the treatment and prevention of VTE, more data should be accumulated to show their ultimate place in therapy.
Authors contribution The paper is designed and writen by its NMA. VK directed and supervised this project. I and LjJ provided assistance in sourcing relevant literature and writing parts of the paper. Conict of interest All authors declare no conict of interest related to this paper. Acknowledgements This work was supported in part by the Serbian Academy of Sciences and Arts and by Research Grant No. 173008/2011 from the Ministry of Science, Republic of Serbia. We thank Jelena M. Antonijevi, and Dr. Sci. Valentina orevi, for language advice and consulting.
References
1. Fisher WD. Impact of venous thromboembolism on clinical managment and therapy after hip and knee arthroplasty. Can J Surg 2011;54:344-51.
Antonijevi, et al
41
2. Schulman S, Majeed A. A benet-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug Saf 2011;34:449-63. 3. Fareed J, Adiguzel C, Thethi I. Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thromb J 2011;9:5. 4. NICE Clinical Guidline 2010 (National Institute For Health and Clinical Exellence) London; www. nice.org.uk; 2010;1-50. 5. Hunt BJ. The prevention of hospital acquired venous thromboembolism. Br J Haematol 2009; 144:642-52 . 6. Kaatz S, Qureshi W, Lavender RC. Venous thromboembolism: what to do after anticoagulation is started. Cleve Clin J Med 2011;78:609-18. 7. Kaatz S, Qureshi W, Fain C, Paje D. Duration of anticoagulation treatment in patients with venous thromboembolism. J Am Osteopath Assoc 2010;110:638-44. 8. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120-38. 9. Goldhaber SZ. Risk factors for venous thromboembolism. JACC 2010;56:1-7. 10. Bauer KA. Duration of anticoagulation: applying the guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2010:210-5. 11. East AT, Wakeeld TW. What is the optimal duration of treatment for DVT? An update on evidence-based medicine of treatment for DVT. Semin Vasc Surg 2010;23:182-91. 12. Galanaud JP, Bosson JL, Qur I. Risk factors and early outcomes of patients with symptomatic distal vs. proximal deepvein thrombosis. Curr Opin Pulm Med. 2011;17:387-91. 13. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008;25:37-44. 14. Prandoni P, Piovella C, Spiezia L, Dalla Valle F, Pesavento R. Optimal duration of anticoagulation in patients with venous thromboembolism. Indian J Med Res 2011;134:15-21. 15. Goldhaber SZ. Pulmonary embolism. In: Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E. Braunwalds Heart Disease. Ninth Edition. Philadelphia. Elsevier Saunders 2012;1679-95. 16. Hyers TM, Shetty HG, Campbell IA. What is the optimum duration of anticoagulation for the management of patients with idiopathic deep venous thrombosis and pulmonary embolism? J R Coll Physicians Edinb 2010;40:224-8. 17. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121:1630-6. 18. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010;376:20329. 19. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504-10. 20. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003;1:28-32. 21. Eischer L, Tscholl V, Heinze G, Traby L, Kyrle PA, Eichinger S. Hematocrit and the risk of recurrent venous thrombosis: a
prospective cohort study. PLoS One.2012;7:e38705. 22. Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007;115:1609-14. 23. Hron G, Lombardi R, Eichinger S, Lecchi A, Kyrle PA, Cattaneo M. Low vitamin B6 levels and the risk of recurrent venous thromboembolism. Haematologica 2007;92:1250-3. 24. Gulesserian T, Hron G, Endler G, Eichinger S, Wagner O, Kyrle PA. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:65-7. 25. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008;168:1678-83. 26. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancyassociated recurrent venous thromboembolism in women with a history of venous thrombosis J Thromb Haemost 2005; 3: 94954. 27. Daneschvar HL, Seddighzadeh A, Piazza G, Goldhaber SZ. Deep vein thrombosis in patients with chronic kidney disease. Thromb Haemost 2008;99:1035-9. 28. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl 6):381S-453S. 29. Schreijer AJM, Cannegieter SC, Meijers JCM, Middeldorp S, Bller HR, Rosendaal FR. Activation of coagulation system during air travel: a crossover study. Lancet 2006;367(9513):832-8. 30. Coppens M, Schreijer AJM, Berger FH, Cannegieter SC, Rosendaal FR, Bller HR. Mechanical prophylaxis for travellers thrombosis: a comparison of three interventions that promote venous out ow. J Thromb Haemost 2007;5:1556-67. 31. Philbrick JT, Shumate R, Siadaty MS, Becker DM. Air travel and venous thromboembolism: a stematic review. J Gen Intern Med 2007;22:107-14. 32. Antonijevic N, Stanojevic M, Milosevic R, et al. Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirtythree-year follow-up. J Thromb Thrombolysis 2005;19:93-5. 33. Antonijevic NM, Milosevic R, Perunicic J, Stanojevic M, Calija B, Vasiljevic Z. Need for more intensive treatment of patients with acute pulmonary embolism caused by heparin- induced thrombocytopaenia Type II. Eur Heart J 2005;26:2745-6. 34. Antonijevi N, Stanojevi M, Perunii J, et al. Thrombocytopenia induced by type II heparin and myocardial infarct: 2 case reports. Srp Arh Celok Lek 2004;132:33-7. 35. Antonijevi N, Stanojevi M, Miloevi R, et al. Heparin-induced type II thrombocytopenia-new views on diagnosis and therapy. Med Pregl 2003;56:247-50. 36. Antonijevi NM, Radovanovi N, Obradovi S, et al. Obstacles in the diagnostics and therapy of heparin-induced thrombocytopenia. Srp Arh Celok Lek 2010;138 Suppl 1:69-73. 37. Antonijevi N, Kanjuh V, Zeevi R, et al. Mogunosti novih antitrombocitnih i antikoagulantnih lekova u okviru primarne perkutane koronarne intervencije. Balneoklimatologija 2011;35:101-19.
42
38. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etixilate- a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27.
39. Friedman R.J, Dahl O.E, Rosencher N. et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thromb Res.2010;126:175182.
Faktori rizika za venski tromboembolizam i trajanje antikoagulantne terapije

Neboja M. Antonijevi, Vladimir Kanjuh, Ivana ivkovi, Ljubica Jovanovi
APSTRAKT Utvrivanje reverzibilnih i ireverzibilnih faktora rizika za venski tromboembolizam (VTE), preduslov je za odreivanje adekvatnog reima tromboprolakse. Podaci ukazuju da najvei procenat plunih embolija nastaje u nehirurkih bolesnika. U hirurkih bolesnika VTE se u velikom broju javlja posle otpusta iz bolnice. Ova saznanja nameu potrebu za adekvatnom zatitom od VTE obolelih od inamatornih oboljenja, akutnih bolesti i drugih nehirurkih oboljenja, kao i optimalizacijom antikoagulantnog reima posle hirurkih intervencija. Utvrivanje faktora rizika za VTE, odreivanje prisustva steene i uroene trombolije, okultnog ili do tada neprepoznatog maligniteta pomoi e denisanju antikoagulantnog reima u hirurkih i nehirurkih bolesnika u sekundarnoj prevenciji VTE. Praenje vrednosti D-dimera, ultrazvuna procena rezidualne venske tromboze, ehokardiografski parametri uz druge relevantne klinike podatke ukazuju na rizik od nastanka rekurentnog VTE. Ove procedure omoguavaju utvrivanje optimalne duine antikoagulante terapije u svakog bolesnika ponaosob, sa posebnom panjom na prisutne komorbiditete i hemoragijsku tendenciju. KLJUNE REI Venski tromboembolizam, tromboprolaksa, rekurentna tromboza, rizik od krvarenja.
43
CONTINUING MEDICAL EDUCATION
Milka Mavija
Department of Ophthalmology, University Medical Center Banja Luka, 78000 Banja Luka
Questions and Answers

(Q & ) . . [This section includes short segments of texts from the published literature or original texts. The main purpose is to provide questions and answers that readers can use to improve their English.] Scripta Medica
DOI: 10.7251/SMD1301043M (Scr Med 2013;44:43-50)
Sanja Ili
Department of Endodontics, Institute of Dentistry, 78000 Banja Luka
Verica Pavli
Department of Periodontology, Institute of Dentistry, 78000 Banja Luka Correspondence Verica Pavli, DDS, Ph.D. Department of Periodontology Institute of Dentistry 78000 Banja Luka
Questions 1. What is the role of the cranial nerves in activities associated with vision and in the act of speaking? 2. What are the main characteristics of central retinal artery occlusion? 3. Describe the Purkinje Effect. 4. How did daltonism get its name? 5. The posterior portion of the eye is vascularized by three circulations (retinal, choroid, and optic nerve). How are each of these affected by hypertension? 6. Which are the key points for assessing ocular trauma? 7. How are specimens collected for microbiological analysis of eye infections? 8. Describe the etiology and diagnosis of left ventricular hypertrophy. 9. Dene the term genomics. 10. Is there a signicant genetic component affecting blood pressure and hypertension? 11. Arterial hypertension has a relatively low prevalence in children compared to adults. At what age should one begin to monitor blood pressure yearly in children? 12. A 16-year-old girl is brought to a physician by her mother, who states that her daughter has been steadily losing weight. The adolescent denies there is a problem and states that she is in no way underweight. The physician determines that the
girl is 5 ft 6 in tall and weights 90 lb. Which of the following laboratory tests is most helpful in assessing the severity of starvation in this patient? A. Complete blood count and differential white blood cell count B. Thyroid function studies C. Serum potassium level D. Determination of albumin in blood E. Liver function studies 13. The adolescent described above is diagnosed with anorexia. After stabilization of her nutritional status on a specialized inpatient unit, she is discharged home, with plans for follow-up therapy as an outpatient. Which of the following treatments have been shown to be effective in treating anorexia nervosa as an outpatient? A. Psychodynamic psychotherapy B. Family therapy C. Brief supportive therapy D. Group therapy E. Insight-oriented psychotherapy 14. A 46-year-old woman with stage III ovarian cancer presents to your outpatient clinic with nausea. The nausea has worsened over the past 2 days, and she is unable to consume anything beyond her medications and a few sips of water without vomiting. She is receiving chemotherapy with carboplatin and paclitaxel and notes that she has not had difculty with nausea during or after chemotherapy because her oncologist administers antiemetics prophylactically before each session. It has been 17 days since her last chemotherapy. The nausea does not seem to occur with movement; it is worse after eating solids and liquids and is accompanied by abdominal distension. She has minimal abdominal pain, which is managed with oxycodone, 10 mg orally 3 times a day. Her last bowel movement was 4 days ago. Abdominal radiography (obstruction series) shows no air-uid
44
levels, no free air, and no evidence of obstruction, but there is a moderate amount of stool in the colon. Which one of the following is the most appropriate antiemetic to prescribe initially to this patient? A. Metoclopramide, 10 mg orally 4 times a day B. Ondansetron, 8 mg orally twice a day C. Promethasine, 25 mg orally (or suppository) every 6 hours D. Lorazepam, 1 mg orally every 6 hours E. Granisetron, 1 mg orally once daily 15. Name the hearing loss due to the aging processes. 16. Will a diet high in fructose, cholesterol, and saturated fats produce brosis of the liver? 17. What is the meaning of editorial style? 18. Water is ubiquitous in biology and in many other areas of nature. However, generally, water in tissues is not in the form of bulk liquid. Water in cells interacts with cell membranes, the surfaces of proteins, the interiors of proteins, and many other biological molecular species. Water plays a fundamental role in many diverse processes because it can undergo structural reorganization. Are the dynamics of water very fast or slow? 19. Because reproduction is arguably the most important event in any animals life, understanding how reproduction is regulated offers important insights into the evolution of a particular species. Learning how social and physiological factors collaborate to control reproductive activity is essential for understanding the selective pressures that shape reproductive control. How does reception of social information reach brain regions responsible for initiating reproductive behaviors? How are gamete (sperm, oocyte) production and steroid hormone release controlled? Ultimately, how do social interactions inuence gene expression to control reproduction? 20. What is the main dental concern for patients treated with the newer drugs for management of osteoporosis and malignant bone pathology? 21. Which serum biomarker may be used to indicate the risk of bisphosphonate-related osteonecrosis of the jaw? 22. What are the newest approaches in treatment of xerostomia? 23. Why do teeth change their color? 24. Which access has better outcome in ST-segment elevation acute coronary syndrome undrergoing early invasive treatment: radial or femoral?
25. Can overweight as dened by body mass index (BMI) actually have a protective association with mortality? Answers 1. Cranial nerve activities associated with vision. Stimulation of the eye produces not only conscious visual sensations but also ancillary responses that utilize many peripheral nerves. The constriction of pupils to bright light and the focusing of the lens are effected via the parasympathetic bers of the oculomotor nerve, whereas dilatation of the pupil in dim light is mediated via sympathetic bers from the upper thoracic spinal cord levels. Pain from irritation of the cornea is transmitted by the trigeminal nerve. Blinking of the eyelid results from stimulation by the facial nerve; movements of the eye and raising the eyelid follow stimulation by the oculomotor, trochlear, and abducens nerves; the secretion of tears from the lacrimal gland results from stimulation of parasympathetic bers of the facial nerve. Act of speaking. Contraction and relaxation of the thoracic and abdominal musculature during exhalation and inhalation, mediated by spinal nerves, are essential preliminaries to the act of speaking. Vowels are formed by the vibration of the vocal cords of the larynx, which are innervated by the vagus nerve; resonance is aided by relaxation of the pharynx and palatine arch muscles (this is especially pronounced in singers), which are innervated by the glossopharingeal and vagal nerves. Certain consonants, such as Ts and Ds, are formed by the action of the tongue, which is innervated by the hypoglossal nerve; others, such as Ss and Cs, are formed by the combined action of the jaw, tongue, and lips, involving the trigeminal, hypoglossal, and facial nerves. The lips alone form the consonant P through activation of the facial nerve. 2. Sudden, severe, and painless loss of vision in one eye is characteristic of central retinal artery occlusion (CRAO). The retina becomes opaque and edematous, particularly in the posterior pole where the nerve bers and ganglion cell layers are thickest. The orange reex from the intact choroidal vasculature beneath the foveola stands out in contrast to the surrounding opaque neural retina, producing the characteristic cherry- red spot. The central retinal artery reopens or re-canalizes with time, and the retinal edema clears. However, the retinal arterial infarction generally has a devastating effect on visual acuity. In one study, 66% of CRAO eyes studied had nal vision worse than 20/400, and 18% had vision of 20/40 or better. Most cases of 20/40 or better vision had a patent cilioretinal artery, which preserves the central macula. Loss of vision to the level of no light perception at all is often associated with choroidal vascular insufciency (ophthalmic artery occlusion) in addition to occlusion of the central retinal artery. 3. Purkinje Effect. The Purkinje effect (sometimes called the Purkinje shift, or dark 2. adaptation) was named after the Czech anatomist, Jan Evangelista Purkyn, who noted that
45
light blue owers appear bluer at dawn or twilight than at midday. At dusk, red owers appear black. The effect occurs because color-sensitive cones in the retina are the most sensitive to yellow light, whereas the rods, which are more light sensitive (and thus more important in low light) respond best to green-blue light, even though they do not distinguish colors. This is why humans become virtually color-blind under low levels of illumination, for instance in moonlight. The insensitivity of rods to long-wavelength light enables us to use red lights under certain circumstances, as in the control rooms of submarines, in research laboratories, or during naked-eye astronomy. Submarines are dimly lit to preserve the night vision of the crewmembers working there, but the control room must be suf ciently lit for reading of instrument panels. Under red light, or with red goggles, the retinal cones receive enough light to provide photopic vision (namely the high-acuity vision required for reading). Because the rods are not saturated by bright light and are insensitive to long-wavelength red light, the individual can remain dark adapted, in case he needs to use the periscope at night, for example. Red lights are also often used in research settings. Many research animals, such as rats and mice, have limited photopic vision, because they have far fewer cone photoreceptors. Red lights keep the animals in the dark (the active period for nocturnal animals), while allowing the human researchers, who have one kind of cone that is sensitive to long wavelengths, to read instruments or perform procedures that would be impractical even with fully dark adapted (but low acuity) scotopic vision. For the same reason, zoo displays of nocturnal animals often are illuminated with red light. The Purkyn effect was discovered in 1819 by Jan Evangelista Purkyn, a polymath (knowledgeable man) who would often meditate at dawn during long walks in the blossoming Bohemian elds. Purkinje noticed that his favorite owers appeared bright red on a sunny afternoon, while at dawn they looked very dark. He reasoned that the eye has not one but two systems adapted to see colors: one for bright overall light intensity and the other for dusk and dawn. Purkinje wrote in his Neue Beitrge (translated from the German): Objectively, the degree of illumination has a great inuence on the intensity of color quality. In order to prove this most vividly, take some colors before daybreak, when it begins slowly to get lighter. Initially one sees only black and grey. Particularly the brightest colors, red and green, appear darkest. Yellow cannot be distinguished from a rosy red. Blue became noticeable to me rst. Nuances of red, which otherwise burn brightest in daylight, namely carmine, cinnabar and orange, show themselves as darkest for quite a while, in contrast
to their average brightness. Green appears more bluish to me, and its yellow tint develops with increasing daylight only. 4. An article entitled Deciency of color vision was published in 1798 by the English chemist, John Dalton. He described his own color blindness. Because of Daltons work, the general condition has been called daltonism, although this term in English now applies more narrowly to deuteranopia alone. Colorblindness, or color deciency, is a sex-linked characteristic found to some degree in 8 % of males and 1.5 % of females. There is no actual blindness but a deciency of color vision. The most usual cause is a fault in the development of one or more sets of retinal cones that react to various wavelengths in light and transmit that information to the optic nerve. This type of color blindness is usually a sex-linked condition. The genes that produce photo-pigments are carried on the X chromosome. If some of these genes are missing or damaged, color blindness will be expressed in males with a higher probability than in females because males lack a second X chromosome. A functional gene on only one of the two X chromosomes in the female supplies the needed photo-pigments. Color blindness can also result from physical or chemical damage to the eye, the optic nerve, or parts of the brain. For example, people with achromatopsia suffer from a completely different disorder, but are nevertheless unable to see colors. All classications of colorblindness are based on subjective defects in perception, even though the specic cause is unknown. Individuals with three-color vision (trichromats) are those with 1) normal vision, 2) weak red vision (protanomaly), or 3) weak green vision (deuteranomaly). Individuals with two-color vision (dichromats) are those who who 1) cannot perceive red (protanopia), 2) cannot perceive green (deuteranopia) or 3) cannot perceive blue (tritanopia). Persons with tritanopia are rare, as are those with no color vision (monochromatomats). Monochromatomas see the environment in shades of light and dark, and some of them experience pain during light stimulation. Color blindness is usually classed as a mild disability, but there are occasional circumstances where it appears advantageous. Some studies conclude that colorblind people are better at penetrating certain color camouages. This might indicate an evolutionary advantage to account for the high prevalence of redgreen color blindness. 5. The retina is the only tissue in the body in which blood vessels can be observed directly. Examination of the ocular fundi enables the physician to observe the effects of hypertension in a unique vascular bed. The three circulations of the posterior portion of the eye derive from branches of the ophthalmic artery. The retinal circulation is particularly sensitive to local tissue metabolic needs (glucose consumption and oxygen use are 3-fold higher than in any other tis-
46
sue in the body) and is susceptible to damage from circulatory dysfunction. Retinal circulation. Changes in retinal blood vessels are the most common vascular lesions in the eye due to systemic hypertension. Hypertensive retinopathies have been classied by a number of investigators (e.g., Keith, Wagner, and Baker, 1939, and those of Scheie, 1953), but these classications are less useful clinically than a careful description of the extent of lesions in the eye. Hypertensive retinopathy may include various combinations of lesions. Some are relatively specic for hypertensive retinopathy, e.g., copper wiring of arterioles, arteriovenous nicking and related crossing changes, as well as arterial macroaneurysms. Additional hypertensive lesions found in other disorders include the cotton-wool spots in diabetic retinopathy, systemic lupus erythematosus, retinal vein occlusions, and acquired immune deciency syndrome. Flame-shaped intraretinal hemorrhages also occur in diabetic retinopathy, profound anemia, the leukemias and other blood dyscrasias. Arterial silver wiring may occur in diabetic retinopathy, collagevascular diseases, and arterial occlusive diseases. Chorioidal circulation. Hypertensive changes in the chorioidal vessels occur much less frequently than hypertensive changes in the retina. Hypertensive chroidopathy occurs because the short choroidal arteries feed at right angles into the choroidal capillaries, allowing direct transmission of systemic blood pressure to the capillaries. Initial changes may include focal regions of choriocapillary nonperfusion resulting from brinoid necrosis of the vessels. These defects are recognized only by the use of specic techniques such as intravenous uorescein angiography. The retinal pigment epithelium over these nonperfused regions may subsequently develop a yellowish coloration called the Elschnig spot. This eventually becomes a scar with a pigmented center and an atrophic surrounding halo. Optic nerve circulation. Hypertensive changes in the optic nerve are relatively uncommon. The principal optic nerve lesion of hypertension is disc edema. 6. Key points for managing ocular trauma include following: -Take an accurate history. -Search for foreign bodies under the upper lid. -Suspect a subtarsal foreign body with persistent pain in an intact eye. -Irrigate chemical injuries immediately with clean water. -Suspect a perforating eye injury if the pupil is not round, a cataract develops rapidly or vitreous hemorrhage is present. 7. Several types of specimens may be collected for the microbiological analysis of the eye infections. These include conjunctival scrapings obtained with a swab or sterile spatula for the diagnosis of conjunctivitis, corneal scrapings collected with a sterile spatula for the diagnosis of kerati-
tis, vitreous uid collected by aspiration for the diagnosis of endophtalmitis, and uid material collected by aspiration from a tissue biopsy for the diagnosis of periorbital cellulitis. Direct inoculation of agar culture plates and preparation of smears in the clinic or at the bedside is recommended for the small volumes of specimens collected from corneal scrapings and vitreous uid. A close working association between the laboratory and ophthalmologist will ensure a supply of appropriate culture media, correct techniques for inoculation media, and rapid transport of plates and smears to the laboratory. 8. Left ventricular hypertrophy (LVH) is the response of the heart to chronic pressure, volume overload, or both. The most common causes of cardiac hypertrophy are hypertension and valvular heart disease. Genetic factors determine the extent of the hypertrophic response to existing stimuli, and several mutations have been identied in kindreds with severe familial forms of LVD. These can occur even in the absence of hypertension. The diagnosis of LVH an be made in several ways, but it is commonly identied by electrocardiogram (ECG) on the basis of increased voltage and repolarization abnormalities, or by an echocardiogram that calculates left ventricular mass (LVM) from measured LV wall thickness and internal chamber dimensions. 9. The totality of DNA possessed by an individual constitutes his or her genome. Genomics, as distinct from genetics, is the study of the organization and evolutionary history of DNA. The total human genome is approximately three billion bases long; this is the product of two parental genomes of three billion base pairs each (i.e., roughly six billion bits of information divided into pairs). 10. There is evidence for a signicant genetic component of blood pressure in humans, and several intermediate phenotypes closely associated with hypertension relate directly to specic genes. Intermediate phenotypes are quantiable biologic traits (such as angiotensinogen levels or salt sensitivity) that, in appropriate combinations, account for a fraction of the overall risk for the development of hypertension. Numerous linkage analyses using 300 to 500 markers spread over all chromosomes suggest several locations for hypertension genes. Some of the more consistent areas are on chromosome arms 1q, 2p, 2q, 8p, 17q, and 18q. Other less consistent regions may still harbor important genes. Genes involving the renin-angiotensin system have been the ones most systematically studied. A family history of hypertension is commonly used as a measure of familial aggregation, and it can be a surrogate measure for undened risk factors shared by the family. Controlling or removing behavioral risk factors confers the
47
greatest benet for individuals with the greatest genetic risk. Interactions between genetic variations and environmental factors such as stress, diet, and physical activity also contribute to the development of essential hypertension. It is well known that hypertensive individuals exhibit a varied response to antihypertensive drugs, likely reecting a wide variety of factors, including differences in pharmacodynamic and pharmacokinetic traits. Pharmacogenetics, the study of genetic variations that inuence responses to pharmacogenetic agents, is an emerging eld based upon genetic-environmental interactions. 11. Measurement of blood pressure in children is recommended yearly after the age of three years. The diagnosis of hypertension in children now uses the fth Korotkoff sound to dene diastolic blood pressure. It also depends on height. The average systolic BP at one day of age is approximately 70 mm Hg in full-term infants, and it increases to approximately 85 mm Hg by one month of age. During the rst year of life, BP increases at a greater rate in premature infants than in full-term infants. BP then increases steadily throughout the rst two decades of life. Greater weight, greater height, and family history of hypertension are known to be associated with higher levels of BP in children and adolescents. 12. The correct answer is D. Determination of the albumin level can help assess the current extent of starvation in a patient. It is an important index in the treatment of anorexic patients. 13. The correct answer is B. Family therapy, both short-term and long-term, has been shown to improve outcomes in adolescent patients with anorexia nervosa. Many of these family treatments are completed in stages, generally beginning with developing parental control over the eating and gradually turning control over to the adolescent as nutritional status improves. Some cognitive behavioral therapies may be effective, but there is little evidence for the others listed. 14. The correct answer is A. Comment: This patients nausea is likely due to gastrointestinal distension and irritation from both constipation and her ovarian cancer; there is possibly a direct effect from the opioid therapy as well. Opioidinduced nausea is primarily mediated by dopamine. In this case, serotonin receptors in the gastrointestinal tract, serosa, and viscera are also involved. Dopamine blockade would likely be helpful for this patient. Metoclopramide, a dopamine D2 receptor antagonist with some peripheral serotonin antagonism, would be the best choice. Prochlorperazine and haloperidol would also be reasonable choices. Enough time has passed since the patients most recent chemotherapy that it should not be a major contributor to her
nausea at this time. Importantly, she does not appear to have a bowel obstruction. It is important to rule out obstruction to preclude the need for surgical intervention or nasogastric tube placement. Obstruction should also be ruled out before administering metoclopramide, given the promotility actions of the drug. Anxiety does not seem to be a major component of the patients condition, and lorazepam alone has poor antiemetic effects. Toxin-induced nausea, such as medication effects and electrolyte disturbances (e.g., hypercalcemia) are mediated through the chemoreceptor trigger zone (CTZ), within the area postrema in the oor of the fourth ventricle. Serotonin and dopamine are the two most active neurotransmitters in the CTZ. Serotonin antagonists, such as haloperidol, metoclopramide, or prochlorperazine, are most effective for treatment of CTZ-mediated nausea. Promethazine is a weak antagonist of dopamine, and it generally acts by inducing sedation via antihistaminic and anticholinergic pathways. Promethazine is not routinely recommended for nausea, given its limited efcacy and wide range of adverse effects. Conclusion: Selection of an antiemetic should consider the mechanism of the drugs action and the putative factors that contribute to the nausea. 15. The term presbycusis refers to the hearing loss due to aging. Aging generally affects the cochlea, but it may also affect the central auditory pathway. The deafness of aging is characteristically bilaterally symmetrical and predominantly affects high tones. The basal turn of the cochlea is involved in perception of high tones, while lower turns are appreciated higher up in the cochlear spiral. Because it is nearest the oval window through which vibrations enter the cochlea, the basal turn bears the brunt of wear and tear and hearing for high tones fails rst. In aged individuals, the ear has likely been exposed to one or more other causes of hearing loss. Presbycusis appears to begin earlier in urban than in rural communities. Pathological changes can affect any of these four sites in the cochlea: a. In sensory presbycusis the organ of Corty in the basal turn of the cochlea atrophies, with disappearance of hair cells. b. Strial presbycusis exhibits patchy atrophy of the stria vascularis, with cystic changes. c. In cochlear conductive prebycusis the basal membrane becomes stiffened and calcied, especially in the basal turn. d. Neural presbycusis involves atrophy of the spiral ganglion with severe loss of ganglion cells. Audiograms reveal that neural presbycusis is associated with severe loss of speech discrimination, and strial prebycusis shows a fairly even hearing loss at all frequencies with good speech discrimination. High tone loss is charac-
48
teristic of the sensory and cochlear conductive forms. 16. A diet high in cholesterol, saturated fats and fructose (i.e., fast food) promotes development of nonalcoholic fatty liver disease (NAFLD), insulin resistance, and metabolic syndrome. The progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), is characterized by inammation and fat accumulation in the liver, which can lead to cirrhosis and ultimately to loss of liver function. A newly developed animal model of NASH shows gene expression typical of metabolic syndrome and NASH with progressive brosis. It is interesting to note that the observed effects were more pronounced in male mice than in females. 17. When editors or typesetters refer to style, they do not mean writing style, but rather editorial stylethe rules or guidelines a publisher follows to ensure clear, consistent presentation of the printed word. Editorial style concerns uniform use of punctuation and abbreviations, construction of tables, section of headings, and citation of references, as well as many other elements that are part of every manuscript. An author writing for a particular publication must follow the style rules established by the publisher to avoid inconsistencies among journal articles or book chapters. For example, without rules of style, three different manuscripts might use sub-test, subtest, and Subtest or E-mail, e-mail or email. Although the meaning of these two words in three variations is the same, and the choice of one style over the other may seem arbitrary (subtest and e-mail are APA style), such variations in style may distract or confuse the reader. 18. The dynamics of water are very fast, picosecond to tens of picosecond on the time scale. Ultrafast infrared (IR) experiments performed on the hydroxyl (OH) stretch of water can be used to measure the dynamics of water molecules under thermal equilibrium conditions. Water at an interface behaves differently in a system where the characteristic nanodimension is relatively large (>10 nm) vs. one in which it is small (<4 nm). Water dynamics depend on the nature of the large molecular structures the water is interacting with, but also to an even greater extent on the size of the nanoscopic water system.1* 19. Reproduction in all vertebrates is controlled by the hypothalamic-pituitary-gonadal axis. In many species the social environment inuences this axis, and consequently reproductive tness. Numerous studies in vertebrates demonstrate activation of reproduction by olfactory, auditory, tactile, and visual social signals; these signals can reect changes in the number, size or axonal densities of gonadotropin-releasing hormone 1(GnRH1) peptide, either delivered
1
directly via neuronal projections in shes or via the hypothalamic-pituitary portal system in tetrapods. The peptide binds to GnRH receptors on these secondary cells to induce synthesis and release of two gonadotropin hormones, LH and FSH, which then target the gonads (testes or ovaries) to stimulate steroid production and gamete development. Social behaviors are dened as interactions among members of the same species that inuence immediate or future behaviors, including production, reception, and interpretation of communicative signals in a context-dependent manner.
This Figure is from an article entitled Social Regulation of Gene Expression in the Hypothalamic-Pituitary-Gonadal Axis by Karen P. Maruska and Russell D. Fernald in Physiology (2011;26:412-23). Reproduced by permission of The American Physiological Society. 20. Recently introduced medications such as bisphosphonates (alendronate, etidronate, clodronate, pamidronate, risedronate, zoledronate, etc.) are used in the therapy of osteoporosis, Pagets disease and the hypercalcemia of malignancy. These new agents broaden the range of current treatment options. Even though contemporary studies suggest positive effects of bisphosphonates used in everyday practice, there are also risks associated with their use, such as inhibition of osteoclast functions that lead to inhibition of normal bone turnover. This can result in impaired wound
We refer to water conned on nanometer length scales as nanoscopic water.
49
healing following trauma (such as dental surgery) or even spontaneous non-healing bone exposure. Because bisphosphonates are preferentially deposited in bone with high turnover rates, the levels of bisphosphonates within jawbones may be elevated selectively. The main dental concern is bisphosphonate-related osteonecrosis of the jaw. Numerous studies indicate a relation between use of bisphosphonates and osteonecrosis after dental extraction. Patients who are taking intravenous bisphosphonates for cancer and must undergo dental extraction have an incidence of osteonecrosis of the jaw of one in 10-15 patients, or 10-15 % of this population. To date the incidence of jaw osteonecrosis in patients treated with intravenous zoledronic acid and subcutaneous denosumab for osteoporosis is unknown, but it is assumed to be low. Since these substances can be considered as drugs, patients should have their oral health checked before treatment. Their bone turnover will be markedly suppressed post-infusion, and dental extractions must be avoided for at least several months. However, strontium ranelate or teriparatide pose no risks for osteonecrosis of the jaw. These agents have completely different mechanisms of action than the bisphosphonates. In fact, teriparatide may be a good treatment option for bisphosphonate-related osteonecrosis of the jaw. 21. C-terminal telopeptide (carboxy-terminal collagen crosslinks, also known as CTX) is a serum biomarker for bone turnover. It can be useful in assessing risk and guiding clinical evaluation of the nonsurgical treatment response as well as a guide for timing of surgery to pose the least risk of complications during healing. All patients with bisphosphonate-related osteonecrosis of the jaw were found to have low bone turnover as measured by C-terminal telopeptide at the time of onset. The morning fasting CTX test results cannot predict exactly who will develop bisphosphonate-related osteonecrosis of the jaw. CTX values are useful for stratication of relative risk: less than 100 pg/mL indicates high risk; between 100 pg/mL and 150 pg/mL indicates moderate risk; above 150 pg/mL indicates minimal risk. 22. Xerostomia is subjective complaint of mouth/oral dryness, caused by a reduction in normal salivary secretion due to different causes. Even though there are many treatment modalities available to enhance salivary ow, the therapy often remains unsatisfactory. Unknown etiology and lack of specic therapy make management of this disease very difcult. Low-level laser therapy (LLLT; low-level laser irradiation, photo-bio-modulation) has been used extensively as a non-invasive tool for reduction of xerostomia. LLLT signicantly enhances salivary secretion and improves antimicrobial characteristics of secreted saliva (increased levels of secretory immunoglobulin A, sIgA). Furthermore, LLLT improves salivary ow and regeneration of salivary duct epithelial cells. It can be safely and effectively used as an advanced treatment modality for reduction of xerostomia.
23. The causes of color changes in vital teeth are: secondary mineralization after trauma, enamel defects, use of systemic drugs such as uoride, tetracyclines (tetracycline, oxytetracycline, doxycycline, minocycline)2*, ciprooxacin, amoxicillin, hemorrhage (after vital extirpation), and exposure to coffee, red wine, tobacco, certain spices, etc. The main causes of the changes in color for nonvital teeth are: pulp necrosis, endodontal drugs and treatment materials such as iodoform, endometasone, and restorative materials, such as amalgam. 24. In patients with acute coronary syndrome (ACS), major bleeding is a signicant predictor of worse outcome. Access site complications represent a signicant source of bleeding for those patients undergoing revacularization, especilly when femoral access is used. Observational data and small randomized trials suggest that radial instead of femoral access for coronary angiography/intervention results in fewer bleeding complications, with preserved and possibly improved efcacy, further translating into mortality benet in higher-risk patients, such as those with ST-segment elevation myocardial infarction (STEMI). In the two large randomized trials: Radial Versus Femoral Access for Coronary Intervention (RIVAL) and Radial Versus Femoral Investigation in ST Elevation Acute Coronary Syndrome (RIFLE-STEACS) investigators report a detailed analysis the radial and femoral approaches in patients with STEMI. The RIVAL trial was performed in 32 countries (7.021 patients), and RIFLE-STEACS trial was performed at 4 Italian centers. In patients with STEMI, radial artery access reduced the primary outcome and mortality. No such benet was observed in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). The radial approach may be preferred in STEMI patients, provided adequate operator and center expertise is present 25. Overweight-obesity is dened as a BMI of 27.8 or greater for men and 27.3 or greater for women. The WHO dened preobesity (overweight) as a BMI of 25 or greater and class (grade) 1 obesity as a BMI of 30 or greater, class 2 as a BMI of 35 or greater, and class 3 as a BMI of 40 or greater. Using a sample of more than 2.88 million individuals with more than 270 000 deaths, it was found (Flegal KM, et al. JAMA 2012;309:71-82) that all-cause mortality hazard ratios (HRs) relative to normal weight (dened as a BMI of 18.5-<25) for overall obesity (grades 1, 2, and 3 combined; HR, 1.18 [95% CI, 1.12-1.25]). Higher all-cause mortality was not observed in individuals with grade 1 obesity. Mortality was signicantly lower among those who were overweight individuals. Body mass index accounts for about two-thirds of the beTetracyclines stain developing teeth, even when taken by the mother during pregnancy. These drugs discolor permanent teeth (yellow-gray-brown), from infancy and childhood to eight years old.
2
50
tween-individual variation in total adiposity. Body mass index not account for sex, race, age, and tness differences in fat mass even at the same body weight. Body mass index is known to be an imperfect predictor of metabolic risk. Some individuals with normal BMI have an overweight-obesity metabolic pattern. Factors such as cardiorespiratory tness are also independent predictors of total mortality in some groups after controlling for BMI, waist circumference, and percentage of body fat. Newer markers such as those representing systemic inammation may also extend risk prediction beyond BMI. Establishing BMI is only the rst step toward a more comprehensive risk evaluation. Literature
Anonymous. Publication manual of the American psychological association, fth edition. Washington, DC, American Psychological Association, 2001. Antonini LG, Luder HU. Discoloration of teeth from tetracyclineseven today? Schweiz Monaatssehr Zahnmed 2011; 121:414-22. Charlton M, Krishnan A, Viker K, et al. The fast food diet mouse: a novel small animal model of NASH with high histologic and physiologic delity to the human condition. Am J Physiol Gastrointest Liver Physiol, doi:10.1152/ajpgi.00145.2011 Fayer MD. Water in a crowd. Physiology 2011;26:381-92. Heymseld SB, Cefalu WT. Does body mass index adequately convey a patients mortality risk? JAMA 2013;309:87-8. Hickish G W. Ear, nose and throat disorders. Edinburgh, Churchill, 1985. Izzo JL, Black HR, eds. Hypertension primer, third edition. Dallas, American Heart Association, 2003. James B, Chew C, Bron A. Lecture notes on ophthalmology, eight edition. Oxford, Blackwell, 1997. Jolly SS, Niemel K, Xavier D, et al. Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. Am Heart J 2011;161:254-60.
Kai T. Gotovi lekovi. Prirunik za farmakoterapiju, deveto izdanje. Beograd, Integra, 2003. Maruska KP, Fernald RD. Social regulation of gene expression in the hypothalamic-pituitary-gonadal axis. Physiology 2011;26:412-23. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397410. McCullough M. New drugs for osteoporosis. Australian Prescriber 2011;34:181. McCullough M, Goss A. Bone turnover markers. Australian Prescriber 2012;35:159. Mehta SR, Jolly SS, Carins J, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012;60:2490-9. Pavli V. The effects of low-level laser therapy on xerostomia (mouth dryness). Med Pregl 2012;65:247-50. Regillo CD. Retina and vitreous. Basic and clinical science course. San Francisco, American Academy of Ophthalmology, 2008. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2012;60:2481-9. Swetz KM, Carey EC, Bundrick JB. Clinical pearls in palliative medicine 2012. Mayo Clin Proc 2012;87:1118-23. Toy E, Klamen, D. Case les: Psychiatry, fourth edition. New York, Lange, 2012. Versalovic J, ed. Manual of clinical microbiology, tenth edition. Washington, DC, ASM Press, 2011.
Medline
52
Quality of life in patients with multiple sclerosis in Republic of Srpska. Tadi D, Daji V. Med Glas (Zenica). 2013 Feb;10(1):113-9. Inuence of the Green Tea Leaf Extract on Neurotoxicity of Aluminium Chloride in Rats. Jelenkovi A, Jovanovi MD, Stevanovi I, Petronijevi N, Bokonji D, Zivkovi J, Igi R. Phytother Res. 2013 Mar 11. doi: 10.1002/ptr.4962. [Epub ahead of print] Evaluation of set-up errors in head and neck radiotherapy using electronic portal imaging. Strbac B, Jokic VS. Phys Med. 2013 Jan 2. doi:pii: S1120-1797(12)00208-6. 10.1016/j.ejmp.2012.12.001. [Epub ahead of print] The analysis of limbs acute ischemia during seasons on the territory of South Serbia. Damnjanovi Z, Jovanovi M, Jankovi I, Cvetanovi V, Smiljkovi I, Jankovi D. Med Glas (Zenica). 2013 Feb;10(1):161-3. Inuence of age and length of service on the level of stress and burnout syndrome. Staneti K, Tesanovi G. Med Pregl. 2013 Mar-Apr;66(3-4):153-62. Ongoing initiatives in the Republic of Srpska to enhance prescribing efciency: inuence and future directions. Markovic-Pekovic V, Skrbi R, Godman B, Gustafsson LL. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):661-71. doi: 10.1586/erp.12.48. Increasing incidence of rubella in Republika Srpska in the period 2006-2010. Ceji V, Naumovi T. Med Glas (Zenica). 2012 Feb;9(1):109-11. PMID: 22634919 [PubMed - indexed for MEDLINE] [Idiopathic scoliosis]. Jandri S. Med Pregl. 2012 Jan-Feb;65(1-2):35-40. Review. Serbian. Digital clubbing as an unusual complication of the secondary hyperparathyroidism associated with atypical neutrophils: a case report. Prodanovic N, Spiric Z, Trninic G, Eric M. Eur Rev Med Pharmacol Sci. 2012 Oct;16 Suppl 4:98-102. Appearance of femoropopliteal segment aneurysms in patients with abdominal aortic aneurysm. Maksi M, Davidovi L, Tomi I. Vojnosanit Pregl. 2012 Sep;69(9):783-6. Risk factors for intraoperative arrhythmias in general surgery patients operated under general anesthesia: our one-year experience. Dosti MP, Tomovi MT, Popovi-Milenkovi MT, Stefanovi SM, Jankovi SM. Med Glas (Zenica). 2012 Aug;9(2):204-10. The incidence of type 1 diabetes in Republic of Srpska (Bosnia and Herzegovina) and Slovenia in the period 1998-2010. Radosevic B, Bukara-Radujkovic G, Miljkovic V, Pejicic S, Bratina N, Battelino T. Pediatr Diabetes. 2012 Aug 28. doi: 10.1111/j.1399-5448.2012.00898.x. [Epub ahead of print]
53
Joef Stefan and the dissolution-diffusion phenomena--not only a historical note. Mitrovic J. Int J Pharm. 2012 Jul 15;431(1-2):12-5. doi: 10.1016/j.ijpharm.2012.04.021. Epub 2012 Apr 13. [Diclofenac induced liver injuries]. Nezic L, Krhenbhl S, Rtz Bravo AE. Praxis (Bern 1994). 2012 Mar 14;101(6):371-9. doi: 10.1024/1661-8157/a000880. Review. German. Galactocele in male infants: report of two cases and review of the literature. Vlahovic A, Djuricic S, Todorovic S, Djukic M, Milanovic D, Vujanic GM. Eur J Pediatr Surg 2012; 22(3): 246-250 Necrobiotic cutaneous granulomas in Nijmegen breakage syndrome. Pasic S, Kandolf-Sekulovic L, Djuricic S, Zolotarovski L, Simic R, Abinun M. J Investig Allergol Clin Immunol 2012; 22: 138-140 Similar developmental patterns of ghrelin- and glucagon-expressing cells in the human pancreas. Vignjevi S, Todorovi V, Damjanovi S, Bude M, Mitrovi O, Djiki D, Drndarevic N, Mii M, Mikovi-Krivokapi J, Djurii S, Nikoli I. Cells Tissues Organs 2012; 196: 362-373 Prognostic value of surviving expression in Wilms tumor. Basta-Jovanovic G, Radojevic-Skodric S, Brasanac D, Djuricic S, Milasin J, Bogdanovic L, Opric D, Savin M, Baralic I, Jovanovic M. J BUON, 2012; 17: 168-173 Tamsulosin efciency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight. Milicevic S. Med Arh. 2012;66(6):391-5. Role of hereditary factors in strabismus occurrence. Regoda V, Sec-Kasumovic S. Med Arh. 2012;66(6):418-9. Hemodynamics of arterial and venous circulation in the intrauterine fetal evaluation. Cancarevic Djajic B, Vilendecic R, Ecim-Zlojutro V, Lucic N, Draganovic D, Savic S. Acta Inform Med. 2012 Dec;20(4):249-53. doi: 10.5455/aim.2012.20.249-253. [Assessment of recombinant human thyrotropin application in following-up patients with welldifferentiated thyroid carcinoma]. Rajkovaca Z, Kovacevi P, Staneti M, Risti S. Vojnosanit Pregl. 2012 Nov;69(11):941-6. Serbian. First-psychotic episode in childhood and adolescence. Radmanovi MB. Psychiatr Danub. 2012 Oct;24 Suppl 3:S388-91.
54
Recenziranje rukopisa naunih saoptenja

Recenziranje je proces procene vrednosti rukopisa naunih saoptenja, procene koju daje strunjak za podruje istraivanja. Uloga recenzenta je dvostruka: on uredniku asopisa daje miljenje o tome da li je rukopis pogodan za objavljivanje, a autorima, osim procene rada, esto pomae da poboljaju rukopis. Ovde opisujemo proces recenziranja, izgled recenzije, osnovna svojstva objektivne i konstruktivne recenzije, primere recenzija i odgovore autora koje su uputili uredniku. Rad na rukopisu od prijema u redakciju do publikovanja Kada rukopis stigne u redakciju, najpre se procenjuje da li odgovara zahtevima asopisa koji su navedeni u uputstvu autorima. Ako je ta ocena zdovoljavajua, veina biomedicinskih asopisa alje rukopis recenzentima, stunjacima koji dobro poznaju to podruje. Nakon eventualnih izmena, dopuna i prihvatanja rukopisa sledi niz postupaka pre njegovog publikovanja (Slika 1).
autorima, a neki im pomau pri planiranju istraivanja i sastavljanju rukopisa. Deava se da urednici objave prirunike kako bi autorima olakali zavrni deo istraivakog procesa.2 Recenzent prihvata ili odbija da obavi recenziju. Ako je prihvati, rok da se ona zavri nikada nije dui od mesec dana. U sluaju da recenzent ne prihvati ponudu urednika, on tu odluku hitro saoptava uredniku kako bi se to pre nala zamena. Recenzent ne navodi razlog neprihvatanja tog posla, ali je najee u pitanju prezauzetost, izbegavanje procene zbog konikta interesa, ili taj strunjak ne eli da posveti vreme proceni nekvalitetnog rukopisa. Poznat britanski asopis BMJ ima na spisku oko 2.500 recenzenata.3 (Uvek se trae novi, na osnovu objavljenih radova i preporuka, a odbacuju se loi recenzenti.) Recenziranje je privilegija i odgovornost. 4 Od recenziranja imaju korist asopisi, autori rukopisa i sami recenzenti. asopisi izuzetno retko pla aju recenzente, ali se recenzentima esto odaje javna zahvalnost tako to se u asopisu na kraju godine objave imena svih recenzenata. Takve spiskove mali asopisi, koji izlaze samo nekoliko puta godinje, obino ne objavljuju jer bi autori lako otkrili ko je bio recenzent. Recenzent pomae asopisu, a istovremeno prua doprinos nauci, jer takav rad obezbe uje kvalitet publikacija. Sem toga, recenzent ima i neposrednu korist jer prvi sazna rezultate koji se nalaze u rukopisu i to mu pomae u vlastitom radu. Me utim, nije eti ki da recenzenti preuzmu bilo kakvu ideju ili podatak iz rukopisa koji recenziraju. Tek kada se taj rad objavi u asopisu, oni ga mogu citirati u svojim publikacijama. Recenzenti su duni da dre u tajnosti podatke iz rukopisa. Izgled recenzije Neki asopisi zahtevaju da se izvetaj recenzenta (recenzija) dostavi u dva dela: 1) pismo upueno uredniku i 2) izvetaj koji e urednik uputiti autoru. U pismu uredniku se navodi ime recenzenta, naslov rukopisa i predlog uredniku (da se rukopis prihvati, odbije, preuredi, dopuni novim eksperimentima, itd.). Odnedavno sva korespondencija autora, urednika i renzenata obavlja se elektronski i sve je vie asopisa koji ne zahtevaju od recenzenta posebno, poverljivo miljenje o radu. Urednik recenziju alje autoru, a ponekad i drugom recenzentu. Recenzija je anoniman dokumenat za autora i za drugog recenzenta. Izuzetak su recenzije otvorenog tipa. Recenzija obino sadri nekoliko delova. Najpre se u jednom pasusu sumira (bez kritike) ono to je uradjeno u radu. Drugi segment sadri optu ocenu (vanost istraivakog pitanja, originalnost rada, jake i slabe strane metodologije, eksperimentalnog dizajna, ocenu statistikog pristupa i interpretacije rezultata). Zatim sledi konstruktivna kritika pojedinih delova rukopisa i na kraju se iznose manje tekstualne i gramatike greke. Na ove poslednje
Slika 1. Redosled rada na rukopisu, od njegovog prijema u redakciju do publikovanja.1 Slian je postupak kada asopis izlazi samo u elektronskom obliku.
Posle zadovoljavajue inicijalne ocene rukopisa, koju daje glavni urednik asopisa (ponekad uz konsultaciji sa lanom redakcionog odbora), trai se da recenzenti daju kompetentno i objektivno miljenje o kvalitetu rada. One rukopise koji ne ispunjavaju zahteve asopisa urednik odbija i oni se vra aju autorima bez slanja recenzentima. U toj fazi poznati meunarodni asopisi odbace do 90% rukopisa. Manji asopisi, zbog nedovoljnog broja kvalitetnih rukopisa, imaju daleko blai kriterijum. Da bi popravili rukopise, urednici ponekad dre kurseve potencijalnim
55
primedbe se esto samo ukazuje, a urednici e kasnije detaljno korigovati te nedostatke. U zakljuku se daje ukupna ocena rukopisa. Sekcije koje se esto sreu u recenzijama date su u nastavku.5 Struktura recenzije - Sumiranje rukopisa (istraivaki problem, cilj istraivanja, zakljuak koji su dali autori) - Opta ocena rukopisa - Konstruktivna kritika (ukazuje se na ono to bi trebalo da se unapredi u svakom poglavlju rukopisa) - Male (minorne) greke - Zakljuak Kako recenzent procenjuje rukopis? Najbolje je da recenzent posebno proceni svaki deo rukopisa. Ovde ukratko opisujemo kako se daje sistematska procena rukopisa empirijskih istraivanja. Ta istraivanja mogu biti kvantitativna (mahom eksperimentalne studije) i kvalitativna. Ova poslednja vrsta istraivanja je danas znaajno unapreena i sve ee se primenjuje u nekim biomedicinskim disciplinama.2 Naslov. Preopiran ili nedovoljno informativan naslov se ponekad sree u rukopisima koje pripremaju poetnici, ali se deava da i iskusniji autori naine grku. Zato recenzent paljivo pregleda naslov na samom poetku i ponovo na kraju itanja rukopisa. Apstrakt. Dobro napisan apstrakt oraspoloi recenzenta. Meutim, ako apstrakt sadri vie problema, to e se negativno odraziti na miljenje o rukopisu. Najvanije odlike apstrakta na koje obraca panju recenzent - Duina apstrakta (nestrukturisan do 150 rei, strukturisan do 250 rei) - Da li je jasna hipoteza ili cilj istraivanja - Jesu li navedene metode kojima se dolo do cilja istraivanja - Da li rezultati pokazuju da je postignut cilj istraivanja - Da li je zakljuak zasnovan na dobijenim rezultatima - Da li se stie utisak da je re o vanom istraivanju i da li je ono originalno Uvod. Recenzent e u uvodu stei jo bolji ili loiji utisak o onom to je saznao iz apstrakta. Najvaniji deo uvoda je cilj saoptenja. tj. pitanje koje je navelo autora na istraivanje. Recenzent proverava da li je i kako autor naveo ta nedostaje naunom znanju i ta je potrebno istraivati, procenjuje da li se u uvodu naznaava kako se prilo reavanju postavljenog pitanja. On oekuje da su u uvodu citirani samo radovi koji su neophodni za odgovarajue tvrdnje, a ne eli da vidi podatake i zakljuke do kojih je doao autor u ovom istraivanju.
Metode. Recenzent obraa panju na dizajn studije, veliinu grupa (laboratorijskih ivotinja, pacijenata i odgovarajuih kontrola), ocenjuje da li su tehnike zastarele i da li je statistika analiza odgovarajua. Procenjuje kako su autori odredili veliinu uzorka i da li je naveden metod procene, nivo signikantnosti (na primer, P<0.05 ili P<0.001) i statistika snaga (na primer, 80% ili 90%). Posebnu panju recenzent obraa na to jesu li pravilno korieni SD, SE i interval pouzdanosti (Codence Intervals, CI).2 Manjkavost nastaje kada se statistika hipoteza testira samo pomou P vrednosti, a nedostaju kvantitativne informacije.6 Opis statistikih metoda treba da je u poglavlju metode, a kada se iznose podaci u poglavlju rezultati navode se statistike metode pomou kojih su analizirani podaci. Najbolje je kada statistiku procenu rukopisa izvri i urednik za statistiku ili lan ureivakog odbora koji je ekspert za biomedicinsku statistiku. Segment teksta u poglavlju materijal i metode u kome se opisuje velicina uzorka7 Koristei NQuery statistical power software (Statistical Solutions, Cork, Irelad), procenili smo da se na uzorku od est osoba moe ustanoviti razlika srednje vrednosti 50% nivoa proteina bazalnog miinog toplotnog oka koji se javlja kod treniranih i netreniranih osoba pod pretpostavkom da je SD razlika jednaka 25% i statistika snaga 80%. Ta veliina efekta i SD su zasnovane na vrednostima ranijih ispitivanja u kojima je istraivan nivo proteina kod miinog toplotnog oka.[19,20]. Rezultati. Recenzent s posebnom panjom procenjuje da li su rezultati prikazani u loginom sledu teksta, tabela i ilustracija. Osim toga, on e ustanoviti da li postoji nepotrebno ponavljanje podataka u tekstu, ako su isti rezultati prikazani u tabelama i ilustracijama. Diskusija. U diskusiji treba naglasiti vane aspekte studije i zakljuke koji iz njih proizilaze. U njoj ne treba ponavljati ono to je dato u uvodu ili rezultatima. U diskusiji treba navesti implikacije, ali i ogranienja studije. Zapaanja treba uporediti s odgovarajuim relevantnim studijama. Poseban problem je kada diskusija sadri neadekvatnu hipotezu, nejasne i nepotkrepljene tvrdnje, krivu interpretaciju literature da bi se potvrdila autorova pretpostavka i kada se ne diskutuje o anomalijama. Reference. Na nepravilan izled referenci se ukazuje autoru ve pri poetnoj proceni rukopisa. Urednici asopisa na te nepravilnosti samo ukazuju, a dunost je autora da ih ispravi pre nego to se rukopis alje recenzentima. Recenzent procenjuje koji su radovi citirani u uvodu, a koji u diskusiji, da li su ukljuene samo stare publikacije, da li u spisku referenci ima previe nepotrebnih samocitata i da li je prevelik ili nedovoljan broj citata. U apstraktima, gotovo redovno, treba izbegavati citate.
56
Recenziranje revijskog lanka Rukopis revijskog lanka treba da sadri poglavlje koje opisuje metode kojim su naeni, odabrani i sintetisani podaci. Ti se metodi moraju opisati i u apstraktu. Od naslova, preko apstrakta, tekstualnog dela, ilustracija i tabela do eventualne diskusije i referenci procena je slina proceni radova u kojima se saoptava originalno istraivanje. Odgovor autora uredniku na primedbe recenzenata Kada autor od urednika asopisa primi izvetaje recenzenata i odluku urednika, on treba da odgovori na svaku, eventualnu, kritiku i sugestiju recenzenta i urednika. U nastavku je dat primer odluke urednika koja je upuena autoru. The large number of manuscripts received by Surgical Laparoscopy, Endoscopy & Percutaneous Techniques necessitates a rigorous selection process. Reviewers of your manuscript have not granted it priority for publication. Regretfully, therefore, we have to reject your manuscript. Copies of the reviews from the review board are enclosed. Please feel free to address the suggested revisions, revise your paper and resubmit it for publication. Please include with your revised submission an itemized, point-by-point response to the comments of the reviewers. The revisions should be completed by 12/30/2012 to avoid being considered as a new submission. Ukoliko su u pitanju samo minorne primedbe koje su uputila oba recenzenta (to se izuzetno retko dogaa) i urednik donese odluku da se rad objavi, rukopis se u nekim asopisima ne vraa autoru na korekcije. Urednik obavesti autora da je rad prihvaen, a male jezike i druge izmene autor e proveriti kada dobije na uvid probni otisak. Kada oba recenzenta predloe da se rukopis odbije, urednik se veinom s tim predlozima saglasi. On alje autoru obe recenzije da mu poslue kako bi sagledao nedostatak istraivanja. Ako ne postoji saglasnost dva recenzenta o vanijim pitanjima, urednik e eventualno angaovati treeg recenzenta da proceni rukopis ili e i bez tree recenzije doneti odluku. Kada je re o vanijim primedbama recenzenata, urednik ispravke koje je uradio autor alje na uvid recenzentima. Zato se od autora trai ne samo da drugaijom bojom slova oznai promene koje je uneo u originalni rukopis, ve da u posebnom dopisu navede ta je povodom svake primedbe recenzenata uradio. To je pomenuti itemized, pointbypoint response to the comments of the reviewers. Takva objanjenja pomau uredniku, a esto i recenzentima, da sagledaju ta (ni)je, zato i kako u rukopisu izmenjeno. Primer odgovora autora na primedbe recenzenata koji je poslao uredniku asopisa2 (Tri recenzenta su dala na desetine primedbi autorima rukopisa, a ovde se navode samo dve-tri.) Recenzent #2: Diskusija je nepotrebno preopirna, treba je skratiti.
Autor: Diskusiju smo skratili i oznaene pasuse izostavili... Recenzent #3: Permanentna bilateralna okluzija karotidnih arterija u pacova je esto korien metod u istraivanju hronine cerebralne hipoperfuzije kod razliitih neurodegenerativnih procesa, ukljuujui starenje i Alzheimerovu bolest. Pitanje je da li je taj model pogodan za ispitivanje propadanja dopaminergikih neurona nakon cerebralne hipoperfuzije kod glodara da bi posluio kao pogodan model za Parkinsonovu bolest. Autori nisu naveli da li je kod ivotinja dolo do pojave tremora i drugih znakova parkinsonizma. Autor: Mi nismo vrili bihevioralno testiranje jer primeene promene mogu biti zbog gubitka dopamina ili efekta hronine hipoperfuzije mozga... Recenzent #3: Naslov rukopisa treba promeniti. Iz njega treba izostaviti ove rei Vaskularni parkinsonizam, Parkinsonova bolest i starost. Autor: Naslov rukopisa smo promenili kako je predloio recenzent. Neki autori nisu upoznati kako se odgovara na pitanja i primedbe koje daju recenzenti. Tako smo u Scripta Medica od jednog autora rukopisa zaduenog za korespondenciju (Corresponding Author), umesto detaljnog obrazloenja izmena primili ovakav odgovor na primedbe dva recenzenta i lektora engleskog jezika: Uradili smo i ispotovali sve to je traio recenzent I (naroito on), recenzent II (koji je dao i dosta nepotrebnih komentara) i III lektor. Korigovano je sve to su sugerisali koautori (ovde se navode imena dva koautora s njihovim titulama), ije miljenje cjenim vie od svih navedenih recenzenata.1
111
Neprihvatanje neke od primedbi recenzenta autor mora da objasni. Nema razloga da se autor ljuti na recenzente ako mu rad loije ocene nego to je oekivao. Nakon odbijanja rada autor nikada ne treba da se ali uredniku ili asopisu. On moe taj rad da poalje drugom asopisu. Recenzenti, a esto i urednici, jesu naunici koji odvoje deo svog dragocenog vremena da bi obavili taj, za progres nauke va an posao. Da bi se izbegli previdi jednog recenzenta, asopis alje rukopis da ga ocene dva, a nekada i
1 Recenzent #1 je veoma ugledan profesor ziologije. On je dao seriju korisnih predloga da se rukopis struno i jeziki pobolja. Recenzent #2 je profesor biohemije i specijalista jedne klinike discipline. Oni su istraivai koji rade na dva razliita univerziteta u SAD.
57
tri recenzenta. Osim recenzenata, i urednici pregledaju i ocenjuju svaki rad. Da bi svi autori na vreme pregledali rukopise koji pristignu u redakciju Scripta Medica i dali saglasnost da mogu biti objavljeni, u uputstvu autorima se kao to to odnedavno zahtevaju mnogi meunarodni asopisi trai od svih autora (ako ih je dva ili vie) da potpiu izjavu o autorstvu.8 Naime, svako od njih treba da opie doprinos radu i tu izjavu potpie. (Nedavno se dogodilo u jednoj bivoj jugoslovenskoj republici da ugledan professor dopie stranog autora u plagiran rukopis i bez znanja tog pojedinca rad objavi u meunarodnom asopisu.1 Pojedinac je za tu svoju publikacju saznao tek kada je plagijat otkriven.) Osim toga, u propratnom pismu treba da se navede sledee: - rad nije ranije publikovan i nije istovemeno podnet za objavljivanje u nekom drugom asopisu, - svi su autori proitali rukopis i odobrili ga - pismena saglasnost ili dozvola je pribavljena od svih osoba koje se pominju u poglavlju zahvalnost, itd.2 Kako asopis procenjuje recenzije i recenzente? asopis procenjuje kvalitet recenzenta tako to se proceni: 1) da li je pristup oceni rukopisa izveden seriozano, 2) da li se citiraju dokazi kako bi se potkrepila kritika koja se alje autoru, 3) da li je kritika rukopisa konstruktivna i ocena objektivna, 4) da li je predlog uredniku jasno obrazloen i 5) da li je recenzent na vreme uradio recenziju. U nastavku su dve recenzije. Prvi primer sadri etiri kratka dela (sekcije), a drugi je napisan u jednom pasusu; ovaj poslednji je povrni prilaz recenziranju.
Prvi primer
Drugi primer
Paljivo sam proitao rukopis i nalazim da je rad sasvim korektan. Rad nema prevelike pretenzije ve elju da ukae na jedan aspekt problema o kome se malo vodi rauna. Metoda je relativno nova i svako saoptenje je dragoceno, pogotovo ako je sa naih prostora, to po mome miljenju treba ohrabriti. Shematski prikazi. tj. grakoni mogu na prvi pogled izgledati kao suvini. ali vizuelni utisak ima odreene prednosti nad tekstualnim. Rad ima odreenu edukativnu ulogu za strunjake ove discipline jer daje korisnu informaciju, Meutim, reference treba srediti prema strogim pravilima i autore treba uputiti u Univerzitetsku biblioteku jer to je posao od desetak minuta (zameniti zareze takama, denisati nain za originalni rad, deo u udbeniku i sl.) Po mome miljenju rad slobodno moe ii u tampu. Kako pronaci dobre recenzenate? Kvalitetne recenzije zna ajno doprinose kvalitetu publikacija u asopisu. Zato bi bilo korisno kada bi urednici mogli unapred da znaju ko su dobri recenzenti ili kako bi se recenzenti mogli usavriti da bolje procenjuju rukopise. U jednoj studiji su uestvovala 308 recenzenata s ciljem da se ustanovi da li specijalne vebe, odgovarajui akademski nivo ili iskustvo u pisanju naunih projekata utiu na kvalitet recenziranja. Ustanovljeno je da su epidemiolozi, strunjaci koji poznaju statistiku i oni strunjaci (bilo koje discipline) koji su bili lanovi nekog ure iva kog odbora asopisa bolje procenjuju rukopise. 4 Postoji opta saglasnost da su najbolji recenzenti istraivai koji su publikovali radove u asopisima. (Ovde se ne ubrajaju oni ija se imena samo dopisuju u publikacijama ili im je doprinos u objavljenim radovima bio minimalan.) Dakle, autori iji su rukopisi vie puta recenzirani u dobrim asopisima imaju iskustvo koje im pomae da budu dobri recenzenti. Da se proces recenziranja ujednai, neki asopisi ponekad dostave recenzentima formulare koji pomau da se rukopis oceni, u celini i u pojedinim delovima, te da se doe do ocene i preporuke o publikovanju rukopisa. Meutim, ti formulari nisu garancija da e svi recenzenti lege artis obaviti procenu. Zato asopisi iz spiska recenzenata izbacuju loe recenzente, tj. ne angauju ih ponovo. Scripta Medica ima trogodinje iskustvo u redovnom recenziranju rukopisa. Neke su recenzije veoma kvalitetne, ali je bilo i povrnih. Pri recenziranju je neophodno izbei sukob interesa. Nije dozvoljeno da recenzent bude iz iste institucije iz koje je prispeo rukopis ili ako su recenzent i autor bilo kad publikovali zajedniki lanak. Te okolnosti moe proceniti redakcija asopisa, ali i sam recenzent moe navesti da zbog sukoba interesa ne prihvata da proceni rukopis. Neki asopisi trae od autora da naini spisak od pet-est strunjaka koji su potencijalni recenzenti. Taj nain izbora recenzenata se danas koristi sve ree.
2b
Scripta Medica 2012;43:32-3.
58
Anonimno ili otvoreno recenziranje? U naunim krugovima i na meunarodnim sastancima posveenim publikovanju biomedicinskih asopisa bilo je puno debata o anonimnosti recenzenata. U malim sredinama koje izdaju lokalne biomedicinske asopise, otvorene recenzije bi imale seriju nedostataka. Retko koji bi recenzent eleo da se javno eksponira kad pie negativnu recenziju lokalnom autoritetu, mada bi otvorena procena vrednosti rukopisa stavljala pred recenzenta veu strunu i etiku odgovornost pri kritici i predlozima da se rukopis pobolja. Zato anonimost recenzenata u takvim sredinama, ipak, ima prednost; tim vie to se tako olakava posao urednicima kada donose odluke da rukopise ne objave. Rajko Igi, glavni urednik Aleksandar Lazarevi urednik Stevan Trbojevi, urednik
Reference
1. 2. 3. 4. 5. 6. Igi R. Publication in peer-reviewed journals. Journal of BUON 2006;11:405-10. Igi R, krbi R. Kako se piu i publikuju saoptenja o biomedicinskim istraivanjima. Banja Luka/Laktai, GrafoMark, 2012. Anonimus. Recenziranje rukopisa. Kontakt (Novi Sad) 1998;6:1-2. Benos DJ, Kirk KL, Hall JE. How to review a paper. Adv Physiol Educ 27;47:-52, 2003. Hall GM (ed.). How to write a paper. Malden, Blackwell, 2008. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336:309-16. Morton J P. Reviewing scientic manuscripts: how much statistical knowledge should a reviewer really know? Adv Physiol Educ 2009:33:7-9. Anonimus. Uputstvo autorima za pripremu rukopisa. Scr Med 2012;43:132-5. www.scriptamedica.com (free access).
7.
8.
59
Uputstvo autorima za pripremu rukopisa

Scripta Medica (SM) je internacionalni asopis Drutva doktora Republike Srpske koji objavljuje originalne lanke (klinika, laboratorijska i epidemioloka istraivanja), ali i lanke koji maju za cilj da edukuju i obavijeste ljekare i strunjake drugih biomedicinskih disciplina. SM, kao optiemedicinski asopis, daje prednost rukopisima o originalnim klinikim istraivanjima. Na engleskom jeziku asopis objavljuje originalne radove, pregledne lanke, specijalne lanke, rjeavanje klinikog problema, prikaze sluajeva, slike iz klinike medicine, istorijske lanke i eseje. Samo na srpskom se objavljuju prikazi knjiga, vijesti, izvjetaji sa naunih skupova, krai edukativni i drugi lanci. asopis je svima, bez naknade, dostupan na internetu (www.scriptamedica.com). Opta uputstva 1. Rukopis Rukopis rada treba dostaviti u .DOC formatu (Microsoft Word, Times New Roman font, veina slova 11 pt). Glavni naslov kucati slovima veliine od 12 pt bold, a naslove poglavlja slovima od 11 pt bold. U tabelama koristiti slova veliine 10 pt, jednostruki prored, a naslovi unutar tabela treba da su veliine 10 pt bold; za glavni naslov tabele koristiti 12 pt bold; legende se ispisuju jednostrukim proredom slovima od 11 pt. Illustracije se dostavljaju u JPG ili TIFF formatu (300 dpi ili bolja rezolucija). 2. Za lijekove i hemikalije koristiti generike nazive. Za instrumente, aparate i ostale ureaje dati njihove nazive, a u zagradi dati nnavesti proizvoaa i grad. 3. Brojeve koji su manji od deset u tekstu treba ispisati reima, a za 10 i vie koristiti numeriku oznaku. Brojeve u tekstu i tabelama treba navesti za vrednosti od koji su nainjene procentualne vrednosti; iza srednje vrednosti stoji standardna devijacija (SD), a iza medijana meukvartalni raspon (interquartile range, IQR). 4. Naslov slike treba da je veliine 10 pt bold; legende kucati jednostrukim proredom, slovima veliine 10 pt. 5. Reference se u tekstu oznaavaju brojevima ispisanim superskriptom iza bilo kog znaka interpunkcije. 6. Jedinice mere, duine, teine i zapremine izraavaju se metrikim jedinicama (na primer, metarm, kilogramkg, litarl) ili njihovim delovima. Temperaturu izraavati u stepenima Celzijusa (oC); koliinu supstance u molima (mol), a pritisak u milimetrima ivinog stuba (mm Hg). Sve vrednosti hematolokih, klinikih i biohemijskih merenja navoditi u metrikom sistemu prema Meunarodnom sistemu mera (International System of Units, SI units).
7. Skraenice koristiti samo za duge nazive, ukljuujui imena hemijskih supstancija. Pun naziv dati kada se isti pojavi prvi put u tekstu, ukoliko to nije standardna jedinica mere. Ako se skraenice koriste u Apstraktu, svaku treba objasniti kada se prvi put pomene u tekstu. Za optepoznate skraenice, kao to su DNK, SIDA, HIV, ATP, ADP, ne treba uvoditi pun naziv. U naslovu lanka mogu se nai samo optepoznate skraenice. 8. Izjava o autorstvu. Da bi se istraiva kvalikovao za autora, mora dati znaajan intelektualni doprinos studiji koja je osnova za lanak (WAME.com, Policy StatementsAuthorship). Autor mora uestvovati barem u jednoj aktivnosti u svakoj od tri sledee kategorije: a. postavljanje istraivakog pitanja, izrada koncepta i dizajna studije, prikupljanje i analiza podataka, b. statistika analiza, interpretacija podataka, obezbeenje sredstava za istraivanje, administartivna, tehnika ili materijalna podrka, nadgledanje celokupnog toka istraivanja, c. pisanje prve verzije ili kritika revizija rukopisa. Izuzetno autor moe biti istraiva koji je kao suspecijalista (na primer biostatistiar, patolog ili epidemiolog) doprineo uskom aspektu rada. Izjavu o autorstvu s navoenjem svog doprinosa mora potpisati svaki autor (ako ih je dva ili vie). Izjava o autorstvu se objavljuje pod naslovom Doprinos autora, a sledi iza Diskusije. Imena autora se u tom poglavlju ne ispisuju, ve samo njihovi inicijali. Glavni (korespondirajui) autor je odgovoran za integritet celokupnog rada. Neodgovorno je izostaviti istraivaa koji je doprineo radu. 9. Izjava o sukobima interesa. Izjavu o deklaraciji potencijalnih sukoba interesa daje i potpisuje svaki autor. (Videti uputstvo koje je dato os strane Svetskog udruenja urednika medicinskih asopisa, World Association of Medical Editors, WAME, www.wame. org ili ICMJE uniform disclosure form for potential conicts of interest, www.icmje.org.) Izjava ukljuuje sve nansijske aspekte (konsultacije, honorare, plaena putovanja na naune i druge skupove, nansiranje od strane dravnih i privatnih institucija, zarada od patenata, itd.) i navoenje organizacija koje imaju nasijski interes ili nansijski konikt s predmetom ili materijalima o kojima se diskutuje u rukopisu. Ukoliko se rukopis prihvati u tampu, urednici e diskutovati s autorima kako e takva informacija biti saoptena itaocima u rubrici Konikti interesa. 10. Zahvalnost. U propratnom pismu, mora se navesti da su autori dobili pisanu saglasnost od svih osoba koje se pominju u Zahvalnosti ili se citiraju kao lina saoptenja. Ovde se navodi i nasijska pomo u obliku poklona opreme, supstancija ili lekova, stipendije i sl. 11. Propratno pismo. Pismo se alje s rukopisom i sadri sledee izjave: a. rad nije ranije publikovan i nije istvremeno podnet za objavljivanje u nekom drugom asopisu, b. svi su autori proitali rukopis i odobrili ga i c. pismena saglasnost ili dozvola je pribavljena od 1) svih
60
osoba koje se pominju u poglavlju Zahvalnost, 2) od pacijenata ili dobrovoljaca koji su uestvovali u studiji i 3) od etikog odbora ustanove za izvoenje studije na ljudima (pacijenti i dobrovoljci) ili viim ivotinjama. [Saglasnost Etikog odbora ustanove (Institutional Ethics Committee, IEC) za izvoenje studije je u skladu s Zahtevima za izradu rukopisa koji se podnose medicinskim asopisima (Uniform Requirements for Manuscripts Submitted to Biomedical Journals, www.icmje.org). Propratno pismo potpisuje korespondirajui autor. 12. Slanje rukopisa. Rukopis i sve priloge (propratno pismo, izjava o autorstvu i izjava o sukobu interesa) slati putem elektronske pote na adresu [email protected], najbolje u jednom fajlu. U nazivu fajla treba da stoji i pezime autora s kojim se vri korespodencija. Potpisani primerak propratnog pisma i izjave mogu se slati putem faksa +387 (51) 329-100. Prijave radova koje nisu u skladu s navedenim instrukcijama nee se razmatrati. 13. Ureivaki proces. Rukopisi koji ispunjavaju osnovne uslove za publikovanje, po proceni redakcije, uputie se recenzentima. Autorima se preporuuje da predloe dva ili vie kvalikovanih strunjaka iz odgovarajueg podruja koji bi mogli biti recenzenti. Preduslov je da su kandidati publikovali najmanje pet laka u asopisima koji su obuhvaeni MEDLINE bazom podataka. Slanje rukopisa, korespodencija s urednicima i uvid u probni otisak rada odvija se elektronskom potom. 14. Ocena rukopisa i revizije. Rukopisi koji su pogodni za slanje recenzentima recenzirae dva recenzenta. Neki e rukopisi biti prihvaeni bez potrebe da se revidiraju, a ako je nuna revizija, glavni autor mora u pismu uredniku odgovoriti na svako pitanje, kritiku, zahtev i sugestiju recenzenata i urednika. U novu verziju rukopisa treba uneti odgovarajue izmene, a urednika asopisa obavestiti ta je sve uraeno po preporukama. Sve izmene rukopisa oznaiti drugom bojom slova i tu verziju rukopisa treba poslati uredniku zajedno s pomenutim pismom u istom fajlu (iji naziv opet ukljuuje i prezime korespondirajueg autora). SM objavljuje oko 60% prispelih rukopisa. 15. Dodatne informacije mogu se nai ili dobiti od: Drutvo doktora Republike Srpske c/o Ms. Biljana Radii Prvog krajikog korpusa 4/I 78000 Banja Luka, Republika Srpska Bosnia i Herzegovina Telefon i faks: +387-(51) 329-100 E-mail: [email protected] [email protected] www.scriptamedica.com
denciju (glavni autor) zajedno s adresom, brojem telefona i faksa i e-adresom. Skraeni naslov s ne vie od 40 slova i praznih mesta takoe treba ovde navesti, a iza toga napisati koliki je broj rei u rukopisu. Originalni lanci mogu sadravati do 2.500 rei, ne raunajui reference i apstrakt. Za rukopise kontrolisanih klinikih istraivanja, autori e dobiti instrukcije od urednika. Naslov treba da ukae na glavnu temu ili poruku lanka. Standardni naslov istraivakog lanka je fraza (ree reenica) koja treba da je koncizna i precizna, informativna i deskriptivna. Kada se u radu opisuje samo metod, naslov treba da ukae da li je u pitanju nov metod ili unapreenje postojeeg. Apstrakt i kljune rei. Za originalne radove apstrakt (do 250 rei) treba da ima sledeu strukturu: Uvod, Materijal i metode, Rezultati i Zakljuak. U njemu treba navesti pitanje ili problem koji se u radu istrauje, metode koje su koriene, dobijene rezultate i, na kraju, da se da odgovor da postavljeno pitanje. Za ostale vrste lanaka apstrakt se pie u jednom pasusu. Svaki apstrakt treba da prui jasnu informaciju. Ispod apstrakta, autori treba da navedu 36 kljunih rei ili kratkih fraza prema terminima Medical Subject Headings MeSH (www.nlm.nih.gov/mesh), na srpskom i engleskom jeziku. Prevod apstrakta, tabela i naslova ilustracija na engleski. Na posebnoj stranici priloiti naslov rada na engleskom jeziku, imena i prezimena autora (bez titular) indeksirana brojevima, zvanini naziv ustanova na engleskom jeziku, structured Abstract (Introduction, Methods, Results, Conclusion). Prevesti nazive tabela, slika i celokupni tekst u njima. Treba se pridravati jezikog standarda British English. [Radovi koji se u celini dostave na engleskom imaju prednost u objavljivanju. Uputstvo za rukopise na engleskom dato je u Instructions for contributors.] Uvod. U poglavlju Uvod, opisati razlog za istraivanje, dati svrhu studije ili objasniti zato je ona vana. Cilj istraivanja moe biti u formi postavke, istraivakog pitanja ili hipoteze. Treba samo citirati radove koji su relevantni. Materijal i metode. Ovo poglavlje opisuje procedure pomou kojih se izvodi studija; opis treba da omogui drugima, ako ele, da studiju ponove. Ako je metod merenja poznat, treba ga citirati i opisati s par reenica. Treba prikazati dizajn studije i navesti koje su intervencije preduzimane, da li postoji saglasnost etikog komiteta o eksperimentima na ljudima i viim ivotinjama, kako je vrena randomizacija, koliko dugo su praeni uesnici, kako su prikupljani podaci i kako je vrena statistika analiza podataka. Treba denisati nezavisne i zavisne varijable. Za lekove i hemikalije koristiti generike nazive, doze lekova i nain davanja. Variabilnost izraziti pomou srednje vrednosti i standardne devijacije (SD). Poto su SD i standardna greka srednje vrednosti (SE) pozitivni brojevi, Council of Science Editors preporuuje eliminaciju znaka +/- sign; umesto njega SD, kao i SE, se daju u zagradama. Na primer, sistolni krvni pritisak grupe zdravih studenata iznosio je 129 mm Hg [SD = 6, n = 87]. Vrednost P moe se koristiti da se odbaci nulta hipoteza, ali treba navesti
Specine instrukcije za pripremu rukopisa

Naslovna strana. Naslovna strana rukopisa sadri naslov lanka, ime i prezime svakog autora (bez titula), naziv odeljenja, ustanove i grada. Na toj stranici navodi se ime autora za korespo-
61
procenu snage studije (power of the study) i statistiki test korien u statistikoj analizi. U revijskim (preglednim) lancima se opisuju metode kojima su locirani, odabrani, pronaeni i sintetisani podaci. Te metode, takoe, treba navesti u apstraktu. Rezultati. Dobijene rezultate treba izloiti logikim tokom korienjem teksta, tabela i ilustracija. Sve ilustracije nose naziv Slike (Figures). Taj deo rukopisa daje odgovor studije na postavljeno istraivako pitanje. Ponekad je to najkrai tekstualni deo rukopisa. Detalji se mogu prikazati u jednoj ili vie tabela i slika. Ne ponavljati podatke iz tabela ili slika u tekstu. U tekstualnom delu treba samo naglasiti najvanije rezultate koji direktno odgovaraju na pitanje iz Uvoda. Tabele. Svaka tabela (4 tabele ili slike su dozvoljene) sa svojim legendama treba da opie o emu je re; redosled im se numerie arapskim brojevima u tekstu. Naslov treba da je iznad tabele, a objanjenja, ukljuujui denicije skraenica, nalaze se ispod tabele. Sve ovo pisati dvojezino (srpski i engleski). Tabele raditi iskljuivo u programu Word (koristiti table-insert-table). U tabeli, u iste elije uneti tekst na srpskom i engleskom jeziku. (Nikako ne praviti dve dabele na dva razliita jezika.) Slike. Sve ilustracije (fotograje, grakoni, sheme) treba numerisati arapskim brojevima redosledom njihovog pominjanja u tekstu (maksimum 4 slike ili tabele su dozvoljene). Sve ilustracije nose naziv Slike. Slova su tamna na beloj podlozi a veliina treba da je itjiva kada se tampanjem umanje. Originalne crtee, EKG zapise i sl. treba skenirati sa barem 300 DPI (JPG ili TIF). Legende za slike kucati s dvostrukim proredom na posebnom listu oznaene Arapskim brojem koji odgovara slici. Simbole, strelice, brojeve ili slova koji su na slici objasniti u legendi. Interna skala treba da se pojavi na mikrosnimku, a metodi bojenja se opisuju u legendi. Tekst legende i sva objanjenja piu se dvojezino. Diskusija. Ukratko navesti glavni nalaz koji se odnosi na svrhu istraivanja ili odgovor na istraivako pitanje koje je postavljeno u Uvodu. Zatim komparirati svoje nalaze s publikovanim radovima; osvrnuti se na ogranienja korienih metoda i navesti implikacije svojih nalaza. Zahvalnost. Navesti one koji su doprineli stvaranju rada, a ne ispunjavaju merila za autorstvo, ako su osobe dale pismeni pristanak za to. Finansijska i materijalna pomo se ovde takoe navodi. Doprinos autora. Ukoliko je rukopis pisalo dva ili vie autora, svaki od njih opisuje doprinos radu (taka 8. ovog Uputstva). Konikti interesa. Autori navode potencijalne konikte interesa (taka 9. ovog Uputstva). Reference. Ispravnost liste referenci je odgovornost autora. Citirati lanke u tekstu rednim arapskim brojevima prema re-
dosledu navoenja u tekstu. Reference se ispisuju prema Vankuverskom stilubroj se u tekstu navodi u superskriptu, nakon bilo kog znaka interpunkcije. Na primer, Vuli and colleagues.12 Kada se citiraju dve reference, one se odvajaju zarezom, bez razmaka. Tri ili vie referenci u nizu se razdvaja crtom (na primer, 3-6 ). Reference koje se eventualno citiraju u tabelama i slikama dobijaju redni broj prema mestu gde se ove ilustracije postave u tekstu. Za citiranje prema Vankuverskom stilu, videti Uniform Requirements for Manuscripts Submitted to Biomedical Journals; to su pravila koja su data od strane Meunarodnog komiteta urednika medicinskih asopisa (International Committee of Medical Journal Editors; www.icmje.org). Ako referenca sadri est autora ili manje, treba navesti sve autore prezimenom, razmak, inicijali, zarez. Ako u pitanju sedam ili vie autora, navode se prva tri i sledi et al. U nastavku su primeri navoenja nekih publikacija, a za ostale uputstvo je na internet stranici: (www. nlm.nih.gov/bsd/uniform_requirements.html). De Lacey G, Record C, Wade J. How accurate are quotations and references in medical journals. BMJ 1985;291:884-6. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Croat Med J 2003;44:770-83. Huth EJ. How to write and publish papers in the medical sciences. Philadelphia: ISI Press, 1982. Davidovi L, Markovi M, oli M, et al. Treatment of traumatic rupture of the thoracic aorta. Srp Arh Celok Lek 2008;136:498-504. Curtis MJ, Shattock MJ. The role of the manuscript assessor. In: Hall GM, ed. How to write a paper. London: BMJ Publishing Group; 1994:89-95. Electronic publications (ove citate treba izbegavati): International Society of Scientometrics and Informatics Web site. Available at: http://www.issi-society.info (accessed March 20, 2012). Lock SP. Journalology: are the quotes needed? CBE Views. 1989:1257-9. Available at: http://gareld.libraryupenn. edu/ essays/v13po19y1990.pdf (accessed Dec 25, 2011).
Revijski lanci
Revijski lanci se piu po narudbi redakcije, na ne vie od 2,500 rei, ne raunajui reference i apstrakt. Uz rukopis se mogu proiti 4 tabele ili ilustracije. Broj referenci je ogranien na 50.
Prikaz bolesnika
Prikazi bolesnika verovatno e biti publikovani ako se u njima opie sledee: nuspojave (tetne ili korisne) ili interakcije lekova koje od ranije nisu poznate; nov, neoekivan ili neoban tok bolesti; uzrona veza izmeu dve bolesti koja ranije nije bila opaena; prikaz, dijagnoza i/ili leenje novih bolesti ili bolesti koje
62
se naglo ire; ranije nepoznata veza izmeu dve bolesti ili raznih simptoma; neoekivan dogaaj u toku bolesti ili leenja pacijenta; ranije nepoznata bolest. SM ne objavljuje prikaze bolesnika koji slue samo u edukativne svrhe (da se opie ono to je poznato, a to su mnogi zaboravili). SM nerado objavljuje prikaze bolesnika koji spadaju u kategoriju retkih sluajeva. Prikaz bolesnika (manje od 750 rei) ukljuuje sledee: naslov (na engleskom i srpskom), prikaz bolesnika sa diskusijom (mogue je priloiti do 3 ilustracije), do 6 referenci i nestrukturisan apstakt na engleskom i srpskom (do 100 rei). Naslov treba da je kratak kako bi olakao elektronsko pretraivanje. Prikaz bolesnika sadri kratke anamnestike podatke, ziki pregled i glavne nalaze svih pretraga, opis leenja, koje su opcije za leenje razmatrane, ishod leenja. Diskusija ukljuuje izjavu da li je u pitanju neobina dijagnoza, prognoza, terapija ili tetna pojava, da li su u literaturi opisani slini sluajevi, ta je neobino kod prikazanog bolesnika, ta bi se u slinim sluajevima moglo drugaije uraditi. Prikaz bolesnika moe imati najvie 5 autora. Veoma kratke prikaze bolesnika (bez ilustracija) primamo kao Pisma uredniku. Autori moraju pribaviti pisani pristanak bolesnika da se lanak o njemu moe objaviti; ako pristanak ne moe da potpie bolesnik, pristanak treba traiti od roditelja ili staratelja. U propratnom pismu treba navesti da je takav dokumenat pribavljen. Izjavu o doprinosu autora (ukoliko ih je dva ili vie) i izjavu o koniktima interesa moraju potpisati autori. U propratnom pismu, autori treba da ukau po emu njihov prikaz bolesnika doprinosi medicinskoj literaturi. Prilozi koji ne sadre tu informaciju vratie se autorima bez ocene rukopisa.
treba da su kratka i konkretna. Ne vie od 5 referenci moe se priloiti, ali ne lustracije ili tabele. Izjavu o koniktima interesa moraju potpisati autori. Urednici imaju pravo da skrate svako pismo.
Uvodnici
Uvodnike pie urednik ili strunjaci po pozivu. Cilj im je da se ukae na lanke koji su objavljeni u asopisu ili da se izraze opta i aktuelna gledita.
Specijalni lanci
Specijalni alanci sadre do 1500 rei. Posveeni su nekom medicinskom problemu, istorijskoj perspektivi, edukaciji, demograji ili savremenim temama. Do 15 referenci i 2 tabele ili ilustracije su dozvoljene. Nestrukturisan apstrakt (do 150 rei) na srpskom i engleskom se prilae uz tekst specijalnog lanka. Izjavu o koniktu interesa moraju potpisati autori.
Slike iz klinike medicine

Urednici e razmatrati originalne, jasne i interesantne slike koje ukazuju na novije ili klasine klinike odlike koje su praene tekstom (uz najvie 3 reference) na ne vie od 200 rei. To saoptenje mogu pisati najvie dva autora. Autori moraju dobiti pismenu saglasnost od pacijenta, bliskog roaka ili staratelja. U propratnom pismu treba navesti da je takava saglasnost pribavljena. Izjavu izjavu o koniktima interesa moraju potpisati autori.
Saoptenje za novinare. Autore interesantnih i vanih lanaka redakcija e zamoliti da napiu tzv. press release saoptenje za novinare. Taj tekst pomae da se poruka ispravno prenese irokoj javnosti. Ni autor ni novinari ne treba da distribuiraju podatke iz nepublikovanih lanaka sve dok ne proe embargo asopisa za sredstva javnog informisanja, tj. dok se asopis ne publikuje. Saoptenje za novinare obino sadri 150 do 250 rei kojima se iznosi glavna poruka. Reenice treba da su kratke, a rei razumljive. Laiku treminologiju treba koristiti kad god je mogue, a tehnike termine i uobiajene strune skraenice treba objasniti kada se koriste prvi put. Takoe, jasnije je umesto procenata koristiti aproksimacije. Na primer, za 9% bolje je navesti jedan od deset ili za 55% vie od polovine. Na kraju ovih saoptenja treba navesti ime, adresu, telefon i e-adresu glavnog ili starijeg istraivaa. Ukoliko je vie autora potpisalo lanak, mogue je da bilo koji bude izabran za komuniciranje s medijima za masovno informisanje. Kada urednik Scripta Medica proceni, asopis moe organizovati konferenciju za novinare kako bi bili predstavljeni zanimljivi lanci. Na konferencji e se distribuirati press release odabranih lanaka, a autor e odgovarati na pitanja novinara. Slanje rukopisa
-Rukopis, tabele, slike i propratno pismo i izjave treba slati elektronskom potom, [email protected], kad god je mogue sve u jednom fajlu koji u nazivu sadri prezime korespondirajueg autora. Propratno pismo i izjave se mogu skenirati i slati elektronski. Izuzetno se ti materijali mogu poslati faksom +387 (51) 329-100. Da se izbegnu kanjenja, preporuujemo autorima da sve potpisane dokumente poalju zajeno s rukopisom. POTPISI - PROPRATNO PISMO - IZJAVA O AUTORSTVU - IZJAVA O KONFLIKTIMA INTERESA
Reavanje klikog problema

Reavanje razliitih klinikih problema, ukljuujui klinike studije, treba da sadri sledee delove: Apstrakt (na srpskom i engleskom), Uvod, Metode ili Prikaz(e) bolesnika, Diskusija, Reference (do 20). Apstrakt se pie u jednom pasusu (nestrukturisano) na do 150 rei. Ovaj tip rukopisa ne sme imati vie od 1400 rei, ne raunajui reference, tabele i ilustracije. Autori moraju dobiti pismenu saglasnost od pacijenta, bliskog roaka ili staratelja. U propratnom pismu treba navesti da je takav dokumenat pribavljen. Izjavu o doprinosu autora (ukoliko ih je dva ili vie) i izjavu o koniktima interesa moraju potpisati autori.
Pisma uredniku
Kada se pismo odnosi na nedavno objavljen lanak u ovom asopisu, ono moe imati do 250 rei, ne raunajui refernce. Sva pisma
63
Instructions For Contributors

Scripta Medica (SM) is a peer-reviewed international journal published under the auspices of the Medical Society of the Republic of Srpska. The journal publishes original biomedical studies, including those addressing ethical and social issues. As a general medical journal, SM gives preference to clinically oriented studies over those on experimental animals. It publishes peer-reviewed original research papers, case reports, review articles, essays, special articles, clinical problem-solving, images in clinical medicine only in English. Book reviews and news are published only in Serbian. The full text of SM is available, free of charge, online at www.scriptamedica.com.
rst mentioned in the text unless it is a standard unit of measure. If abbreviations are to be used in the Abstract, each should be explained when rst mentioned in the text. Well-known abbreviations, such as DNA, AIDS, HIV, ADP, ATP etc, need not be introduced by the full name. Titles should include abbreviations only when the abbreviation is universally accepted. 8. Authorship statement. To qualify for authorship, one must made substantial intellectual contributions to the study on which the article is based (WAME.com, Policy StatementsAuthorship). The author should participate at least in one of these three categories: a. research question, conception and design, data acquisition and analysis, b. statistical analysis, interpretation of data, provision of funding, technical or material support, overall supervision of the project. c. drafting or critical revision of the manuscript. In some research projects may participate experts (such as biostatisticians or epidemiologists) that may not be equally familiar with all aspects of the work (for example, some clinical variables or laboratory measurements), but they may be qualied as the authors. A statement acknowledging contribution to the manuscript should be signed by all the authors. It will be published in the section Author Contributions. The corresponding author is responsible for the integrity of the work as a whole. It is dishonest to omit mention investigator who had important engagement with some aspects of the work. 9. Financial disclosure. A disclosure statement declaring any potential conict of interest must be signed by each author. (See the policy statement on conict of interest issued by the World Association of Medical Editors, WAME, www.wame.org or ICMJE uniform disclosure form for potential conicts of interest, www.icmje.org.) This disclosure includes all af liations or nancial involvement (e.g., employment, consulting fee or honorarium, gifts, stock ownership or options, travel/accomodations expenses, grants or patents received or pending, and royalties) with any organization having a nancial interest in or nancial conict with the subject matter or materials discussed in the manuscript. This information will be held in condence while the paper is under review. If the manuscript is accepted for publication, the editors will discuss with the author how such information is communicated to the reader in the section Conicts of interest. 10. Acknowledgment statement. The cover letter must state that the authors obtained written permission from all individuals named in an Acknowledgment or cited as personal communications. 11. Consent statement and permission obtained by the institutional ethics committee (IEC). A cover letter should state that written informed consent was obtained from all subjects (patients and volunteers) included in the study, and that the study was approved by the IEC.
General instructions
1. Manuscripts should be submitted in the .DOC format (Microsoft Word), using the Times New Roman font. The text should be single spaced 11 point. The main heading should be 12 point bold. Subheadings should be 11 point bold. Tables must be 10 point, single spaced; headings within tables should be 10 point bold; the main table heading should be 12 point bold; legends should be single spaced in 11 point. Illustrations can be submitted in either JPG or TIFF format (300 dpi or higher resolution). 2. Drugs and chemicals should be indicated by generic names. Instruments, apparatus or other devices are indicated by trade names, with the producers name and place of production indicated in brackets. 3. Numbers in text and tables should be provided if expressed as %; means should be accompanied by SDs, and medians by interquartile range (IQR). In text, use following rule: spell out numbers up to ten and then use numerical designation for 10 and above. 4. All images must have minimum resolution of 300 dpi. The main gure heading should be 10 point bold; legends should be single spaced 10 point. 5. References should be indicated in the text sequentially in the Vancouver numbering style, as superscripted number after any punctuation mark. 6. Units of measure, length, height, weight and volume are to be expressed in metric units (e.g., meterm, kilogramkg, literl) or subunits. Temperature should be in degrees Celsius (oC); quantities of substances are given in moles (mol), and blood pressure is expressed as millimeters of mercury (mm Hg). All values of hematological, clinical and biochemical measurements use the metric system according to the International System of Units (SI units). 7. Abbreviations may be used for very long names, including those of chemical compounds. The full name should be given when
64
The majority of these instructions are in accordance with Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org). 12. Cover letter. The letter accompanying the submission should include the following: a. A statement that the paper has not been previously published, nor is it concurrently submitted to any other journal, b. A statement that the manuscript has been read and approved by all authors. c. Assertion that written acknowledgments, consent statements and/or permission by the institutional ethics committee were obtained. This letter should be signed by corresponding author. 13. Submission of manuscripts. Manuscripts and all enclosures (cover letter, authorship statement and nancial disclosures) should be sent by e-mail to [email protected], preferably in one le. Signed copies of the cover letter and various statements may be faxed to +387 (51) 329-100. Submissions that do not comply with these instructions will be returned, unread. 14. Editorial process. Manuscripts deemed suitable for publication by in-house assessment will be reviewed by two or more outside experts. Contributors are encouraged to provide names of two or more qualied reviewers with experience in the subject of the submitted manuscript, but this is not mandatory. Page proofs of accepted articles will be sent to the corresponding author, and the corrected proofs should be returned within three days. The entire process, from the initial submission of the manuscript to the nal review, including the sending and receiving of page proofs, can be completed online. 15. Review procedure. Manuscripts suitable for peer review will be sent to two outside reviewers. Some manuscripts may be accepted without revision, but if revision is required, the corresponding author must address each question, criticism and suggestion from the reviewers and editor. These topics can be addressed in a letter to the editor along with a revised manuscript. The acceptance rate for SM is around 60%. 16. For further information, please contact us at the following address: Drutvo doktora Republike Srpske c/o Ms. Biljana Radii Prvog krajikog korpusa 4/I 78000 Banja Luka, Republic of Srpska, Bosnia & Herzegovina Phone & Fax: +387-(51) 329-100 E-mail: [email protected] [email protected] www.scriptamedica.com
the departments and institutions of the author(s) in the order they are listed. The title page must also include the name of the corresponding author, (along with address, phone and fax numbers and e-mail address) to which the work should be attributed. A short running title should have no more than 40 characters, including spaces. The word count should be indicated as well. Original articles may have up to 2.500 words, excluding references and abstract. The title should identify the main topic or the message of the paper. The standard title of a research paper is a phrase (rarely a sentence) that identies the topic of the paper; it should be concise and precise, informative and descriptive. The title of a descriptive paper should include the necessary description, function, purpose, animal species or population. When a method is described, the title should indicate whether it is new or improved. Abstract and key words. Structured abstracts should be included in papers that report original research. Abstracts are limited to 250 words in four labeled paragraphs: Introduction, Materials and Methods, Results, and Conclusion. The abstract should state concisely the question that was asked or the objectives of the study, the methods that were used, the results obtained, and adequately answer the question posed in the introduction. The abstract should provide pertinent information when read alone. Below the abstract, authors should provide 3-6 key words or short phrases, according to terms from the Medical Subject HeadingsMeSH (www.nlm.nih.gov/mesh). Introduction. Generally, this section provides the motivation for the paper (i.e., what is missing or unknown in the research literature at this time), an overview of the scientic theory or conceptual models on which the research was based, and the purpose of the study and why it is important. Cite only relevant references. Materials and methods. This section accurately describes the procedures used to carry out the study; it should be complete enough to permit others to replicate the study. Describe the methodological design, subjects, data sources, data collection methods, and any statistical and analytical procedures. These ve parts may not be needed in all papers. Short papers may include these details in different paragraphs, but titled subsections may be used in longer papers. The Methods section should describe how the research was structured, how subjects or groups of subjects (dened by sex, age, and other characteristics) and how the subjects were chosen and assigned to these groups. Identify all drugs and chemicals by generic names, exact drug dosages and routes of administration. Variability should be expressed in terms of means and standard deviations (SD). Because SD and SEM are positive numbers, we recommend elimination of a +/- sign; instead, the SD may be given in brackets. For example, systolic blood pressure in group of healthy students was 129 mm Hg [SD = 6, n = 87]. A p-value can be used to dis-
Specic instructions for a manuscript

Title page. The title page of the manuscript contains the title of the article, the full name of each author (without titles), and
65
prove the null hypothesis, but the authors should also give an estimate of the power of the study and state the exact tests used for statistical analysis. Results. This section presents ndings in logical sequence using the text, tables and illustrations. This section should show how the results of the study answer the research question. This may be shortest part of the entire paper. Details may be presented concisely in one or more tables or gures. Do not repeat the data presented in tables or illustrations in the text. Emphasize or summarize only important observations and how these answer the question posed in the introduction. Tables. Each table (4 tables or gures are permitted) with its legends, should be self-explanatory and numbered in Arabic numerals in order of their mention in the text. The title should be typed above the table, and any explanatory text, including denitions of abbreviations, is placed below the table. Illustrations (Figures). All gures (photographs, graphs, or schemes) should be numbered with Arabic numerals in the order of their mention in the text (a maximum of 4 gures or tables may be submitted). All lettering should be dark against a white background and of sufcient size to be legible when reduced for publication. Do not send original artwork, x-ray lms, or ECG tracings but rather photographs of such material. Images need to be at least 300 DPI (JPG or TIF les). Figure legends should be typed double-spaced on a separate page with Arabic numerals corresponding to the gure. All symbols, arrows, numbers, or letters should be explained in the legend. An internal scale should appear on photomicrographs, and methods of staining should be described in the legend. Discussion. Briey state the principal nding that relates to the purpose or research question posed in the Introduction and follow with an interpretation of the results obtained. Compare your ndings with work reported previously by others. Discuss the implications of your ndings and their limitations with respect to the methods used. Acknowledgments. List all persons as well as nancial and material supporters who helped to realize the project, even if they did not meet the criteria for authorship. References. The reference list is the responsibility of the authors. List all the papers or other sources cited in describing previous or related research. Cite references in the text sequentially in the Vancouver numbering style, as superscripted number after any punctuation mark. For example: as reported by Vuli and colleagues.12 When two references are cited, they should be separated by comma, with no space. Three or more consequtive references are given as a range with an en rule. References in tables and gures should be in numerical order according to where the item is cited in the text. For citations according to the Vancouver style, see Uniform Requirements for Manuscripts Submitted to Biomedical Journals; this source gives the rules and formats established by the International Committee of Medical Journal
Editors (www.icmje.org). If there are six authors or fewer, list all six by last name, space, initials, comma. If there are seven or more, list the rst three in the same way, followed by et al. For a book, list the editors and the publisher, the city of publication, and year of publication. For a chapter or section of a book, give the authors and title of the section, and the page numbes. For online material, please cite the URL and the date you accessed the website.. Online journal articles can be cited using the DOI number. Do not put references within the Abstract section. All titles should be in English (the name of the original language should appear in brackets). See examples below that conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: De Lacey G, Record C, Wade J. How accurate are quotations and references in medical journals. BMJ 1985; 291:884-6. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Croat Med J 2003; 44:770-83. Huth EJ. How to write and publish papers in the medical sciences. Philadelphia: ISI Press, 1982. Davidovi L, Markovi M, oli M, et al. Treatment of traumatic rupture of the thoracic aorta. Srp Arh Celok Lek 2008; 136: 498-504. Curtis MJ, Shattock MJ. The role of the manuscript assessor. In: Hall GM, ed. How to write a paper. London: BMJ Publishing Group; 1994: 89-95. Electronic publications: International Society of Scientometrics and Informatics Web site. Available at: http://www.issi-society.info Accessed March 20, 2012. Lock SP. Journalology: are the quotes needed? CBE Views. 1989:1257-9. Available at: http://gareld.libraryupenn. edu/ essays/v13po19y1990.pdf. Accessed April 25, 2012.
Review article
Review articles are written by individuals who have studied a particular subject or area extensively, and who are considered experts. For these reviews, the word count may not exceed 2.500 words, excluding references and abstract. The manuscript may have up to 4 tables or illustrations, and as many as 50 references.
Case report
Case reports are most likely to be published if they describe any of the following: an unreported drug side effects (adverse or benecial), drug interactions; a new, unexpected, or unusual manifestation of a disease; previously unsuspected causal association between two diseases; presentations, diagnosis and/ or management of new and emerging diseases; an unexpected association between diseases or symptoms; an unexpected event
66
in the course of observing or treating a patient, ndings that shed new light on the possible pathogenesis of a disease or an adverse effect; a previously unknown disease. Scripta Medica does not publish instructive case reports, that is, presentations that make important teaching point of what is already well known but often forgotten. Case reports (no longer than 750 words) should include the following: title, case presentation (including up to three illustrations) and discussion, references (up to six), and an unstructured abstract in English or Serbian. The abstract may be a single paragraph containing no more than 100 words, and followed by key words. Title should facilitate retrieval with electronic searching. Case presentation should include the history, examination and investigations adequately, description of treatments, state have all available therapeutic options been considered, and are outcomes related to treatments. Discussion includes following: state does the case have an unusual diagnosis, prognosis, therapy or harm; report of a literature review of other similar cases and is this different; explain rationale for reporting the case; what is unusual about the case; could things be done differently in a similar case? Case reports may have as many as ve authors. A very short case, a novel use of equipment, or new information about a particular disease can be submitted as a Letter to the Editor. Consent for publication must be obtained from the patients involved; if this is not possible, permission from a close relative or guardian must be obtained before submission. Authors should indicate in a cover letter how the case report contributes to the medical literature. Submissions that do not include this information will be returned to authors prior to peer review. For all case reports, informed written consent is required; the cover letter should state that consent was obtained. Authorship statement and nancial disclosure should be presented.
obtained. Authorship statement and nancial disclosure should be presented.
Letter to the editor

If the letter refers to a recent journal article, it should not exceed 250 words, excluding references. All letters should be brief and to the point with no more than ve reference citations. Figures or tables are not permitted in this format. Financial disclosure should be presented.
Editorial
Editorials are solicited by the editor to provide perspective on articles published in the journal and/or to express the general policies or opinions of the Editorial Board.
Special article
Special articles of 1500 words or less may be devoted to any medical problem, historic perspective, education, demography, or contemporary issues. Up to 15 references may be cited, and the piece may contain 2 tables or illustrations. An unstructured abstract in English (150 words or less) should accompany a specic article. Finacial disclosure should be presented.
Images in clinical medicine

The editors will consider original, clear and interesting images that depict novel or classic clinical pictures submitted along with a descriptive paragraph of up to 200 words. The report may include two authors and three references. The authors must obtain a signed, informed consent from the patient or from a close relative or guardian. The cover letter from the corresponding author should state that written consent was obtained.
Press Release. The authors of a particularly interesting or signicant articles may be asked by the editor of the Scripta Medica, or directly by the media, to write a press release, a text that will help spread the message to wide audience. Neither authors nor journalists should distribute unpublished reports until the journals media embargo has expired. Press release should be between 150 and 250 words long and covey the main message in short sentences and understandable terms. Lay terminology should be used whenever possible, and technical words and abbreviations should be explained when rst used. For lay readers and listeners approximations are preferable to percentages when reporting data. For example, 9% becomes nearly one in ten, and 55% becomes more than half. The press release should contain the name address, telephone, and e-address of the primary or senior author, but if there are multiple authors, one could be selected to talk to the media. When appropriate, Scripta Medica may organize a press conference to present interesting articles. The authors cwill be invited, and the press releases will be distributed.
SUBMISSION OF PAPERS - Manuscripts, tables and gures should be emailed to [email protected], whenever it is possible, all in one le. Signed cover letter and the statements can be scanned and submitted electronically together with previous materials or faxed to +387 (51) 329-100. To minimize delays, we advise that you prepare signed copies of all statements before submitting the manuscript. SIGNATURES - Cover letter - Authorship statement - Financial disclosure statement
Clinical problem-solving
Solutions for various clinical problems, including certain clinical studies, should include the following sections: Abstract, Introduction, Methods or Case(s) Presentation, up to four tables or illustrations, Discussion, References (maximum 20). The unstructured Abstract must be in English and be limited to 150 words, and followed by key words. This type of communication should not exceed 1400 words in all, including references and tables. Authors must obtain signed informed consent directly from the patients involved or from a close relative or guardian before submission. The cover letter should note that consent was

Scripta Medica Volume 44 Issue 1

Uploaded by

Copyright:

Available Formats

Scripta Medica Volume 44 Issue 1

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Scripta Medica Volume 44 Issue 1

Uploaded by

Copyright:

Available Formats

44

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Scripta Medica (Banja Luka)

Aleksandar Lazarevi Stevan Trbojevi

IZDAVAKI SAVJET/PUBLISHING COUNCIL

Prof. dr Sinia Miljkovi Prof. dr Milan Skrobi

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

IMAGES IN CLINICAL MEDICINE

Case Reports and Adverse Drug Reactions

Trans-Apical Trans-Catheter Aortic Valve Implantation: The Berlin Experience : J. COOCKBURN

Outpatient utilization of systemic antibiotics in the Republic of Srpska V. MARKOVI PEKOVI,

On Keratoconus Incidence in ProspectiveRefractive Surgery Patients

LETTER TO THE EDITOR

Burnout Syndrome Among Residents of Family Medicine M. JERINI

Questions and Answers M. MAVIJA, S. ILI, V. PAVLI

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

/In This Issue

(Blastomyces/Pleumocystis jiroveci), (Bero J. L.). ( . . .) ; . Q & A . , , ( M. .) . SM . , , . ; . , , . Medline ( ). SM - . , . Scripta Medica

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Case Reports and Adverse Drug Reactions

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Outpatient Utilization of Systemic Antibiotics in the Republic of Srpska

Vanda Markovi Pekovi1 Svjetlana Stoisavljeviatara2 Ranko krbi2

Submitted: February 23, 2013 Accepted: April 20, 2013

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Table 2. Ten most prescribed antibiotics for systemic use (DDD)

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Vanbolnika upotreba antibiotika za sistemsku primjenu u Republici Srpskoj

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Submitted: January 2, 2013 Accepted: February 3, 2013

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

33 % (4 of 12) 50 % (6 of 12) 0 % (0 of 12) 17 % (2 of 12)

14 % (2 of 14) 0 % (0 of 14) 29 % (4 of 12) 57 % (8 of 14)

Abbreviations: RH = right hemisphere, LH = left hemisphere

BDI-II Mean (SD)

Men/Women (n = 45) (n = 35) 10.14 (7.30)/13.25 (8.35)

Men RH/Men LH (n = 25) (n = 20) 8.96 (6.92)/11.60 (7.51)

Women RH/Women LH (n =15) ( n=20)

12.47 (7.97)/13.85 (8.74) 1.211 (DF =33) >0.05

4.568 (DF =78) <0.01

3.198 (DF =43) <0.01

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Uticaj pola i lateralizacije lezije na teinu postapoplektine depresivnosti

Robert L. Epstein Greg L. Epstein

Abbreviated UVA-Riboavin Corneal CollagenCross-linking for Keratoconus and Post-LASIK Ectasia

Submitted: January 30, 2013 Accepted: March 28, 2013

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Group> 20minute 30minute Kmax Decrease(better) 9 6 Increase(worse) 2 3 Same 0 3

Kmax Decrease(better) Increase(worse) Same

1month 13(28.3%) 19(41.3%) 14(32.7%)

3months 15(41.7%) 12(33.3%) 9(25%)

6months 18(52.9%) 11(32.4%) 5(14.7%)

1year 7(53.8%) 4(28.6%) 3(21.4%)

Note: Same=Five measurement Kmax average is within 0.678D or pre-operative average

Scripta Medica Vol. 44 No 1 May 2013. www.scriptamedica.com

Kmax Decrease(better) Increase(worse) Same

1month 3(33.3%) 4(44.4%) 2(22.2%)

3months 1(11.1%) 5(55.6%) 3(33.3%)